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Abstract 
Background: The oral cancer microenvironment is an evolving landscape comprised of 
different cell types. As the disease progresses environmental conditions within this landscape 
change and its composition must evolve and adapt to this for the tumour to develop. Since the 
discovery of mRNA and miRNA in extracellular vesicles (EVs) much interest has focused on 
the contribution of EVs to cancer. Here the role of EVs in oral cancer progression is explored. 
 
Methods: EVs were purified from the conditioned media of oral squamous carcinoma 
cells (OSCC) by serial centrifugation and size exclusion chromatography before characterisation 
with electron microscopy, western blotting and tuneable resistive pulse sensing. Next generation 
sequencing and mass spectrometry were used to identify the RNA and protein contents of these 
EVs. Bioinformatic approaches were used to correlate the contents with tumour stage of the 
producing cell. A fluorescence staining technique was used to image the transfer of EVs to cells 
of the tumour microenvironment in vitro and the impact of this uptake assessed in normal oral 
fibroblasts (NOF). 
 
Results: EVs of between 50-200 nm were produced by cells throughout oral cancer 
progression. These EVs were positive for markers CD63 and TSP1 but negative for the golgi 
body marker GM130. Transcriptomic and proteomic techniques have identified miRNA families 
and proteins changing in abundance in EVs with tumour stage including miR-200, miR-34, 
nespirin 1 and syndecan 4. EVs were taken up by cells of the tumour microenvironment. This 
uptake caused no change to NOF proliferation but activated them into a cancer associated 
fibroblast phenotype. 
 
Conclusions: EVs from OSCC are produced throughout tumorigenesis and their contents 
could reflect the status of the producing cell enabling them to act as diagnostic markers. EV 
uptake by NOFs caused them to become activated into a pro tumorigenic phenotype. 
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1. Introduction 
1.1. Cancer 
Cancer is one of the modern world’s biggest killers; in the UK it kills someone 
every four minutes. In 2014 Cancer Research UK released the worrying forecast that 1 
in 2 people will have cancer at some point in their lifetime (Cancer Research UK., 
2014). Often referred to as a disease of old age, cancer is significantly more common in 
people over the age of 60, and with improvements in modern medicine and lifestyle 
allowing people to live longer; so, cancer rates are rising. Medical dictionaries define 
cancer as a disease caused by an uncontrolled division of abnormal cells. These cells 
arise from a series of mutations caused either by carcinogens such as those found in 
tobacco smoke, alcohol and other chemicals, or by errors in replication, which naturally 
increase with age. Despite the rising number of cases, the mortality rates have been 
falling since the late 1970s with the advent of improved screening programmes and new 
generations of therapeutics. However oral cancer mortality rates are slowly on the rise, 
increasing by 10% in the last decade and 92% since the late 1970s (Cancer Research 
UK., 2014). 
 
1.2. Oral Cancer 
1.2.1. Introduction and statistics 
Oral cancers are a subset of head and neck cancers: this collection of tumour types 
covers those arising from the tongue, throat and the mucosal layers of the oral cavity. 
Cancer Research UK figures released in 2014 place the number of cases at 6767 per 
year with the number of deaths at 2119 per year. These figures account for 2% and 1% 
2 
 
of all cancer cases and deaths in the UK. Of the 18-people diagnosed with this disease 
every day the majority are men, it is most prevalent in the 50-74 age group and five-
year survival rates are currently at 50% (Cancer Research UK., 2014). As with many 
cancers the causes are linked to drinking alcohol, smoking tobacco and poor diet. More 
than two thirds of male cases and half of female cases are linked to tobacco use. The 
human papilloma virus (HPV), that also causes cervical cancer, has been associated 
with the risk of oral cancer and has recently become the focus of a vaccine programme 
in the UK (Waller, 2008). 
 
1.2.2. Stages of oral cancer  
Tumourigenesis is an increasingly well-defined process initiated following 
multiple genetic alterations caused by exposure to carcinogens in tobacco smoke, 
alcohol or viral infections as described by Knudson’s two hit hypothesis (Knudson, 
2001). In oral cancer these mutations, often transforming growth factor alpha (TGF-α) 
and epidermal growth factor receptor (EGFR) overexpression (Todd et al., 1997), set the 
afflicted cell on the path of tumorigenesis. This leads to cells acquiring some or all of 
the hallmarks of cancers as described by Hanahan and Weinberg (Hanahan and 
Weinberg, 2011, 2000). Cells which only develop the first three hallmarks: evasion of 
growth suppressors, sustained proliferative signalling and resisting cell death form 
benign or pre-malignant dysplasias. Dysplasias are defined as an abnormality of 
development or an epithelial anomaly of growth and differentiation (Reibel, 2003). 
Often referred to as premalignant lesions they are sometimes the first indication of an 
impending cancer in the oral cavity. Leukoplakias are a white plaque that forms on the 
oral mucosa and which cannot be identified as any other condition (Lodi et al., 2006); 
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similarly, erythroplakia (Reibel, 2003) is a red lesion which cannot be identified as any 
other condition. Dysplasias are the physical evidence of cells which have acquired those 
initial hallmarks of cancer allowing aberrant replication to establish itself within a 
population. 
Continued exposure to these carcinogens causes increasing damage with Kirsten 
rat sarcoma viral oncogene homolog (KRas) mutations, adenomatous polyposis coli 
(APC), tumour protein 53 (P53) and anaphase promoting complex subunit Doc1 (Doc1) 
inactivation, the overexpression of c-myelocytomatosis viral oncogene (MYC) and 
downregulation of E-cadherin (Todd et al., 1997). This results in the progression from 
dysplasia to a malignant carcinoma with the cells acquiring the final three hallmarks of 
cancers: induction of angiogenesis, replicative immortality and invasion and metastasis. 
Carcinomas are a type of cancer that arises from epithelial cells and account for 90% of 
all oral cancers (Markopoulos, 2012). 
 
1.3. Composition and conditions of the tumour microenvironment 
A developing cancer can be thought of as a distinct organ comprising of multiple 
cell types each with distinct roles essential to the function of the whole. Constantly 
changing environmental pressures will drive the need of a tumour to recruit and 
manipulate normal cells like epithelial cells, fibroblasts, keratinocytes and macrophages 
into the developing mass termed the tumour microenvironment (TME) (figure 1.1). 
 
1.3.1. Epithelial cells and keratinocytes 
Epithelial cells and keratinocytes are the normal cells of the oral mucosa and are 
found as a stratified squamous epithelium with thin flat cells on the topmost apical layer 
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above layers of more regular cuboid cells. Some areas of oral epithelium are 
keratinized; like the dorsal surface of the tongue, palate and gingiva. Keratinized 
epithelium has a topmost layer of keratinocytes which are differentiated epithelial cells 
that are almost completely filled with keratin to produce a barrier (Collins and Dawes, 
1987). Epithelial cells are often the cells from which oral cancer will arise, however the 
majority of them have too short a life span (14-24 days) to accumulate the necessary 
genetic changes to develop into a tumour (Squier and Kremer, 2001). An epithelial 
layer, whether keratinized or not, is constantly being replaced with cells dividing and 
becoming progressively more differentiated as they rise up the epithelial layers. Within 
an epithelium there exists a population of stem cells; these have a low proliferative rate 
and a high self-renewal capacity. This population is maintained by asymmetric division. 
Asymmetric division (figure 1.2) gives rise to a new stem cell and a more differentiated 
“normal” cell. In this way the number of stem cells remains at a constant level whilst a 
continuous supply of cells is fed into the differentiation pathway (Thomson et al., 1999). 
It is in this population of cells that tumorigenic mutations can occur. 
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Oral cancer microenvironment 
 
 
Figure 1.1 Changing oral cancer microenvironment from a healthy epithelial layer to a fully 
developed squamous cell carcinoma. Tumourigenic mutations are acquired by the stem cells and as 
the tumour progresses additional cell types are recruited into the surrounding area particularly 
macrophages and neutrophils. The surrounding stromal cells are altered by signals from the 
tumour cells forming activated or cancer associated fibroblasts which benefit a developing tumour. 
The final image in the set shows a fully developed tumour that has begun to metastasise. This 
tumour has established its own blood and lymphatics supply and has established an invasive front 
which is breaking through the basement membrane and is beginning to metastasise to secondary 
sites. 
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Symmetric and asymmetric division 
 
 
Figure 1.2 Symmetric division as undergone by normal cells and asymmetric division as 
undergone by epithelial stem cells. Symmetric division gives rise to two identical daughter cells 
whereas asymmetric division gives rise to a new epithelial cell and a new stem cell; it is this 
process that creates a pool of cells with a lower turnover rate in which carcinogenic mutations can 
accumulate. 
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1.3.2. Fibroblasts 
Fibroblasts are the cells responsible for secreting the extracellular matrix and are 
abundant within the TME. The fibroblasts within a tumour however are very different to 
those found in normal tissue. In wounded tissue fibroblasts become activated to form 
myofibroblasts (Majno et al., 1971), a similar phenomenon is seen in cancer. Cancer-
associated fibroblasts (CAFs) have a more spiny morphology and have been identified 
by a range of different markers including alpha smooth muscle actin (α-SMA) (Serini et 
al., 1998; Tomasek et al., 2002), platelet derived growth factor (PDGF) receptor α/β, 
tenascin-C, periostin, neural/glial antigen 2 (NG2), fibroblast specific protein (FSP) and 
fibroblast activation protein (FAP) (Prime et al., 2016; Togo et al., 2013). With so many 
different markers it is highly likely that there are actually a number of different sub-
populations present in a tumour potentially with subtly different functions. The 
activation of fibroblasts to form CAFs is driven by the epithelial cells producing protein 
factors such as transforming growth factor beta (TGF-β), tumour necrosis factor alpha 
(TNF-α) and interleukin (IL)-1 α/β. Also implicated are the miRNAs miR-210, miR-21, 
miR-146a, miR-27, miR-155 and miR-200b (Pang et al., 2015; Tanaka et al., 2015; Yao 
et al., 2011).Interestingly it has also been observed that cigarette smoke, a major risk 
factor for oral cancer can regulate some of these miRNA (Pal et al., 2013). The 
relationship between fibroblasts and cancer cells is actually a reciprocal one, as once 
activated, the fibroblasts release a range of molecules including prostaglandin E, 
stromal cell derived factor 1, bone morphogenetic protein 4, activin A, matrix 
metalloproteinases, hepatocyte and keratinocyte growth factors and insulin like growth 
factor 2. This potent cocktail can drive cell growth (Castells et al., 2012; Olumi et al., 
1999), metastasis, angiogenesis and immune escape (Leef and Thomas, 2013; Togo et 
al., 2013). They have also been seen to facilitate evasive resistance by giving alternative 
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angiogenesis pathways to tumours treated with VEGF inhibitors (Sun and Nelson, 
2012).  
 
Interestingly, CAFs have also been seen to release pro-inflammatory cytokines 
(Muppalla et al., 2013) indicating that CAFs have more in common with myofibroblasts 
than just morphology. Rudolf Virchow first postulated that inflammation accelerated 
cancer growth in 1863. Although some of his theories on cancer origins were shown to 
be incorrect by subsequent scientists, his thoughts on inflammation have become widely 
accepted as shown in recent reviews on the subject (Coussens and Werb, 2002; Ostrand-
Rosenberg and Sinha, 2009). 
 
Activated fibroblasts are not the only fibroblasts found in and around a tumour. 
Senescence is a state where cells are no longer capable of dividing but remain viable 
and metabolically-active. This self-imposed limit on replication is normally triggered in 
response to extreme cellular stress or to DNA damage and therefore acts as a tumour 
suppressing mechanism. However, fibroblast senescence has recently been shown to be 
induced by tobacco and alcohol and that this senescence actually precedes the dysplasia 
in a pre-malignant oral fibrosis condition (Pitiyage et al., 2011). This is a very 
interesting observation particularly when viewed alongside other data; co-culture 
experiments of senescent prostate or lung fibroblasts with their pre-malignant epithelial 
counterparts stimulates cell growth as well as invasion and migration (Bavik et al., 
2006). One of the key contributions from senescent fibroblasts to the TME is the 
senescence-associated secretory phenotype or SASP. This is a combination of 
favourable protein factors including IL6 and matrix metalloproteases (MMPs), IL8, 
vascular endothelial growth factor (VEGF) and osteopontin (Coppé et al., 2008; Pazolli 
9 
 
et al., 2009). These factors contribute to a range of processes including epithelial cell 
proliferation, possibly leading to the dysplasias it precedes. Another beneficial aspect of 
the SASP is the induction of epithelial to mesenchymal transition (EMT) (Coppé et al., 
2008). This is a phenomenon where epithelial cells transition from an adhesive 
phenotype to a more migratory phenotype similar to that seen in mesenchymal cells. It 
is often thought of as being the first step necessary for tumour metastasis. However, this 
theory has potentially been disproved with data emerging showing EMT is non-essential 
for metastasis (Zheng et al., 2015), but it remains to be seen if this will be true in other 
models. 
 
1.3.3. Endothelial cells 
The induction of angiogenesis is one of the extended hallmarks of cancer 
described by Hanahan and Weinberg in their 2011 sequel, the next generation (Hanahan 
and Weinberg, 2011). A study published in 2007 showed that oral cancer patients with 
the most heavily vascularised tumours had five-year survival rates of up to 50% lower 
than patients with poorly vascularised tumours (Miyahara et al., 2007). This clearly vital 
process is mediated by endothelial cells. In humans, the cells of the vascular 
endothelium exhibit different characteristics depending on their organ of origin 
(Langenkamp and Molema, 2009). In recent years, studies have shown that the 
endothelial cells seen in tumours exhibit further heterogeneity. A study from 2000 
identified 13 novel protein markers for colon carcinoma endothelial cells (St Croix et 
al., 2000), similar differences have also been observed in ovarian cancer (Lu et al., 
2007). An interesting molecular difference between tumour and non-tumour endothelial 
cells, is that tumour endothelial cells are more responsive to VEGF (Matsuda et al., 
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2010). Additionally, they express high levels of the receptor for epidermal growth factor 
(EGF) (Amin et al., 2006). These molecular variations would combine to give tumour 
endothelial cells a doubly more responsive phenotype towards angiogenic factors, 
reflecting the need of tumour endothelial cells to handle the more demanding conditions 
of the tumorous pseudo organ. 
 
A paper from 2003 describes how the endothelial cells from a renal carcinoma 
were resistant to vincristine (Bussolati et al., 2003). This trait is seen in hepatocellular 
carcinoma with both 5-fluoruracil and adriamycin (Akiyama et al., 2012; Xiong et al., 
2009). This is an interesting development in the study of tumour angiogenesis, next to 
the tumour cells themselves the endothelial cells will be the fastest replicating cells 
within the microenvironment and highly vulnerable to many of the chemotherapy agents 
in use. That the endothelial cells have a way to offset this potential weakness to the 
tumour is fascinating. Many drugs will circulate around a tumour using the vasculature, 
meaning endothelial cells also represent the first contact of the tumour tissue with any 
cytotoxic compounds and being able to remove some of these from circulation without 
cost to themselves is a subtle advantage to the tumour. 
 
Recent studies have demonstrated a role for endothelial cells in tumour 
development beyond angiogenesis. Several studies have implicated endothelial cells in 
cancer metastasis. Metastasis to the blood vessels require the tumour cells overcome 
two challenges, first they must cross a barrier. Secondly the cells must acquire a motile 
phenotype, either by cytoskeletal remodelling or because of chemotactic gradient. 
Endothelial cell expression of Akt-1 was seen to be pivotal to preventing the invasion of 
prostate cancer cells through an endothelial cell layer (Gao et al., 2018). It’s loss in 
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endothelial cells caused increased phosphorylation of β catenin and disruption of the 
tight junctions. Aa study in oral cancer demonstrated the endothelial cells were capable 
of secreting EFG which could induce epithelial to mesenchymal transition in head and 
neck cancer cells (Zhang., et al 2014). This transition gives the cells a more motile 
phenotype and is thought to be essential for metastasis. Another study in oral cancer 
show another endothelial cell secreted protein contributing to a different element of 
metastasis, interleukin 6 (IL6) secreted by endothelial cells establishes a chemotactic 
gradient enabling the movement of cancer cells towards the blood vessels (Kim et al., 
2017).  
 
1.3.4. Immune cells 
Many of the cells of the innate immune system have been found in the 
microenvironment of different tumour types and it has been shown that these cells can 
have both pro and anti-tumour roles. Macrophages are phagocytic cells formed by 
differentiating monocytes. In normal tissues these cells are essential for the clearance of 
apoptotic cells and control of epithelial cell turnover (Geissmann et al., 2010; 
Medzhitov, 2008). In patients with oral cancer an increased number of macrophages 
within the TME correlates with significantly worse outcome (Liu et al., 2008). During 
differentiation monocytes can become either M1 like or M2 like macrophages and 
although both are found in tumours there are contradictory studies describing their 
respective roles. M1 macrophages have been shown to exhibit strong anti-tumour 
behaviours by some groups (Beatty et al., 2011; Fridlender et al., 2009). This subtype is 
more commonly associated with the early stages of tumour progression and the removal 
of macrophages from a tumour in mouse models of breast cancer by depletion of the 
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macrophage growth factor colony- stimulating factor 1significantly impedes the 
development of a cancer (Lin et al., 2001). They also release a variety of chemokine and 
cytokines which can promote tumour development (Yang et al., 2008). M2 macrophages 
are more common in later stage cancers and as a result are frequently shown to have a 
role in metastasis (Na et al., 2013; Yang et al., 2015). 
 
It is interesting to note that M2 macrophages have well documented anti-
inflammatory properties (Bouhlel et al., 2007) in contrast to the M1 macrophages which 
are known to be pro- inflammatory. Prolonged inflammation has come to be accepted as 
a favourable backdrop for the development of a tumour, being included as one of the 
next generation hallmarks in 2011 (Hanahan and Weinberg, 2011). This would suggest 
that the ratio of M1 to M2 macrophages in cancer is dependent on the stage of the 
cancer and the need for their other abilities to take precedence at any given stage in the 
cancer’s life span.  
 
The infiltration of neutrophils in head and neck squamous cell carcinomas has 
been associated with worse outcome (Trellakis et al., 2011), conversely however in 
gastric cancer high neutrophil count is associated with a favourable prognosis (Caruso 
et al., 2002). Neutrophils have been linked to genetic instability in a mouse model of 
tumour initiation via an inducible nitric oxide synthase (Sandhu et al., 2000). They have 
also been seen to increase tumour cell proliferation by transfer of neutrophil elastase to 
neighbouring tumour cells, the elastase enhances platelet derived growth factor 
signaling (Houghton et al., 2010). In a reciprocal exchange interleukin 8 produced by 
melanoma cells increases β2 integrin expression on the neutrophils. This changes the 
interaction between neutrophils and melanoma cells in a way which favours the 
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movement of the melanoma cells across the endothelium (Huh et al., 2010). In a breast 
cancer model interleukin 17 (IL-17) producing γδ T-cells cooperate with neutrophils to 
promote metastasis (Coffelt et al., 2015). First the T-cells release IL-17 this promotes 
the invasion of neutrophils into the tumour. These neutrophils then supress cytotoxic T 
lymphocytes which would normal inhibit metastasis (Coffelt et al., 2015).  
 
Another class of immune cells, regulatory T cells have been implicated in the 
suppression of anti-tumour immune responses. In oral cancer increasing FOXP3 mRNA 
expression correlates with increasing malignancy (Schipmann S et al., 2014), this 
transcription factor helps to recruit the regulatory T cells into the cancer micro 
environment to supress the anti-tumour effects. CD-3 positive T-cells have also been 
implicated in oral cancer progression with a higher level of these cells in biopsies of 
oral dysplasias correlating with the prevention of transformation into a carcinoma 
(Öhman et al., 2015). Using a range of mouse models for oral cancer a study showed 
that different levels of different T-cells are associated with more or less aggressive 
tumours. Less aggressive slower growing tumours were associated with increased CD-8 
positive T-cells whereas more aggressive metastatic tumours were associated with 
increased CD4 positive regulatory T-cells (Judd et al., 2012). This study neatly 
encapsulates the dynamic nature of the immune component of the tumour 
microenvironment. As the tumour progresses and its demands change the composition 
of the immune component will be altered with it.  
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1.3.5. Changing conditions in the microenvironment 
Tumour formation is a very good example of the evolutionary phenomenon niche 
construction occurring on a cellular level. Niche construction is the process by which an 
organism shapes the niche it inhabits further tailoring it to suit its needs against those of 
potential rivals. The organisation of cells to form tissues within the human body is very 
highly conserved to allow adequate circulation and for the tissues to perform their 
biological role. By necessity, the growth and turnover of tissues is kept in check by 
homeostatic processes. The mutations that cause tumorigenesis disrupt this process 
causing a series of dramatic changes in the conditions of the surrounding tissue (figure 
1.3). As soon as a cell has acquired sufficient mutations it begins to replicate 
incessantly. This replication causes an increase in the size of the tissue causing cells to 
grow further from their nearest blood vessels. Once cells are further than the 2 mm 
diffusion limit from a blood vessel they will begin to experience hypoxic conditions 
(Rouwkema et al., 2008). Another early change is caused by the innate immune system. 
Our immune system is programmed to recognise and remove transformed cells arising 
from replication errors, which should normally include cancer cells. Macrophages 
neutrophils and leukocytes in the vicinity of the developing tumour will be driving the 
establishment of localised inflammation. 
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Oral cancer tumourigenesis 
Figure 1.3 The progression of oral cancer with the carcinogenic mutations that cause the transition 
between the stages. As tumorigenesis of oral cancer progresses from normal epithelium through to a 
metastatic carcinoma the changing environmental pressures experienced by the growing cells are also 
indicated. 
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As a carcinoma progresses it will establish its own blood supply; however, despite this, 
many tumours will have a necrotic centre comprising cells that have starved to death. A 
large number of dead or dying cells will change the pH of the blood circulating in the 
surrounding vessels due to the breakdown products of the cells causing acidosis. 
Because tumours distort the ordered formation of tissues to such an extent they can also 
change the biomechanical forces experienced by the surrounding tissue (Dvorak., 2011). 
This effect is particularly apparent where tissue has a very physical role to perform such 
as that found in the mouth or oesophagus. 
 
Once a tumour is advanced enough to be diagnosable it is hoped that a patient 
would be treated, which will often include either chemo or radiotherapy. Both 
therapeutic approaches will have a dramatic impact on the conditions of the tumour, as 
both are highly cytotoxic and will have the greatest impact on those cells that are 
rapidly replicating. In an established tumour this potentially results in a collapse of the 
tissue structure and vasculature along with an increase in the number of dead cells. 
These effects will again cause acidosis and hypoxia within the surrounding area (Chiche 
et al., 2010). 
 
1.3.6.  Discovery of extracellular vesicles 
In 1987 Rosemary Johnston was studying the fate of the transferrin receptor 
during the maturation of sheep reticulocytes. Using immunogold labelling and 
transmission electron microscopy (TEM) she observed the receptor being removed from 
the membrane and trafficked to multivesicular bodies (MVB), which when they fused 
with the plasma membrane released transferrin containing vesicles from the cells 
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(Johnstone et al., 1987). This is widely considered as the starting point for a new field of 
research. However, the first mention of the term exosomes, that Johnstone is often 
credited with coining in this paper, was actually seen in a report from 1981. The study in 
question observed various cell lines releasing vesicles with 5’-nucleosidase activity. 
When visualised using TEM, these vesicles were between 500 to 1000 nm in size and 
often contained a second smaller population of vesicles of 40 nm in size (Trams et al., 
1981). It was their suggestion that all of the vesicles should be termed exosomes.  
 
It wasn’t until the early 2000s that these vesicles were seriously considered as 
anything more than cellular waste removal systems. In 2006 and 2007 it was 
demonstrated that extracellular vesicles (EVs) contained both mRNA and miRNA 
which could be transferred between cells (Ratajczak et al., 2006; Valadi et al., 2007). A 
few years later another landmark was reached, the discovery that melanoma and ovarian 
cells produced significantly more EVs than healthy cells (Logozzi et al., 2009; Taylor 
and Gercel-Taylor, 2008). Since then research in this area has bloomed with increasing 
numbers of groups working to elucidate the roles EVs play in both healthy and diseased 
tissues. EVs have been isolated and investigated from an increasing range of biological 
fluids and the culture medium of various cell lines. 
 
1.3.7. What’s in a name? 
Names and definitions are an important part of any scientific field but are doubly 
important to an emerging field as it takes shape. The International Society for 
Extracellular Vesicles (ISEV) has endeavoured to grapple with this issue in various 
position papers and meetings (Gould and Raposo, 2013; Hill et al., 2013; Witwer et al., 
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2013). Currently there are as many as four major classes of EVs being studied: 
exosomes, microvesicles, apoptotic extracellular vesicles and large oncosomes.  
  
The vesicles Johnstone and her colleagues observed came to be known as 
exosomes and these were distinguished from other EVs by their formation in MVB 
inside the cell (figure 1.4). The majority of studies on PubMed (4334) are focused on 
exosomes. These are normally described as being between 30-100 nm in size. A second 
class of EVs is seen to bud off directly from the plasma membrane that have been 
termed microvesicles and range from 100-1000 nm in size (Akers et al., 2013). The 
overlapping size ranges of these different EVs present one of the biggest challenges for 
the field, as current techniques for extracting them from cell culture media or biological 
fluids are incapable of distinguishing between EVs of the different classes. This is 
because existing methods are only capable of separating the EVs by their size or 
density. Perhaps one of biggest problems with this is many of the protein markers for 
different subclasses of EVs have been determined by studies using size or density-based 
separation methods where there will undoubtedly have been some crossover of EVs 
types inevitably making the definitions of some groups inconsistent with what they are 
actually studying. A further complication is that there are numerous papers which still 
use older terminology, some of which relates to the producing cells or tissues to 
distinguish the EVs such as oncosomes (Di Vizio et al., 2009) or prostasomes (Aalberts 
et al., 2012). It is almost certain that the majority of groups are working on preparations 
containing a mixture of the different subclasses within a density and/or size range 
created by their chosen extraction protocol. 
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Apoptotic bodies are vesicles released by apoptotic cells as they break down (Kerr 
et al., 1972, Gregory and Pound., 2011). Similarly, to exosomes these have previously 
been viewed as waste disposal systems however it has been demonstrated that they 
actually play a part in the signalling process of apoptosis (Hawkins and Devitt, 2013). 
The final class of EVs is relatively new; large oncosomes are around 1-10 μm in size 
and bleb from the plasma membrane of cancer cells and are thought to function in very 
different ways to the other smaller EVs (Di Vizio et al., 2012; Meehan et al., 2016; 
Minciacchi et al., 2015; Morello et al., 2013). 
  
Regardless of the terms used to describe them, or the challenges with defining 
them, these EVs are now a pivotal part of the future of cancer treatment with a vast 
range of possibilities as a source of biomarkers, therapy vehicles or a previously 
unknown signalling system to understand and exploit. 
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Mechanisms of EV release 
 
 
Figure 1.4 Mechanisms of EV release. Exosomes are shown forming in MVBs by inward 
invagination of the late endosomal membrane (1). They are then trafficked either to the lysosome 
and degraded (2) or to the plasma membrane where they undergo fusion releasing the intact 
internal vesicles in to the extracellular spaces. In addition, some EVs can bud directly from the 
plasma membrane in the form of apoptotic bodies and microvesicles. 
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1.3.8. Biogenesis of extracellular vesicles from MVB 
The formation of the vesicles derived from MVB is still not clearly understood. 
Whilst the process has been visualised using electron microscopy and the stages are 
well known, the individual mediators and regulators are not. Johnstone’s early work 
showed that the process involved invagination of the limiting membrane that resulted in 
a structure that budded into the lumen of the late endosome (Johnstone et al., 1989). 
This allows the forming exosome to capture proteins and nucleic acids from the 
cytoplasm. Initially the orientation of the membrane relative to the plasma membrane 
was unclear. It was later shown that the membrane underwent two inversions, the first 
upon endocytic internalization, and the second as the intraluminal vesicles budded off 
into the late endosomal lumen (Février and Raposo, 2004; Lakkaraju and Rodriguez-
Boulan, 2008). The second inversion is an essential one as it allows exosomes to present 
membrane proteins in the same orientation as the cellular membrane therefore retaining 
activity in the extracellular space. Vesicles are not directed to a lysosomal compartment 
as usual but are directed by a range of proteins and endocytic components to fusion with 
the plasma membrane and the extracellular space. Currently the mechanisms that drive 
and facilitate this process are divided into endosomal sorting complex required for 
transport (ESCRT) dependent (figure 1.5) and ESCRT independent mechanisms (figure 
1.6). 
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ESCRT-dependent mechanisms of EV formation 
 
 Figure 1.5 ESCRT-dependent formation of vesicles in MVBs begins the sequential recruitment of 
the ESCRT complex components to the site of invagination (1&2). The next steps are the closure 
of the “neck” by the combined action of VSP4 Alix and ESCRT-III forming the complete vesicles 
within the MVB (3&4) which can then be trafficked to the plasma membrane and released (5). 
There are still many gaps in our understanding of this mechanism as it relates to vesicles that are 
released from the cell. 
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1.3.8.1.  ESCRT - dependent mechanisms  
ESCRT is the endosomal sorting complex required for transport, a well 
characterised complex with integral roles in intracellular transport and vesicle 
formation. There are four ESCRT complexes - 0-III each of these has been, or is being, 
studied in the context of exosome production. Several groups have focused on 
individual members of these complexes following their detection in proteomic studies 
of vesicles. HRS, an ESCRT-0 member has been established as a requirement for 
exosome production in several cell models (Colombo et al., 2013; Gross et al., 2012; 
Hoshino et al., 2013; Tamai et al., 2010), Depletion of another ESCRT-0 component 
STAM1 also reduced exosome production (Colombo et al., 2013). With the involvement 
of two of the complex members it is highly likely that depletion of the remaining 
components will show similar results. 
  
To date only one ESCRT-I component has been implicated, with TSG101 
depletion reducing exosome secretion in various cells (Colombo et al., 2013; Abrami et 
al., 2013; Baietti et al., 2012). However, this had no impact in oli-neu oligodendroglial 
cells, which revealed the existence of an ESCRT independent system for the first time 
(Trajkovic et al., 2008). It is here the picture becomes less clear whilst ESCRT II and III 
components are seen in proteomic studies of exosome contents, more detailed 
experiments are showing conflicting results from different research groups. In their 
shRNA screen of ESCRT proteins in HeLa-CIITA cells one group saw no impact of 
ESCRT-II proteins on exosome production and ESCRT-III data was inconclusive 
(Colombo et al., 2013). However, (CHMP4 an ESCRT-III member) has been shown to 
play a part in exosome secretion in MCF-7 cells (Abrami et al., 2013). It is possible that 
ESCRT-II maybe the odd complex out and plays no role in the production and secretion 
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of exosomes, but this is highly unlikely. During canonical vesicle budding in the MVBs 
the four ESCRT complexes are recruited in sequence to the site of invagination. ESCRT-
0 initiates the process and each complex interacts with the other to form ESCRT-III 
within the neck formed by the membrane invagination. ESCRT-III then draws closed the 
two sides of the neck and is broken down itself by a VPS4 VTA1 complex (Henne et al., 
2011). While it is a possibility that vesicles which become exosomes exhibit some 
differences to this process; it is more likely that they are formed via an identical process 
but exhibit different protein surface markers changing their eventual traffic destination. 
Currently there is no evidence to support either hypothesis. 
  
Alix is a protein that associates with ESCRT-III and has been implicated in 
conflicting roles. Depletion of Alix in HeLa-CIITA cells showed no clear effect on 
exosome production, whereas in primary dendritic cells from various donors its 
silencing decreased exosome production in half of the cells tested (Colombo et al., 
2013). This data raises an interesting possibility that the mechanisms producing 
exosomes are different in healthy and diseased cells. It has also been observed that Alix 
silencing decreased production of exosomes but increased the production of vesicles 
generated from outward budding of the plasma membrane (Bissig and Gruenberg, 
2014). Further contradictions are seen surrounding the VPS4 protein which is involved 
in the final steps of intraluminal vesicle formation. This protein has multiple isoforms 
which appears to be complicating the picture. In HeLa-CIITA cells silencing of the B 
isoform increased secretion of exosomes, (Colombo et al., 2013). However, in MCF-7 
cells when silencing both isoforms independently and in combination, and an effect was 
only observed when they were silenced in concert which was a decrease in secretion 
(Abrami et al., 2013). The authors of the first study postulated that silencing of the B 
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isoform could lead to compensation by the A isoform or an alternative role for the B 
isoform in HeLa cells. It is worth noting that because these vesicles are often released as 
a stress response, experiments relying on silencing of a particular protein need to be 
planned and interpreted with caution as observed effects may not be the direct result of 
silencing alone. 
26 
 
 
 
ESCRT-independent mechanisms of EV formation 
 
Figure 1.6 ESCRT-independent formation of vesicles and their subsequent release. The process is 
initiated by changes in lipid membrane composition at the site of invagination with an increase in 
PLD2 and ceramide concentration (1) the properties of the membrane are altered driving inward 
curvature at this point it is assumed that proteins like VAMP and SNAREs will be involved in 
completing the formation of the vesicles within the MVBs (2 & 3). After their formation the 
MVBs can fuse with the plasma membrane and release their contents from the cells. 
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1.3.8.2. ESCRT - independent mechanisms  
ESCRT - independent mechanisms for exosome production are less well 
characterised, but mammalian cells lacking key ESCRT components can still form 
MVB and exosomes (Stuffers et al., 2009). These mechanisms are thought to rely on 
lipids and are frequently studied using disruption of lipid biogenesis. In 
oligodendroglial cells, inhibiting neutral sphingomyelinase reduces production of 
ceramide. Ceramide is hypothesised to induce the characteristic curvature of the 
membrane in MVBs that leads to exosomes (Trajkovic et al., 2008). Like ceramide, 
cholesterol is abundant in exosomes and an important component of MVB. In the same 
oligodendroglial cells its accumulation, mediated either by drugs or genetic mutation, 
causes an increase in vesicle secretion (Strauss et al., 2010). Another candidate is 
phospholipase D2 (PLD2) which is enriched in exosomes and has been shown in two 
different cell lines to be required for exosome biogenesis (Baietti et al., 2012; 
Laulagnier et al., 2004). It is believed to play a similar role to, or work in concert, with 
ceramide in facilitating inward curvature of the membrane in the early stages of 
exosome formation. Studies of ESCRT independent pathways for the biogenesis of 
exosomes are hampered by the major contributions of key lipids. Because cellular 
membrane is comprised of the same components, albeit in different proportions, it is 
highly likely that disrupting the synthesis of one of these components alters the plasma 
membrane stability possibly leading to an increase in the numbers of vesicles formed by 
direct budding of the plasma membrane. Until a reliable method for separating the 
classes of vesicle is available this problem will remain. 
  
The same issue is highlighted by a study which focuses on the regulation of 
exosome secretion. RAB-27a, a member of the abundant GTPase family, has been 
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shown to be the leading regulator of exosome secretion. However, it’s silencing in 
mouse tumour cells revealed the presence of different subpopulations of vesicles 
obtained from the standard extraction protocols (Bobrie et al., 2012). Its silencing led to 
reduced levels of some of the accepted markers of exosomes but not others. They 
demonstrated neatly using electron microscopy and sucrose density gradients that this 
was caused by the presence of different populations with diverse physical properties and 
possibly different origins (Bobrie et al., 2012). This issue is one facing all researchers in 
this field, with extraction protocols currently unable to separate vesicles of different 
origins the possibility of the different subpopulations of vesicles playing different roles 
cannot be eliminated. The RAB family of GTPases has numerous members implicated 
in control of exosome secretion including 2B, 5A, 9A, 11, 35, and both 27A and B they 
are thought to function by blocking the release of vesicles from the cell (Kowal et al., 
2014). However, there is still work required to clarify this and to clarify the proportion 
of the effects caused by changing exosome secretion as opposed to other secretion 
mediated by RAB proteins. SNARE proteins like VAMP-7 and 8 as well as SNAP-23 
have been shown to play a role in calcium ion - mediated fusion of other secretory 
bodies with the plasma membrane (Puri and Roche, 2008; Rao et al., 2004; Tiwari et al., 
2008) and targeting of these in combination with or independently of RAB proteins 
could help with solving this problem. 
 
1.3.9. Formation of microvesicles and large oncosomes 
Both these EV subtypes form from the outer plasma membrane of a cell as 
opposed to the internal membranes. Whilst some of the processes are similar there are 
some subtle differences. Many of the conditions required for the formation of EVs from 
29 
 
the outer membrane come under the control of the enzymes responsible for regulating 
the fluid state of membranes (Singer and Nicolson, 1972). These changes are thought to 
be induced by changing calcium ion levels which are required by scramblase and 
floppase type enzymes. Once these are activated they begin to modify the lipid 
arrangement within the plasma membrane (Piccin et al., 2007), a major change is the 
externalisation of phosphatidylserine (PS) (Lima et al., 2009). Cholesterol is another 
major player in this process as shown by its depletion impairing the production of EVs 
from monocytes (Del Conde et al., 2005). This is likely to be linked to the recruitment 
or formation of lipid raft domains which are seen to be abundant in these microvesicles. 
These changes to the lipid composition make the membrane more amenable to the 
curvature necessary to form EVs (figure 1.7). 
  
It is at this juncture that proteins are likely to play their part. One such protein 
could be Ras homolog gene family, member A (RhoA) a small GTPase which together 
with some downstream kinases have been identified as regulators of microvesicle 
release (Li et al., 2012). Other proteins including ADP ribosylation factor 6 (ARF6) 
(Muralidharan-Chari et al., 2009), calpain a cytoskeletal regulator which is calcium- 
dependent (Crespin et al., 2009), and Ras homolog gene family, member C (RhoC) 
(Cussac et al., 1996) have all been studied in the context of microvesicle release. 
However, there is a distinct issue facing scientists when trying to elucidate the 
mechanisms responsible for forming these vesicles subtypes, that of reliably ensuring a 
pure preparation of a single subtype. In the experiments that have identified RhoA as a 
potential regulator of microvesicle release the vesicles were isolated by serial 
centrifugation culminating in a spin at 100,000 x g speeds at which a mixed population 
of vesicles will be pelleted (Li et al., 2012). The study that linked ARF-6 to 
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microvesicle formation by contrast performed experiments on a population of vesicles 
pelleted at 10,000 x g as well as the 100,000 x g population (Muralidharan-Chari et al., 
2009). Whilst this is a commonly seen approach to separate “microvesicles” and 
“exosomes” it is still slightly flawed as there will inevitably be some crossover of 
subtypes in the two different pellets. Unfortunately, at this stage a better approach to 
solving this problem has yet to be found by the EV community but it does highlight the 
extreme importance of a robust system of definitions being adhered to. 
 
The term oncosome has been used by a variety of groups to distinguish EVs 
derived from cancerous cell or biofluids. More recently the term large oncosomes has 
been used to describe a potentially new subset of EVs. These large oncosomes are 
around 1-10 µm in size and released from the outer membrane of cancer cells (Di Vizio 
et al., 2012; Minciacchi et al., 2015; Morello et al., 2013). Formation of these large EVs 
is thought to be linked to the amoeboid phenotype; this is adopted by invading cancer 
cells to overcome problems with breaking down surrounding matrices (Wolf et al., 
2003). Cells with this phenotype have a membrane highly prone to blebbing which is 
under the control of RhoA and Rho-associated protein kinase (ROCK), both of which 
are linked to microvesicle formation (Oppel et al., 2011). This blebbing is the precursor 
to formation of large oncosomes. After treatment with EGF prostate cancer cells were 
seen under live microscopy to enter an amoeboid state and release these blebs as intact 
vesicles (Di Vizio et al., 2009). Because they are formed from the membrane of cells in 
an amoeboid phenotype their formation is likely to be dependent on proteins that 
regulate both mechanisms such as diaphanous related formin 3 (DIAPH3) (Hager et al., 
2012) and ARF6, which is highly abundant in large oncosomes (Di Vizio et al., 2012).   
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Microvesicle formation 
 
 Figure 1.7 A possible mechanism of microvesicle formation with the initial changes in lipid 
membrane composition driven by calcium-dependent floppase and scramblase enzymes (1-3) 
allowing the outward budding which is then probably chaperoned by a number of proteins under 
the control of RhoA/C ROCK and ARF6 signalling (5-6). The final steps involve cytoskeletal 
remodelling mediated by calpain to remove the vesicle and reform the lipid bilayer behind it. 
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1.4.  Packaging of EVs 
1.4.1. Proteins 
From their initial discovery there has been increasing evidence indicating the 
presence of some guiding system behind the packing of these EVs. But while there are 
several steps in their biogenesis at which such a system could be involved we are still 
some way from a definitive understanding of such a system. The studying of it is 
complicated by the fact cells can produce multiple distinct populations of EVs at any 
given point in their life cycle. For example, the colon cancer cell line LIM1863 releases 
two distinct populations of EVs; one that bears markers of the apical membrane and 
trafficking systems while the other carries markers of the basolateral membrane and 
trafficking systems (Tauro et al., 2013). It is likely that similar systems exist in other 
cells and given the 3D cell spheroid model system used in this study it is highly possible 
that a contact-based mechanism could play a role in determining vesicle contents 
although as yet there has been no evidence for such a mechanism. This work also 
highlights one of the weaknesses common to much of the work done in this area; many 
laboratories work with cells in a 2D culture system and as such the cells and by 
extension the EVs are likely to show differences between in vivo and in vitro conditions. 
However even 3D culture models will have their limitations, most cells exist in vivo in 
close proximity to or even contact with other cells, 3D culture with multiple cell types 
would obviously not be a practical system to study EVs. 
  
Whatever the subclass of EVs their biogenesis begins with changes in the 
membrane. Lipid rafts are good candidates for sorting these regions and the membrane 
proteins within them. GM1, Lyn, flotillin-1 and stomatin all of which have been 
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associated with lipid raft domains have been detected in EVs (de Gassart et al., 2003). 
The study went on to demonstrate that the Lyn found in the EVs is further processed 
post-sorting by caspase-3. The fact post-translational modification is occurring in the 
EVs is compelling evidence for the presence of a deliberate packing process. Lipid rafts 
are known to associate with numerous protein types and the idea that rafts change the 
membrane properties allowing the curvature characteristic of vesicle formation would 
suggest that whole rafts are incorporated into EVs bringing with them their anchored 
proteins (de Gassart et al., 2003). 
  
Post-translational modification of proteins by ubiquitination is a common method 
for cells to divert proteins into degradation processes (Hicke., 2001). After 
ubiquitination the proteins are packaged into EVs formed in MVBs with the help of the 
ESCRT complexes. Some of these EVs will follow the normal degradation pathway and 
be trafficked to the lysosome while others could be released from the cell as exosomes. 
Research on the ubiquitination status of EV proteins shows that major 
histocompatibility complex class II (MHC-II) complexes are not ubiquitinated, 
(Gauvreau et al., 2009) suggesting that two mechanisms for loading these proteins into 
MVBs exist. Further work has shown that in immature dendritic cells a ubiquitin-
dependent method is used, and the receptors are degraded. After the cells have been 
activated however, a ubiquitin independent method is used, and the cells release EVs 
bearing the MHC-II complex that can interact with T cells (Buschow et al., 2009). In 
dendritic cells at least, the ubiquitination status of a protein appears to be sufficient to 
determine the fate of the vesicle containing that protein.  
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However, this is not the case for all proteins or all cells. Epstein Barr virus (EBV) 
protein LMP2A is highly ubiquitinated in exosomes (Ikeda and Longnecker, 2007) and 
the Nedd4 family interacting protein 1 which aids in the ubiquitination of proteins that 
cannot be bound by certain ubiquitin ligases is required for the Nedd4 family proteins to 
be present in exosomes (Putz et al., 2008). In cases such as these where the proteins are 
ubiquitinated prior to loading into MVBs it is likely that a second signal is present either 
on the protein to determine which vesicle type it is packaged into or on the surface of 
the vesicle that distinguishes those that head to the lysosome from those which are 
released. 
  
A candidate for this second signal is phosphorylation, another common protein 
modification which has also been implicated in selecting proteins destined for EVs. In 
Alzheimer’s disease the tau protein is aberrantly phosphorylated and then added to EVs 
which facilitates its spread (Saman et al., 2012). This would suggest that there are other 
parts to this system, possibly proteins that bind preferentially to the aberrantly 
phosphorylated tau protein to manipulate it into place within the EVs. A recent study 
has identified another fascinating possibility: They observed the common vesicle 
markers CD63 and CD81 co-localizing on the cell membrane with complex N linked 
glycans and then demonstrated that the same N linked glycans were necessary for the 
presence of a CD81 associated protein and subsequently the presence of CD81 in these 
EVs (Liang et al., 2014). The hypothesis they put forward, that the glycans identify 
discrete membrane domains that give rise to EVs, links well with the earlier work on 
lipid rafts. Proteins could then be directed to these domains by glycosylation or other 
modifications and either integrated into the membrane or anchored to it prior to the 
inward curvature. 
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Several less conventional processes for the sorting of individual proteins have also 
been reported to date. The degradation of the AP2 adaptor complex drives the binding 
of heatshock protein 70 (HSC70) and Alix, both commonly found in EVs, to a site on 
the transferrin receptor prior to it being sorted into EVs (Géminard et al., 2004). 
Interestingly this study actually identifies a peptide sequence on the transferrin receptor 
with which both proteins can interact, and this sequence encompasses the internalisation 
sequence for this receptor. In B cells the sorting of CD23, another membrane protein, 
into exosomes was shown to be dependent on both CD23 sheddase and a disintegrin and 
metalloproteinase domain-containing protein 10 (ADAM10). These enzymes act 
together to cleave the CD23 from the membrane prior to its entry to the endosomal 
sorting pathway (Mathews et al., 2010).  
 
A recent study has identified the KRas mitogen activated protein kinase kinase 
(MEK) signalling pathway as being responsible for regulating the sorting of argonaute 2 
(Ago2) into exosomes from colon cancer cells (McKenzie et al., 2016). Ago2 is a 
critical component of the RNA induced silencing complex (RISC) and can bind to 
RNA. Ago2 sorting into exosomes regulates in turn the levels of three candidate miRNA 
sequences (McKenzie et al., 2016). Whilst neither KRas or MEK are the actual 
mediators of the sorting the fact they are involved in its regulation is highly significant 
for cancer research as mutations to either or both genes are common to many cancers 
suggesting by extension a mechanism by which vesicle packaging can be altered in 
cancerous cells compared to normal cells. 
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1.4.2. Nucleic acids 
Like protein sorting, despite the circumstantial evidence for a sorting process for 
nucleic acids into EVs the details of such a process are still scarce. A limited study using 
differing serial centrifugation protocols to separate the different subclasses of EVs by 
size alone identified differences in the RNA profiles of the subclasses. Their data, whilst 
allowing for the limitations of the method, is interesting. They showed that apoptotic 
bodies contained large quantities of ribosomal RNA whereas exosomes contained very 
little and microvesicles contained little or no RNA (Crescitelli et al., 2013). These 
differences not only indicate the presence of a sorting mechanism but also offer hope for 
distinguishing between the EV subclasses in the future. Although they went on to note 
that the EVs displayed significant variation in size and appearance under electron 
microscopy even within the same size brackets. This would suggest either that cells are 
producing different types of each subclass at any given point in time or that the size of 
EVs is not strictly controlled during their release. A similar study carried out on EVs 
produced by a panel of prostate cancer cell lines showed that the genomic DNA content 
varied between cell lines and within subpopulations (Lázaro-Ibáñez et al., 2014). 
  
It has been hypothesised by several groups that a signalling motif exists in RNA 
destined for EVs that are released from the cell; this hypothesis was recently proved for 
miRNA. The group used microarray analysis to identify miRNA enriched in EVs 
compared to the whole cell and then performed sequence alignment to identify 
conserved regions to each set. They were able to identify two four base pair motifs 
(GGAG and CCCU) that were common to the miRNAs enriched in the EVs alongside 
several longer motifs that were common to miRNA enriched in the cells (Villarroya-
Beltri et al., 2013). Using site directed mutagenesis they were able to subsequently 
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reverse the enrichment of miR-601. They went on to demonstrate that the ribonuclear 
protein hnRNPA2B1 could recognize this motif and was responsible for packing these 
miRNA into the EVs when sumoylated (Villarroya-Beltri et al., 2013). This is a huge 
landmark for the field of EV research, it has given us the first part of a system that we 
can exploit for medical purposes or use to help map the rest of the system in detail for 
the first time.  
 
An alternative mechanism was proposed by another group. This group approached 
the sorting from a homeostatic approach, demonstrating that an abundance of the target 
for a given miRNA leads to its depletion in MVBs and exosomes whereas 
overexpression of the miRNA itself leads to it being enriched in MVBs and exosomes 
(Squadrito et al., 2014). This suggests that EVs actually do function as a form of waste 
disposal, albeit one that mostly functions in response to stress caused by artificially 
driven overproduction rather than during maturation as was seen with the transferrin 
receptor. 
 
1.4.3. Lipids 
Whilst their formation and size differ, the lipid membrane composition of these 
EVs is similar and often reflects the producing cell. The cholesterol to phospholipid 
ratio of the vesicular membrane is similar to that of the plasma membrane (Vidal et al., 
1989), however there are some major differences. The lipid bilayer of these EVs is 
typically enriched for cholesterol, sphingomyelin, ceramide (Laulagnier et al., 2004; 
Trajkovic et al., 2008) and PS but interestingly not lysobisphosphatidic acid which is 
typical of the intraluminal vesicles of MVB where exosomes are formed (Brouwers et 
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al., 2013; Karine Laulagnier et al., 2004; Llorente et al., 2013; Wubbolts et al., 2003). 
The particular distribution of the lipids in the vesicle membrane is highly characteristic 
of lipid rafts and these domains have been linked to the production of exosomes 
(Matsuo et al., 2004). Another study used the membrane analysis techniques 
fluorescence anisotropy, nuclear magnetic resonance and electron spin resonance to 
compare the physical properties of EV membrane with plasma membrane. They 
discovered that despite the similarities in major contents, the membrane of these EVs 
has different properties; it appears to be more fluid with a very rapid “flip-flop” between 
the membranes (Brouwers et al., 2013). 
  
As the life cycle of a cell progresses its needs change and it is reasonable to 
assume that the EVs produced will change accordingly. A study that followed exosome 
production by maturing reticulocytes showed that their physical properties changed 
throughout the maturation period. By the end of the seven-day period the cells produced 
fewer exosomes that were around 10% larger than earlier days (Carayon et al., 2011). 
They also observed differences in the lipid composition of the exosomes, with those 
produced at day 2 having a four times higher ratio of cholesterol esters to free 
cholesterol when compared to those from day 4 and 7 (Carayon et al., 2011). It is 
possible that similar changes occur in other models, but this has not yet been reported. 
 
1.5. Uptake of EVs 
There are a variety of well-established mechanisms by which materials from the 
extracellular spaces can be internalised across the plasma membrane of a cell. 
Interestingly the uptake of EVs appears to make use of nearly all of these. Endocytosis 
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is a well-studied process that involves the cell engulfing the molecule in an energy 
intensive process. Because it relies on the expenditure of energy its involvement with 
EV uptake can be simply tested by incubating the cells at 4oC (Christianson et al., 2013; 
Escrevente et al., 2011), which shows that internalization of EVs is dramatically 
reduced by this step. There are different types of endocytosis, one of these is clathrin 
mediated. Clathrin is a well-characterised protein that forms a triskelion shape made up 
of three heavy and three light chains. These chains assemble together to form a coated 
pit which deform the cells membrane until it collapses into a vesicular bud. The 
vesicular bud will then pinch off; now inside the cell it is uncoated and fuses with the 
endosome releasing its contents (Kirchhausen, 2000). Blocking of this process either by 
treatment with chlorpromazine (Escrevente et al., 2011) or inhibition of dynamin2 
(Vallee et al., 1993) was shown to reduce the uptake of EVs. There are also clatherin- 
independent pathways; one of these relies on caveolae. Caveolae are small depression in 
the outer membrane formed by the protein caveolin-1 (Doherty and McMahon, 2009). 
the silencing of this protein was shown to impair the uptake of EVs in one experiment 
(Nanbo et al., 2013) but in another set up was seen to increase the uptake of EVs 
(Svensson et al., 2013). The reasons for this duality are unclear, whilst it indicates the 
potential for some flexibility in this system, it also could suggest that in some cells the 
silencing of caveolin-1 causes changes to the membrane composition, possibly 
lessening its rigidity, that make the uptake of EVs more efficient. 
  
Macropinocytosis is another endocytic pathway, albeit a dramatically different 
one. The membrane forms large distinctive protrusions from the cell surface these can 
then surround an area of the extracellular space which is then internalized either by 
direct fusion with the plasma membrane or by fusion with another protrusion (Swanson, 
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2008). As with the other mechanisms researchers have blocked this process by the 
inhibition of Na+/H+ exchange or by small molecule inhibitors of ras-related C3 
botulinum toxin substrate (rac-1) 1) (Fitzner et al., 2011) both of which have reduced 
EV uptake by microglia. However, there are other studies using different inhibitors that 
have found no impact on EV uptake (Christianson et al., 2013; Feng et al., 2010; Nanbo 
et al., 2013). 
  
Phagocytosis is a highly specialised form of endocytosis that is normally 
associated with the internalisation of large objects like bacteria by macrophages. 
However, an interesting study with leukaemia cell-derived EVs showed that they could 
only be taken up by macrophages and not other cells suggesting this is occurring by 
phagocytosis (Feng et al., 2010). Further experiments using inhibitors of 
phosphoinositol 3 kinase (PI3K) (Feng et al., 2010), to stop phagocytosis, and EVs 
stained with the pH sensitive dye pHrodo, which can visualise them inside the acidic 
phagosomes, (Montecalvo et al., 2012) confirm a role of phagocytosis in uptake of EVs. 
  
Because of the fluid properties of membrane, it is also possible that EVs can be 
taken up by direct fusion with the plasma membrane. Direct fusion between two lipid 
bilayers can occur readily in an aqueous environment and this process can be visualised 
by fluorescent lipid dequenching. Experiments using this technique have shown the 
possibility of some EV uptake via this pathway (Parolini et al., 2009) it is likely that this 
mechanism owes much to the lipid raft like membrane composition of EVs (Valapala 
and Vishwanatha, 2011). What is clear however is that this is a pH-dependent process 
which is likely to limit its capacity under physiological conditions (Parolini et al., 
2009). 
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It is apparent from the range of research being done that there is no one pathway 
responsible for EV uptake. There is good, albeit at times contradictory, evidence for 
each of them being involved in EV uptake. There are a few reasons why this isn’t a 
simple question to answer. The first lies in the limitations of the tools available to 
researchers to study this. Uptake of EVs can be visualised using a range of lipophilic or 
carboxyfluorescein succinimidyl ester (CFSE) dyes which whilst very stable can 
potentially introduce artefacts. The lipophilic PKH dyes in particular will form micelles 
in organic material. Another possible approach to visualising EV uptake is to use 
fluorescence tagged versions of marker proteins, whilst these are highly specific there 
are two uncertainties. First there is an uncertainty over whether every EV in your 
sample will carry that protein and second there is the uncertainty over whether the 
addition of a bulky fluorophore will change the behaviour of the tagged protein. 
Currently without super resolution adaptation the physical resolution of fluorescence 
microscopy is also inadequate to resolve an individual vesicle meaning that unless they 
aggregate, or the dye diffuses throughout the receptor cell the quantification of the 
uptake will not be accurate. 
  
Aside from the technical difficulties there are two different but overlapping 
problems introduced by the nature of the EVs themselves. It is possible that different 
populations of EVs are taken up preferentially by different routes depending on the cell 
type they are docking with. This is probably mediated by protein/protein or protein/ 
lipid interactions between the EV and the target cell. If this is the case then manual 
transfer of EVs between 2D culture models is going to create a few issues. Firstly, any 
EV sample will contain multiple subtypes and secondly, they may not be delivered in 
either a physiologically relevant dose or to an appropriate cell type leading to the cells 
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taking them up in ways they wouldn’t normally do so or less efficiently than other cells. 
 
1.6. The role of EVs in normal processes 
To date EVs have been found in a range of biological fluids including: urine (Sato 
et al., 1990), saliva (Palanisamy et al., 2010), synovial fluid (György et al., 2012), 
cerebrospinal fluid (Marzesco et al., 2005; Street et al., 2012), bronchialveolar fluid 
(Admyre et al., 2003), nasal fluid (Lässer et al., 2011), uterine fluid (Al-Dossary et al., 
2013; Griffiths et al., 2008), amniotic fluid (Keller et al., 2007), breast milk (Lässer et 
al., 2011b), blood (Chargaff and West 1946; Wolf, 1967) and seminal plasma (Saez et 
al., 2003). The fact that EVs have been discovered in such a wide range of fluids in 
healthy individuals indicates a variety of roles in normal processes. The EVs in urine 
like those initially found in blood were suggested to be involved in the disposal of 
unwanted proteins and lipids from the cell (van Balkom et al., 2011) but it is also 
possible that they can signal along the nephrons (Knepper and Pisitkun, 2007). 
 
 In saliva EVs have been shown to contain tissue factor and can initiate blood 
clotting of vesicle free plasma (Berckmans et al., 2011), which led to the interesting 
suggestion that these EVs could be an evolutionary keepsake where licking a wound 
initiates the healing process. EVs from synovial fluid have been shown to carry 
functional integrins which can mediate anchorage to cell surface adhesion molecules 
and possibly deliver autoantigens (Skriner et al., 2006). In the male reproductive system 
proteins are transferred by EVs to the immature sperm cells during their transit through 
the epididymis (Sullivan et al., 2005). There are many hypothesised roles in mother-
foetal communication and placental organization currently being explored; immuno-
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competent EVs have been discovered in breast milk raising the possibility of a role in 
conferring viral resistance (Admyre et al., 2007). 
  
EVs have long been studied in the context of coagulation and the increased 
formation of platelet-derived EVs have been shown to enhance thrombin generation and 
induce thrombosis in different experimental conditions (Chen et al., 2013; Suades et al., 
2012). The immune system seems to make extensive use of EVs with mature dendritic 
cell derived EVs being potent inducers of antigen specific immune responses (Segura et 
al., 2005). A similar role has been observed with keratinocyte derived EVs in mice 
(Kotzerke et al., 2013); while T-regulatory cells produce EVs that contain miRNA 
capable of suppressing pathogenic T-helper cells (Okoye et al., 2014). In recent years it 
has also become apparent that EVs are an important aspect of the interactions between a 
foetus and a mother during pregnancy (Arck and Hecher, 2013; Chua et al., 1991) with 
dysregulation in this process linked to preeclampsia and miscarriages. In lung injury 
EVs derived from marrow cells can modulate the expression of prosurfactant B in 
marrow cells starting the repair of this process (Aliotta et al., 2007). 
  
Bone calcification is another area in which EVs have been investigated for many 
years, our current understanding suggests that these EVs originate from the plasma 
membrane of mineral forming cells and can then go on to induce calcification during 
endochondral bone formation (Golub, 2009). These EVs contain and can transfer bone 
morphogenetic protein, VEGF and bone sialoprotein (Nahar et al., 2008). EVs from 
hepatocytes have also been shown to transfer proteins in liver (Conde-Vancells et al., 
2010, 2008). This signalling has been shown to function both in the cases of liver 
damage (Royo et al., 2013) and in normal cellular proliferation (Lee et al., 2008). 
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1.6.1. Role of EVs in disease states 
With such a wide and varied number of roles within the human body it is 
inevitable that EV signalling and its dysregulation will play a part in different disease 
states. 
1.6.1.1. Cardiac disease 
Following a myocardial infarction, EVs from cardiac progenitor cells have been 
shown, by transfer of conditioned media from cardiac progenitor cells with and without 
EVs, to limit the damage by inhibiting cardiomyocyte apoptosis thereby improving the 
heart’s ability to function (Barile et al., 2014). They also play a role in mediating the 
cytoprotective action of mesenchymal stromal cells in response to hypoxia induced 
pulmonary hypertension (Lee et al., 2012). However, during myocardial ischemia EVs 
are produced bearing the hypoxia inducible factor-1α (HIF-1α) which initiates the 
production of TNF-α by macrophages which is damaging to the cardiomyocytes (Yu et 
al., 2012). 
 
1.6.1.2. Neurological diseases 
In neurological pathologies EVs have been implicated in a variety of roles. Most 
recently they have been shown as a mechanism for the release of prions (Arellano-
Anaya et al., 2015). The EVs released by prion infected cells have been shown to have 
distinctive structural differences when compared to normal EVs with an increased 
number of membranes and a larger diameter (Coleman et al., 2012). EVs have also been 
linked to Alzheimer’s disease, astrocytes release highly pro-apoptotic EVs (Wang et al., 
2012) driving the later phase of the disease, but they have also been shown to have a 
role in clearing the amyloid-β fibrils (Yuyama et al., 2012). In Parkinson’s disease EVs 
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have been shown to transfer α-synuclein helping to spread the disease through the 
central nervous system (CNS) (Boelens et al., 2014) and a similar phenomenon is seen 
in amyotrophic lateral sclerosis with the transfer of superoxide dismutase -1 (SOD1) 
(Gomes et al., 2007). 
  
Multiple sclerosis (MS) is another neurological condition where EVs involvement 
is well studied. In MS EVs can both disrupt the blood brain barrier which allows the 
migration of inflammatory cells into the CNS and induce the migration of those 
inflammatory cells (Jy et al., 2004; Sheremata et al., 2006). Additionally, these EVs are 
found in the plasma of patients during relapses offering a potential prognostic marker 
(Sheremata et al., 2006). There is also some evidence beginning to appear that links 
EVs to strokes, with a raised level of EV release from activated endothelial cells being 
correlated with ischemic events and neurological damage in patients (Lee et al., 2012). 
 
1.6.2.  Role of EVs in cancer 
1.6.2.1. Anti-tumorigenic effects 
EVs appear to be similarly duplicitous and flexible in their functions in cancer 
development with research revealing both pro and anti-tumorigenic properties and traits. 
This is to be expected if cells are producing different types of EVs at different stages of 
their life cycle and in response to different stimuli or changing conditions in the 
surrounding environment. 
1.6.2.1.1. Immune activating effects 
In vitro studies have shown that EVs produced by melanoma cell lines contain 
antigens which can exert a potent effect on dendritic cells upon their uptake causing 
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CD8+ T cell dependent anti-tumour effects in established murine tumours (Wolfers et 
al., 2001). This discovery has actually led to a dendritic cell-based immunotherapy 
model being investigated. It is however extremely peculiar that a cancer cell would 
produce EVs capable of mobilising the immune system against them in such a way and 
it is doubtful that these EVs are constitutively secreted. A likely explanation for this 
could be they are released for a short window during which dendritic cells attract the T 
cells into the tumour microenvironment to support angiogenesis and once there they 
produce a signal to stop the production of those EVs to stop them exerting an anti-
tumour effect. 
 
1.6.2.1.2. Induction of apoptosis 
The other major anti-tumorigenic role of these EVs is induction of tumour cell 
apoptosis. Pancreatic tumour cells produce EVs that are reported to increase Bax 
expression whilst decreasing BCL-2 expression, driving tumour cells towards the 
mitochondrial apoptotic pathway (Ristorcelli et al., 2009). Another anti-survival effect 
of this interaction is decreased expression of the intra-nuclear target of the Notch-1 
signalling pathway and activation of the apoptotic pathway (Ristorcelli et al., 2009). 
The production of EVs capable of decreasing their own proliferation is an extremely 
puzzling trait for a cancer cell to possess, however it is possible that these EVs aren’t 
intended to target other tumour cells in vivo, but to target cells of the immune system 
but with the absence of these targets in vitro are being taken up by the tumour cells. 
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1.6.2.1.3. Therapy vehicles 
There are other more indirect ways in which EVs can have anti-tumorigenic 
effects. One of these is as a drug delivery vehicle, EVs being lipid enclosed and 
potentially generated from a patient's cells, are an attractive prospect for a drug delivery 
vehicle and this review (Tominaga et al., 2015) gives a nice summary of the range of 
compounds that are currently being studied or have already been successfully loaded 
into EVs. One of the more interesting studies has been performed with curcumin, 
experiments that deliver this drug encapsulated in EVs show it to have a significantly 
improved absorption and bioavailability over unencapsulated curcumin (Sun et al., 
2010). This approach is now in clinical trials and has yielded promising results in 
pancreatic cancer patients (Gupta et al., 2013). This approach, the direct loading of 
drugs into EVs is one of two avenues for therapeutic delivery involving EVs.  
 
The second is an older one based around the immunogenic capacity of exosomes 
released from dendritic cells, a field summarised well by the review of Chaput et al. 
(2006). It is based around the ability of dendritic cells when challenged by tumour 
antigens to produce EVs that can stimulate the induction of cytotoxic T cells against the 
tumour (Zitvogel et al., 1998). One of the great advantages to this approach is that the 
treatment is uniquely tailored to an individual patient using their own cells to generate a 
personalised vaccine against their own tumour removing immunogenicity issues and 
optimizing efficiency. This concept has been proved on a scale suitable for medical 
application and has led to clinical trials in both melanoma and lung cancer patients with 
mixed results (Escudier et al., 2005; Morse et al., 2005). 
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1.6.2.1.4. Biomarkers 
A simple search on PubMed for EVs and biomarkers reveals that there are nearly 
2000 papers on the subject and 1500 of these have been published since 2009. Whilst 
this rapid expansion owes much to improving technology it is also partly a result of the 
changing environment in cancer therapy today to place a greater emphasis on 
personalised treatment. Because EVs are produced by cancer cells and are found in 
biological fluids they have huge potential as both diagnostic and prognostic markers. In 
oral cancer for instance the availability of EVs in saliva offers the tantalising prospect of 
a “liquid biopsy” where a simple saliva sample could replace the invasive excision of 
tissue for analysis. A recent study showed that saliva from oral cancer patients contained 
a higher number of EVs and that there is a limited degree of molecular differences 
between the EVs of healthy individuals and cancer patients (Zlotogorski-Hurvitz et al., 
2016). The findings of this paper are limited by the techniques they used – namely 
ELISA and western blotting but other studies have begun to use mass spectrometry 
techniques to screen the contents of salivary EVs (Kawahara et al., 2016; Winck et al., 
2015).  
 
There are numerous similar studies using the same kind of screening of EVs from 
biological fluids summarised in several recent reviews (Ciardiello et al., 2016; 
Kinoshita et al., 2016). In the last few years a company in the US, Exosome 
Diagnostics, has completed clinical trials of an EV based diagnostic kit for certain brain 
cancers and is aiming to bring them to clinics in America in the next 12 months, the 
company also intends to expand its repertoire of kits into other cancers. 
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1.6.2.2.  Pro-tumorigenic effects  
Alongside these anti-tumour effects EVs have been seen to play a role in many of 
the hallmarks of cancer described by Hanahan and Weinberg (Hanahan and Weinberg, 
2011, 2000). 
 
1.6.2.2.1. Angiogenesis 
Angiogenesis is the development of new blood vessels within the growing 
tumorous mass. A paper from 2002 demonstrated that EVs rich in sphingomyelin 
released from cancer cells could promote angiogenesis (Kim et al., 2002). More recent 
papers suggest that both protein and RNA species within the EVs could also play a part. 
Cell lines derived from both renal cancer and leukaemia have been shown to produce 
EVs that promote angiogenesis in endothelial cells (Chen et al., 2014; Mineo et al., 
2012). The renal cancer cell derived EVs increased VEGF expression at both the mRNA 
and protein levels by down regulating hepatocyte cell adhesion molecule (hepaCAM), 
suggesting that the EVs contain a miRNA for the hepaCAM mRNA (Chen et al., 2014). 
The leukaemia derived EVs promoted angiogenesis via the activation of the proto-
oncogene tyrosine protein kinase (Src) possibly indicating the presence of a Src binding 
kinase in these EVs (Mineo et al., 2012). 
  
Cancers are characterised by rapid replication, this accelerated growth frequently 
leads to hypoxia as the growing cancer becomes too large for local vasculature to 
maintain. In a recent study researchers cultured hypoxia resistant multiple myeloma 
cells in a state of permanent hypoxia, they found that these cells produced a greater 
number of EVs than the parent cell line in similar conditions (Umezu et al., 2014). They 
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went on to demonstrate that these EVs contained significant quantities of miR-135b, 
which targets the factor inhibiting hypoxia inducible factor 1 (FIH-1) and was shown to 
suppress this protein in endothelial cells. This action resulted in an increase in the 
formation of endothelial tubes (Umezu et al., 2014). A particularly fascinating paper 
released in 2008 describes a novel way in which EVs can contribute to angiogenesis. In 
a glioma model they demonstrated that the EVs can transfer an oncogenic mutated 
version of the EGFR, this mutant version is associated with aggressive brain tumours 
but only a small percentage of cells may express this receptor (Al-Nedawi et al., 2008) 
those cells that do express it are shown to transfer it via EVs to those that don’t. The 
arrival of this oncogenic receptor changes the regulation of genes under its control 
promoting angiogenesis. Given that this problem is common to many, if not all cancer 
types, it is likely that similarly capable EVs can be produced by other cancer cell lines 
under these conditions. However, it is worth noting that there are some studies that 
show EVs inhibiting angiogenesis. One study showed that miR-29a and miR-29c 
transferred by EVs inhibited angiogenesis in a gastric cancer model (Zhang et al., 2016). 
The weakness of this study is that it uses overexpression of miR-29a and c in HEK293T 
cells to produce EVs carrying miR-29a and miR-29c which are then transferred to 
gastric cancer cells. Whilst there may be some of these RNA species in non-engineered 
EVs in the TME it may not be present in sufficient quantities to drive these changes. 
 
1.6.2.2.2. Immune evasion and suppression 
As discussed previously, cancer cell EVs provide a range of tactics for immune 
activation. Perhaps characteristically, other tumour vesicle types have been shown to 
have immuno-suppressive roles; melanoma and colorectal cancer cell derived EVs 
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contain the death ligands: factor related apoptosis ligand (FasL) and TNF related 
apoptosis inducing ligand (TRAIL) which can trigger the apoptotic death of activated T 
cells (Andreola et al., 2002; Huber et al., 2005). Ovarian tumour derived EVs can also 
impair T cell receptor signalling through down regulation of CD3-ζ chain expression 
impairing T cell mediated immune functions (Taylor et al., 2003). In mice with OVA-
expressing tumours the immune responses could be suppressed by MHC class II bearing 
EVs produced by the tumour cells (Yang et al., 2012).  
 
Lymphoblastoid cell lines were also shown to produce “killer” EVs containing the 
Fas ligand and bearing the MHC class II allowing them to reduce T cell responses by 
inducing apoptosis in these cells (Klinker et al., 2014). A subtler approach is adopted by 
prostate cancer cell lines, which produce EVs bearing ligands for the NKG2D receptor 
on their surface allowing them to down-regulate NKG2D and its cytotoxic response in 
natural killer cells and CD8+ T Cells in a dose dependent fashion (Lundholm et al., 
2014). In cervical cancer, EVs are produced bearing ectonucleotidases, which hydrolyse 
adenosine phosphates to release adenosine, these can then suppress the proliferation and 
activation of cytotoxic CD8+ T cells in vitro by production of large amounts of 
adenosine (de Lourdes Mora-García et al., 2016). Another recent paper demonstrates a 
similar ability in leukaemia but again one mediated by a different mechanism; in this 
case EVs produced by leukaemia cells carry both the tax oncoprotein and a range of 
miRNA which activate nuclear factor kappa B (NF-κB) and cause an increase in the 
induction of apoptotic markers (El-Saghir et al., 2016). The range of mechanisms used 
by cancer cell derived EVs to reach the same objective is a real insight into the extent of 
cancers exploitation of this system. 
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1.6.2.2.3. Suppression of apoptosis 
Like immune evasion the bypassing or prevention of apoptosis is another 
necessary step for a developing tumour. Extracellular survivin is a potent apoptosis 
inhibitor and has been shown to be released in EVs produced by HeLa cells following 
irradiation to trigger a stress response (Khan et al., 2009). Bladder cancer cell lines were 
shown to produce EVs capable of inhibiting apoptosis in a more complex fashion, they 
upregulated synthesis of B cell lymphoma 2 (Bcl-2) and cyclin D1 whilst reducing the 
levels of Bax and caspase 3 suggesting a mixture of mRNA and miRNA for the affected 
proteins being present in the EVs (Yang et al., 2013). It is worth considering that these 
responses are likely to be triggered by stress stimuli like hypoxia and that the 
production of proteins such as survivin will be critical to the survival of the producing 
cell. The release of this hard-won advantage into the extracellular space in EVs seems 
like a waste of work by the cell; however, the picture is not as simple as one cell, or a 
small group, of them fighting to avoid apoptosis. Cancer cells will produce a range of 
different EVs creating a communal pool for all cells in the surrounding area to access. 
Some of these EVs will be “reserved” or targeted for certain cells. This would represent 
a premade source of survivin or other urgently required molecules for all cells to utilise.  
 
When EVs released from CD133+ breast cancer cells are taken up by receptor 
positive cells the proliferation of these cells is increased and apoptosis following 
doxorubicin treatment is suppressed. However, the same effect was not observed after 
uptake of CD133- cells indicating a change in packaging of EVs in the different breast 
cancer cell lines (Shi et al., 2015). Recent data appears to show that this aspect of EVs 
contribution to cancer is driven by exchanging EVs between the stromal and cancer 
cells. Experiments with an osteosarcoma model show EVs from mesenchymal stem 
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cells that have been exposed to stress caused osteosarcoma cells to become more 
resistant to apoptosis. Further experiments showed that these EVs transfer miRNA 
which regulate the expression of PTK2 a versatile non-receptor tyrosine kinase with 
roles in cell cycle progression proliferation and apoptosis (Vallabhaneni et al., 2016). 
There are other examples of the signalling going in the opposite direction, EVs 
produced by various cancer cell lines have all been shown to activate the mitogen 
activated protein kinase (MAPK) pathway in monocytes which improves their survival 
in inflammatory conditions (Song et al., 2016). What these recent revelations suggest is 
that there is a reciprocal relationship between the stromal cells and the cancer cells to 
keep each other alive in the face of changing conditions to support the long-term 
development of tumour. 
 
1.6.2.2.4. Activation of stromal cells 
EV exchange between the cancerous and non-cancerous cells of a TME is not just 
used to keep cells alive. Cancer cells have been shown to produce EVs that activate or 
differentiate the surrounding non-cancerous stromal cells. In the case of fibroblasts this 
activation is particularly useful to the developing tumour. A single dose of EVs from 
prostate cancer cells was able to transform bone marrow mesenchymal stem cells or 
patient fibroblasts into myofibroblasts (Chowdhury et al., 2015; Webber et al., 2015). 
These αSMA positive cells were seen to secrete high levels of VEGF-A, HGF and 
MMP1,3 and 13, which enable fibroblasts to drive tumour angiogenesis, proliferation 
and invasion respectively (Chowdhury et al., 2015). It was demonstrated that a fraction 
of the total cellular TGFβ was localized to the EVs (Chowdhury et al., 2015) which 
enabled them to drive the myofibroblastic differentiation upon uptake.  
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When cells were treated with a similar dose of soluble TGFβ however the cells 
were seen to differentiate into morphologically similar myofibroblasts, but those cells 
were unable to promote angiogenesis or tumour proliferation (Webber et al., 2015) in 
the same way as those activated by EV delivered TGFβ. This suggests that the delivery 
of TGFβ to cells via EVs is either targeted to a specific subset of the fibroblast 
population or that because the TGFβ is delivered alongside other components its activity 
in the receptor cell is modified thereby allowing it to secret the beneficial proteins in 
sufficient quantities. It was previously demonstrated that the TGFβ is neither detectable 
in EVs from every prostate cancer cell line nor is it enclosed within the EVs but bound 
to their surface by betaglycan (Webber et al., 2010). In a more recent publication it was 
shown that the ability of the EV tethered TGFβ to activate fibroblasts requires the 
presence of heparan sulphate chains on the surface of the EVs (Webber et al., 2015). 
What is interesting about this data is it illustrates the importance and potential 
complexity of the relatively unstudied EV surface interaction with other cells and 
proteins. With the large variation of heparan sulphate additions possible it is likely that 
different chains result in a slightly different effect of the protein on the target.  
 
Recently, large oncosomes have also been shown to activate prostate fibroblasts 
through AKT1 kinase activity which is specific to this class of EVs in the plasma of 
prostate patients (Minciacchi et al., 2017). The uptake of these large oncosomes by 
fibroblasts causes the AKT1 kinase to activate the MYC pathway allowing the 
reprogramming of the cells. In a pancreatic cancer model a similar activation of 
fibroblasts on EV uptake was shown to be mediated by EV delivered miR-155 (Pang et 
al., 2015). The fact this ability appears to be common to EVs produced by different 
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tumour types each of which uses different mechanisms to produce the same effect 
reflects how beneficial the activated fibroblasts are to the developing tumour. 
 
1.6.2.2.5. Invasion and metastasis 
Metastasis is a complex series of events that contribute to cancer cells being able 
to invade tissues as far as the bloodstream or lymphatic vessels and then travel to a new 
site and propagate again. This process can be broken down into a number of required 
phases many of which EVs have been shown to facilitate. The first step is the 
breakdown of the extracellular matrix freeing space for cells to move. Both cancer cells 
and neighbouring stromal cells have been shown to produce EVs that contain high 
levels of various protease enzymes involved in the degradation of cell-cell and cell-
matrix junctions (Shimoda and Khokha, 2013). These include the matrix 
metalloproteinase MMP14 which is normally a membrane-bound protein, research has 
shown this can be released from the cells on vesicle membranes allowing them to access 
membranes the cell cannot reach (Hakulinen et al., 2008).  
 
Following the breakdown of cellular junctions, the cancer cells need to be able to 
cross the weakened extracellular matrix requiring dramatic reorganization of the 
cytoskeleton, something that EVs produced by breast cancer cells have been observed 
doing (Wang et al., 2014). In another study in breast cancer, EVs containing miR-200 
family microRNA were shown to transfer these to non-metastatic cells which led to 
them acquiring metastatic potential (Le et al., 2014). The miR-200 family regulates 
epithelial-mesenchymal transition (Yuan et al., 2014) a process where epithelial cells 
become less adherent and more capable of migration and one that is considered to be an 
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essential part of the metastatic process. Experiments in bladder cancer have identified 
several other miRNAs that are abundant in the EVs produced by the cells including 
miR-23B, miR-224 and miR-291. Further investigations have shown that blocking 
vesicle release by inactivation of Rab27B blocked the acquisition of metastatic 
properties (Ostenfeld et al., 2014). The interesting thing about this experiment is that the 
miRNA in question are tumour suppressing. The group’s hypothesis is that in order to 
progress to metastasis the tumour must remove these using the vesicle export system. 
Obviously, this doesn’t explain how EVs generated by breast cancer cells can drive the 
generation of metastatic traits. However, what it does reveal is the intricacies of this 
system, EVs containing these unwanted molecules must end up somewhere, the 
question of where they are going and how they are directed there is an important one for 
the future.  
 
An alternative strategy has been demonstrated in a different breast cancer model, 
working with cancer models in orthotopic mice a group has shown that fibroblasts 
release EVs that cause the mobilization of Wnt-planar cell polarity signalling in the 
cancer cells driving metastasis (Luga et al., 2012). This is a fascinating revelation 
particularly as it was identified in a live animal model, but it is unlikely to be the whole 
story. It is highly probable that before fibroblasts release such EVs they must be 
reprogrammed by the cancer cells, possibly by EVs which they have produced first. A 
more recent paper has identified something similar in a pancreatic cancer model. 
However, in this model they used CAFs in culture as opposed to an animal model. They 
showed that these EVs containing a complex of annexin 6 LDL receptor related protein 
and thrombospondin 1 (TSP1) which can only form in the CAFs is necessary for the 
cancer cells to develop the invasive properties (Leca et al., 2016).  
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EVs inherent stability in the bloodstream means they can reach distant targets. 
This means they can potentially travel ahead of detached cancer cells and prepare the 
ground for their arrival. This is the “seed and soil” theory of metastasis and it is still a 
controversial one. Experiments in mice models have shown that EVs released by 
melanoma cells are targeted to the lymph nodes and trigger changes in extracellular 
matrix deposition and vascular proliferation, along with changes that help recruit the 
melanoma cells (Hood et al., 2011). Such EVs are likely to be common to other cancers 
too particularly those with preferential metastatic destinations like breast and prostate 
cancers. A recent study showed this to be partially true in metastatic osteosarcoma cells, 
they produced EVs which not only preferentially localised to the lungs, a major site of 
osteosarcoma metastases, but were also capable of increasing metastatic behaviour in 
poorly metastatic clones (Macklin et al., 2016). These EVs contain a range of proteins 
with roles in processes essential for metastasis (Macklin et al., 2016). Another group 
has also focused on the protein contents of EVs in relation to metastasis identifying 
EGF-like repeat and discoidin I-like domain-containing protein 3 (EDIL3) as being 
critical for the acquisition of invasive properties of breast cancer cells and accelerating 
lung metastasis in vivo (Lee et al., 2016). 
 
1.6.2.2.6. Drug resistance 
The final major role these EVs can serve in cancers is supporting drug resistance. 
This can be acquired through a variety of mechanisms and EVs have been shown to 
both directly play a role in the resistance and act to transfer this resistance through the 
tumour environment. Studies in platinum resistant ovarian cancer cells have shown that 
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in response to cisplatin treatment cells dramatically increase their production and 
release of EVs and the EVs contain high concentrations of cisplatin (Safaei et al., 2005). 
It is assumed that these EVs are designed to take the cisplatin on a one-way trip 
possibly to be removed in the urine. Such a mechanism could be present in other cancer 
cells as a response to other drugs but has not yet been seen. Another method of EVs 
aiding in resistance is seen with the antibody-based Herceptin (trastuzumab). Human 
epidermal growth factor receptor 2 (HER-2) overexpressing tumour cell lines have been 
shown to release EVs with a full length and active form of the HER-2 molecule on their 
surface capable of binding the trastuzumab in place of the target cells (Ciravolo et al., 
2012). Although it hasn’t been seen with other similar treatments, all antibody-based 
therapies will be vulnerable to a similar mechanism.  
 
Vesicle transfer has been shown to confer resistance across a population in several 
models to date. In prostate cancer docetaxel resistant cells can transfer resistance to both 
docetaxel and doxorubicin sensitive cells. This is thought to be via transfer of the 
multidrug resistance protein 1 (MDR-1)/P-glycoprotein (P-GP) transporter (Corcoran et 
al., 2012). Vesicle mediated transfer of docetaxel resistance has also been studied in 
breast cancer models with one group implicating the transfer of miRNAs notably miR-
100 miR-222 and miR-30a. Interestingly one of the pathways these miRNAs are 
involved in is membrane vesiculation (G. Chen et al., 2014; Mineo et al., 2012). The 
implication of this is that increased vesicle production is involved in the resistance to 
the drug in a similar fashion to ovarian cancer cells and cisplatin. The same group has 
also identified the vesicle-mediated transfer of P-GP transporter to sensitive cells as a 
mechanism of conferring resistance (Lv et al., 2014) P-GP is a membrane protein 
transporter capable of transporting drugs rapidly out of the cell. 
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Transfer of resistance is not just limited to cancer-to-cancer cell transfers. Normal 
cells have been shown to gift cancer cells with resistance through vesicular transfer of 
miRNA and proteins. In a model using multiple myeloma cells and bone marrow 
stromal cells EVs produced by the stromal cells promoted several pathways including 
p38, p53, protein kinase B (AKT) and c-Jun N-terminal kinase, all of which are linked 
to survival (Wang et al., 2014). The group offers three possible explanations for this 
effect: the presence of ligands for anti-apoptotic pathways on the surface of the EVs, the 
presence of whole receptors for these pathways in EVs, or the direct transfer of 
transcription factors miRNA or mRNA for pro-survival genes by EVs. This latter 
method is used by mesenchymal stem cells to transfer functional anti-miR-9 to 
glioblastoma cells (Munoz et al., 2013), which causes the miR-9 suppression of P-GP to 
be reversed allowing the transporters to export temozolomide.  
 
In situations like this where the surrounding normal cells are delivering essential 
components to cancer cells it is likely that a currently unseen transfer occurs from the 
cancer cells to the normal cells first. This transfer would change vesicle production in 
the normal cell altering the contents and any targeting on the surface along with the 
number produced to meet the demands of the cancer cells. It is also probable that the 
components being transferred by normal cells are produced in higher quantities or are 
not possible for the cancer cells to produce themselves. A recent publication reveals data 
that shows transformed fibroblasts can be resistant to gemcitabine and can transfer this 
resistance to the cancer cells by increasing zinc finger protein SNAI1 (Snail) expression 
(Richards et al., 2016). CAFs are dramatically altered in comparison to normal 
fibroblasts and part of this alteration may include changes to vesicle secretion as is seen 
in the differentiation of stem cells monocytes and colon cancer cells. In a model of 
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differentiating stem cells and monocytes where the differentiated cells were seen to 
release EVs containing 14-3-3 proteins which could activate dermal fibroblasts (Median 
and Ghahray., 2010). Experiments in colon cancer cell lines showed treatment with 
sodium butyrate increased EV release (Lucchetti et al., 2017) and these EVs had 
different phenotypic effects on recipient cells. A study published this year identified the 
transfer of miR-21 from CAFs and cancer associated adipocytes. The miR-21 
transferred can confer paclitaxel resistance on binding to apoptotic protease activating 
factor 1 (APAF1) (Au Yeung et al., 2016). As with the CAFs it is likely that the cancer 
associated adipocytes are altered from their normal form in ways that change EV 
production. 
 
1.6.2.2.7. Extracellular vesicles and oral cancer 
To date there is a limited number of studies focusing on the EVs produced or 
found in oral cancer. One focus of these studies is the diagnostic/prognostic potential of 
the EVs, having identified miR-1246 and miR-21 as potential markers of oral cancer 
(Takeshita et al., 2013; Tanaka et al., 2013). These biomarker discovery studies have 
also focused on saliva as a source of EVs (Iwai et al., 2016; Yap et al., 2016 Kawahara 
et al., 2016 and Winck et al., 2015) with saliva being an abundant and available biofluid 
in contact with oral cancer it is a logical source of EV based biomarkers. A group in 
China has investigated the role of what they term circulating microparticles in 
promoting angiogenesis in oral cancer (Ren et al., 2016), these are pelleted at 50,000 x g 
from the blood of patients with oral cancer. Whilst these are unlikely to all be from a 
cancerous cell they were capable of promoting human umbilical vein endothelial cells to 
form tubules and proliferate. A study demonstrated that EVs from oral cancer cells 
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could activate MAPK/ERK and JNK-1/2 pathways in vitro which promoted 
proliferation and migration of oral cancer cells (Sento et al., 2016). Perhaps the most 
interesting discovery in this paper is that fact that the ability of EVs to drive these 
changes could be blocked by continuous heparin treatment of the cells. The treatment 
with heparin delayed the uptake of the EVs significantly for four hours after which time 
the vesicle uptake resumed as normal. Heparan sulphate proteoglycans (HSPGs) are 
thought to function as receptors for cancer cell derived EVs on the target cells 
(Christianson et al., 2013) making it a desirable focus of research for potential clinical 
applications. 
 
1.7. Future challenges  
Research into EV signalling over the past decade has begun to create a map of 
interactions occurring in both normal conditions and during disease. New interactions 
between EVs and cells are being frequently identified and what is obvious is that these 
EVs represent an extremely powerful and versatile system involved in a huge number of 
processes, including unexpected ones like interspecies communication (Mu et al., 
2014). Our increasing understanding of EV-mediated signalling in the cancer 
microenvironment offers a new range of therapeutic options and strategies to be 
explored. If the signalling can be disrupted then some of the advantages it brings to a 
cancer will be lost, either enabling the patients’ immune system to clear out the cancer 
or increasing the efficacy of existing chemotherapeutics. There is also the possibility of 
utilising vesicle signalling to deliver drugs and several promising combinations are 
being explored in vitro. One group has developed a technique that enables them to 
create EVs with specific contents and targets that can deliver therapeutic siRNA against 
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Alzheimer’s disease in mice with high specificity and low immunogenicity (Alvarez-
Erviti et al., 2011; Cooper et al., 2014). Although in its infancy the potential of this 
system is huge and could become a key therapeutic strategy within the next decade. 
There is also interest in using EVs as a source of biomarkers both for diagnosis and 
prognosis with EVs found in urine or blood replacing more invasive biopsies. Exosome 
Diagnostics are currently working on introducing a microfluidics platform to remove 
EVs from biofluids and analyse them quickly and cheaply. This platform could be 
endlessly adaptable with EVs capable of giving information on various cancer types as 
well as neurological disorders. 
 
There are still several key challenges facing the field in the next few years. Firstly, 
finding a robust extraction technique that is capable of separating or distinguishing the 
vesicle subclasses. This would allow standardisation of both research techniques and 
terminology. It is currently expected that the exosome subclass has the greatest 
biological impact and some research has seemed to support this with the finding that the 
larger microvesicles contain no RNA (Crescitelli et al., 2013). However, the research is 
still hampered by current extraction techniques and the overlapping size ranges of the 
EVs. It is also important that universal quantification and purity scales are introduced, 
there are a growing number of groups using innovative transfer experiments to elucidate 
the effects EVs from one cell type can have on another cell type but without such 
quantification and purity measurements there is still the question of the dose of EVs 
being biologically relevant and pure. A group in Cardiff has proposed using the ratio of 
protein per particle as an indication of purity (Webber and Clayton, 2013). This method 
offers a simple way to obtain the purity of the EVs but does only allow for protein-
based contamination of the extractions.  
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Although EV-based therapy methods are currently undergoing clinical trials there 
are very few papers that include information on the number of EVs used to treat cells or 
animals with many groups only using a weight of protein to give any indication of the 
amount of EVs used. This is a deeply flawed measurement as EV preparations are very 
variable in purity and not all the protein present in the majority of preparations will be 
EV associated. 
  
Another key area for the next decade of EV research is to try and unravel the 
composition of the total population of EVs in a given microenvironment and the impact 
this can have. There are also questions surrounding the availability of the EVs: are all 
EVs available for all cells or are some like those containing drugs prevented from 
entering cells by some mechanism? Already an increasing amount of work is being done 
on 3D multiple cell type models more like the in vivo environment and this approach is 
going to become essential to understanding the complexity of vesicular signalling, 
particularly in cancer research. As more details on the mechanisms that target proteins 
and RNA to these EVs appears there will be an increase in the possible uses of EVs as a 
therapy delivery system. 
  
Four years ago, an editorial piece was submitted to the Bioessays journal 
(Sverdlov, 2012) entitled Amedeo Avogadro’s cry: What is 1 μg of exosomes? In it the 
author raised several key points that the EV field needed to address, notably the need for 
a more robust system for quantifying exosomes than by weight of protein but also the 
idea that miRNA transfer by EVs causing behavioural changes may not be as simple as 
first thought. The basis for his argument is that simple calculations of the number of 
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miRNA present in a tissue and the number of miRNA that could physically be within a 
vesicle means there are anywhere between 1010- 10240 combinations of miRNA cargoes in 
EVs. Because our current understanding of EVs has them existing as a heterogeneous 
population it is statistically very unlikely therefore that a large enough pool of EVs with 
the required miRNA to produce an effect will exist or be separable from the mass of 
other EVs in experiments. 
  
Despite the weaknesses and outstanding questions posed by our current 
understanding of the field, there have been many important and exciting revelations to 
date. Vesicle signalling has been shown to be a sophisticated and powerful mechanism 
that all cells can make use of. It has been shown to drive progression of phenotypic 
change allowing regulation of complex processes requiring the interaction of multiple 
cell types. It has been shown to deliver information in multiple directions with high 
specificity. With a potentially infinite number of combinations of cargoes and surface 
components the circulating EV population can be viewed like a communal Swiss army 
knife, with different attachments contributed by different cell types at different points in 
their life cycle. Each of the subsets or combinations of them can be used to perform a 
particular task in response to external stimuli or changing conditions. Being readily 
available, this pool offers a lifeline in the form of a faster response to potentially fatal 
changes like hypoxia, it allows advantageous mutations occurring in a single cell to be 
rapidly shared amongst a growing population of cancer cells and it offers new routes 
from therapeutic intervention and diagnostic tools. 
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1.8. Hypothesis and Aims 
The hypothesis for this study is that EV signalling between oral squamous cell 
carcinoma (OSCC) cells and surrounding stromal tissues contributes to oral cancer 
progression. To test this hypothesis the project will focus on four separate areas or 
questions. Firstly, are vesicles released by oral cancer cells and do the physical 
characteristics of these vesicles with respect to production rates, morphology or markers 
change with tumour stage? Methods for the isolation and characterisation of EVs from 
the culture media of oral cancer cells will be optimised and used to count and size any 
vesicles produced by cells representative of different stages of oral cancer. Transmission 
electron microscopy will be used to compare the morphology of any vesicles produced. 
Western blotting for proteins marker identified in the literature will be carried out to 
characterize both the potential origins of the vesicles as well as to place them in context 
of vesicles purified in other published studies. 
 
Secondly, what are the genomic and proteomic contents of these vesicles and is 
there any variation in these contents with tumour stage? Next generation sequencing and 
mass spectrometry techniques in combination with bioinformatics tools will be used to 
identify the miRNA and protein contents of these vesicles and explore any changes with 
disease stage. 
 
 Can the EVs produced by oral cancer cells be taken up by neighbouring cells of 
the tumour microenvironment and lastly are the EVs capable of inducing any changes in 
those cells? To study this signalling a fluorescence microscopy-based technique will be 
used to visualise the uptake of oral cancer derived EVs by other cells of the tumour 
microenvironment. Functional assays for behaviours beneficial to progression of a 
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tumour will then be used to determine if the OSCC EVs are capable of effecting these 
processes.  
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2. Materials and methods 
2.1. Materials 
All chemicals were routinely purchased from ThermoFisher or Sigma. Cell culture 
medium and supplements were purchased from Sigma, unless otherwise stated. 
2.2. Cell lines and tissue culture 
All cell lines were frozen or brought mycoplasma free and media from cell lines 
was routinely sent for mycoplasma testing throughout the project to ensure they 
remained mycoplasma free. 
2.2.1. OSCC cell line panel 
A panel of cell lines was assembled from those previously purchased from ATCC 
and held in the lab (H357) or gifted by Professor Keith Hunter. These cells were 
representative of the stages of oral, specifically tongue, cancer: mild and severe 
dysplasia, carcinoma and a metastatic deposit from a lymph node. 
  
H357 was established from OSCC of the tongue from a 74-year-old male patient 
who smoked between the ages of 17 and 20. The carcinoma was a STNMP stage 1, well 
differentiated, node negative tumour. This cell line was maintained in Dulbecco's 
Modified Eagles Medium (DMEM) supplemented with 10% (v/v) FBS, 2 mM L-
glutamine, 100 I.U./mL penicillin and 50 to 100 μg/mL streptomycin. Cells were 
passaged at 70-80% confluency. 
  
The following cell lines were maintained in KGM medium (DMEM: F12 (3:1 
v/v)), 10% FBS, 2 mM L-glutamine, 100 I.U./mL penicillin and 50 to 100 μg/mL 
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streptomycin.1.8 mM Adenine, 1.45x103 mM Hydrocortisone, 10 ng/ml epidermal 
growth factor, 10-10 M cholera toxin and 5 μg/ml insulin and passaged at 70-80% 
confluency. 
  
D20 was established from a leukoplakia (a white lesion of the oral mucosa) 
situated on the lateral tongue of a 50-year-old non-smoking male and was found to be 
immortal after over a hundred passages. 
  
D35 was established from an erythroleukoplakia (a red and white non-
homogenous lesion of the oral mucosa) situated on the lateral tongue of 68-year-old 
male smoker and was found to be immortal after over a hundred passages 
  
B22 was established from the lymph node metastasis of an 88-year-old smoking 
male. The tumour originated in the tongue, was stage four, and well differentiated with 
invasion of multiple nodes. 
  
2.2.2. Stromal cell panel 
OKF6 (ATCC) is a normal oral keratinocyte cell line that was immortalized by the 
over-expression of hTERT (Dickson et al., 2000). This cell line was grown in defined 
serum free keratinocyte growth medium (Gibco). 
 
HMEC1 (ATCC) is a human dermal microvascular endothelial cell line isolated 
from human foreskins and immortalized by the addition of a pSVT vector containing 
the Simian virus 40A gene product large T antigen. This cell line was grown in MCDB 
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131 medium (Gibco) supplemented with 2 mM L-glutamine, 1.45x103 mM 
Hydrocortisone and 10 ng/ml epidermal growth factor. 
 
Normal oral fibroblasts (NOFs) were donated by healthy volunteers or NHS 
patients according to University of Sheffield Ethics Approval 3463 or NHS Ethical 
Approval 09/H1308/66, respectively (table 2.1). NOFs were cultured in DMEM 
supplemented with 10% (v/v) FBS, and 200mM L-glutamine. Cells were passaged at 
70-80% confluency. 
Name Gender Age Site  Smoking 
status 
Ethics 
type 
DENF008 F 18 buccal NS University 
NOF803 M 45 buccal NS University 
NOF804 F 34 buccal NS University 
NOF805 F 28 buccal S University 
NOF806 F 26 buccal S University 
NOF316 F 22 gingival NS NHS 
NOF319 M 73 gingival NS NHS 
NOF335 M 47 gingival S NHS 
Table 2.1 Details of patient fibroblasts used during this project detailing age gender smoking 
status and site of the extraction.  
 
2.2.3. Routine cell culture and maintenance  
All cells were cultured in a 37oC, 5% CO2 environment. Cell culture was carried 
out inside a class 2 tissue culture hood to ensure sterility. Cells were cultured in 
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appropriate sized flasks or plates according to experimental demands. Upon reaching 
70-80% confluency the medium was removed, and cells washed twice with PBS before 
being treated with trypsin EDTA solution at 37oC for 5 min. Trypsin was neutralised by 
the addition of the appropriate FBS containing medium before centrifugation at 1000 x 
g for 5 min in a bench-top centrifuge (Harrier 18/80). The resultant pellet was re-
suspended in the appropriate medium before reseeding at the required density. 
 
2.2.4. Cell counting and seeding 
Where a particular number of cells was required for an experiment, cells were 
counted using a haemocytometer before reseeding. 10 μl of cell suspension was placed 
on a haemocytometer slide and the cells counted under a microscope. Cells with 
anomalous morphologies or those outside of the grid squares were not counted; the final 
averaged count was multiplied by 10,000 to give the number of cells per ml of 
suspension. 
 
2.2.5. EV-depleted serum 
For experiments requiring EV to be harvested from the culture medium, vesicle-
depleted serum was used when making the culture medium to avoid contamination with 
bovine vesicles. Serum was depleted of vesicle contaminants by centrifugation at 
100,000 x g, overnight at 4oC in a Beckman TLA100.3 angled rotor followed by filter 
sterilisation with a 0.2 µm syringe filter. 
 
2.2.6. Preparation of whole cell lysates. 
Cells were cultured, as previously described, either in 6 well plates or T75 flasks 
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to confluency before being placed on ice. Culture medium was removed, and the cells 
washed twice with PBS before the addition of 1 ml 1x RIPA buffer containing complete 
mini EDTA-free easy protease inhibitors (Roche). After 5 min cells were scraped and 
the resulting suspension transferred to a microcentrifuge tube and clarified by 
centrifugation at 8000 x g for 10 min at 4oC (Heraeus Fresco 17). The supernatant was 
transferred to a fresh tube and stored at -80oC. 
 
2.2.7. Preparation of conditioned medium for tunable resistive pulse 
sensing  
To determine the vesicle production rate of each cell line the following protocol 
was developed. One million cells were seeded in a T25 flask and left to adhere 
overnight. The medium was then removed, and the cells washed three times with PBS 
before 2 ml of medium supplemented with 10% (v/v) EV depleted FBS was added and 
the cells incubated for 24 h. The conditioned medium was centrifuged as follows: 300 x 
g 10 min, 3,000 x g 15 min and 10,000 x g 40 min. The medium was diluted 1/10 with 
filtered PBST and filtered through a 0.2 µm centrifugal filter unit (Millipore) prior to 
analysis.   
 
2.3. EV extraction and physical characterisation 
2.3.1. ExoQuick extraction 
Conditioned medium was centrifuged at 3000 x g for 15 minutes to remove cell 
debris, the supernatant was incubated overnight at 4oC with ExoQuick precipitation 
reagent at a ratio of 1:5 (v/v). The mixture was centrifuged for 30 min at 1500 x g and 
the supernatant removed. The pellet was washed with PBS and centrifuged at 1500 x g 
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for 5 min to remove any excess precipitation reagent before being re-suspended in PBS. 
2.3.2. Valadi et al, extraction  
The method of Valadi et al. (2007) was performed as follows. Conditioned 
medium was centrifuged at 300 x g for 10 min to remove whole cells. Cell debris and 
large EVs were removed from the supernatant by centrifugation at 16,500 x g for 15 
min followed by filtration with a 0.22 µm filter. Small EVs were pelleted by 
centrifugation at 100,000 x g for 90 min in a Beckman TLA100.3 angled rotor. The 
pelleted EVs were then re-suspended in PBS. 
 
2.3.3. Théry et al, extraction  
The method of Théry et al. (2006) was performed as follows. Conditioned 
medium was centrifuged at 300 x g for 10 min to remove whole cells. Cell debris was 
removed from the supernatant by centrifugation at 3,000 x g for 15 min. Large EVs and 
small debris were removed by centrifugation at 10,000 x g for 40 min. Small EVs were 
pelleted by centrifugation at 100,000 x g for 90 min in a Beckman TLA100.3 angled 
rotor and then re-suspended in PBS. 
 
2.3.4. Hybrid protocol 
A hybrid protocol was created to isolate EVs from small volumes of conditioned 
medium (up to 30 ml). The protocol uses a serial centrifugation approach adapted from 
that described by Théry et al. (2006) and Valadi et al. (2007) with all steps being carried 
out at 4oC. The medium was first centrifuged at 300 x g for 10 min to remove whole 
cells, the supernatant was then centrifuged for 15 min at 3,000 x g to remove cell debris. 
The supernatant was then re-centrifuged at 10,000 x g for 40 min (Beckman Coulter 
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Avanti J26 with a JA 12 conical rotor) and the supernatant filtered through a 0.2 µm 
filter to remove any additional cell debris or large EVs before ultracentrifugation. The 
filtered supernatant was centrifuged at 100,000 x g for 90 min in a Beckman TLA100.3 
angled rotor to pellet the small EVs. The pellet was then washed by the addition of 1 ml 
of PBS and a second spin at 100,000 x g for 90 min to remove soluble protein 
contaminants before re-suspending in the appropriate buffer. EVs were typically 
resuspended in PBS for storage at -20oC and subsequent use in transfer experiments or 
RNA extraction, lysis buffer (RIPA Buffer containing 1x Complete mini Protease 
inhibitors (Roche) and storage at -80oC for western blots, or 2% PFA and storage at 4oC 
for electron microscopy. 
 
2.3.5. Size exclusion chromatography  
To isolate EVs from larger volumes of conditioned medium (above 30 ml) that 
would yield the required amount of protein and RNA for mass spectrometry and small 
RNA sequencing, size exclusion chromatography (SEC) was used as an alternative 
method. Conditioned medium was prepared as previously described. The medium was 
processed by the following serial centrifugation steps: 300 x g for 10 min to remove 
detached cells 3,000 x g for 15 min to remove cell debris and 10,000 x g for 40 min to 
remove large EVs. The supernatant was concentrated down to a volume of <1 ml using 
a Vivaspin 20 (100 kDa MW cut off) centrifugal device at 6,000 x g. A SEC column was 
prepared by allowing 15 ml of Sepharose CL-2B (GE) slurry to settle under gravity in 
an Econopack column (Biorad). A top bed support was placed on the Sepharose column 
and the ethanol removed by washing with 2 bed volumes of PBS. The concentrated 
medium was allowed to enter the Sepharose before the addition of PBS + 0.03% (v/v) 
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Tween-20 (PBST) to elute the column and twelve 0.5 ml fractions were taken. 
2.3.5.1. Analysis of SEC fractions 
SEC fractions were analysed for EV and soluble protein concentration by TRPS 
using the qNano instrument (Izon) and BCA assays, respectively. For both small RNA 
sequencing and mass spectrometry analysis a high yield of pure EVs was required. To 
achieve this, SEC fractions containing abundant EVs, but low soluble protein were 
pooled and EVs pelleted by centrifugation at 100,000 x g for 90 min at 4oC. 
 
2.3.6. EV quantification by tuneable resistive pulse sensing 
EV concentration and size distribution were determined by tuneable resistive 
pulse sensing (TRPS) using a qNano instrument. Calibration was performed using 
CPC100B calibration particles (Izon) with a modal diameter of 114 nm diluted 1/2000 
(v/v) in PBST. EV samples were diluted 1/10 (v/v) in PBST and then filtered through a 
0.2 μm centrifugal unit. EV and calibration samples were analysed with the same 
NP100 nanopore with the same settings for voltage, nanopore stretch and pressure. 
Settings were chosen that gave an optimum separation of particles from the background 
noise and a constant flow rate of particles. Runs were recorded for 200 particles or 2 
min whichever came first. 
 
2.3.7.  Electron Microscopy of EV samples 
2.3.7.1.  Preparation of solutions 
2.3.7.1.1. 2% and 4% W/V Paraformaldehyde 
2 or 4 g of paraformaldehyde powder (BDH Chemicals) were dissolved in 90 ml 
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of 0.1 M sodium phosphate buffer by heating to 65oC whilst stirring. If necessary drops 
of 1 M NaOH were added until the solution became clear. The solution was made up to 
100 ml with 0.1 M sodium phosphate buffer cooled and filtered. Aliquots were stored at 
-20oC. 
 
2.3.7.1.2. 4% W/V Uranyl Acetate 
2 g of uranyl acetate powder (Agar Scientific) was dissolved in 50 ml distilled 
water and stored in the dark at 4oC. 
 
2.3.7.1.3. Uranyl Oxalate 
4% (w/v) uranyl acetate was mixed with 0.15 M Oxalic acid (Sigma) (0.945 g in 
50 ml distilled water) in a 1:1 ratio and stored in the dark at 4oC. 
 
2.3.7.1.4. Methyl Cellulose 
196 ml of distilled water was heated to 90°C and 4 g methyl cellulose added 
(Sigma, 25 centipoise, M-6385) whilst stirring. This suspension was rapidly cooled on 
ice whilst stirring until the solution had reached 10°C. The solution was left overnight at 
4°C with the stirrer on low then left to “ripen” for 3 days at 4°C. The solution was made 
to final volume of 200 ml in distilled water before centrifugation for 95 min at 100,000 
× g, 4°C and the supernatant stored for up to 3 months at 4°C. 
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2.3.7.2. Fixation 
Samples were prepared for electron microscopy using the following method as 
described by Théry et al. (2006) taking care at all stages to keep the grids wet on the 
membrane side and dry on the opposite side. EV pellets were re-suspended in 50 μl 2% 
paraformaldehyde (PFA) fixative and placed on ice. For each sample three 8 μl drops of 
the PFA suspended EVs were placed onto a square of parafilm in a petri dish and a 200 
mesh formvar coated grid was placed membrane side down on each drop using a pair of 
forceps. Grids were then left for 20 min in a dry environment to allow adsorption. The 
grids were then washed once in PBS by floating them membrane side down on a 100 μl 
drop on the parafilm before being transferred to a 50 μl drop of 1% glutaraldehyde for 5 
min. 
2.3.7.3. Contrasting 
Following the treatment with glutaraldehyde the grids were given 8 washes of 2 
min each in distilled water by flotation on drops on parafilm. After the wash steps the 
grids were contrasted and embedded first in a 50 μl drop of pH 7 uranyl-oxalate 
solutions for 5 min and then for 10 min in a 50 μl drop of 9:1 (v/v) 2% methylcellulose: 
4% Uranyl acetate solution on ice. The grids were then gently blotted on Whatman no.1 
filter paper to remove the excess liquid before being allowed to air dry prior to storage. 
The grids were imaged using a Tecani Spirit G2 at 80 kV. 
 
2.4. Protein Analysis 
2.4.1. BCA Assay 
Protein concentration was estimated by micro BCA assay using the following 
technique. Bovine serum albumin (BSA) standards of known concentration (0 to 1 
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mg/ml) were prepared in the same buffer as samples were made in. All samples were 
tested in duplicate with 10 μl of each sample and standard added to a microplate. 200 μl 
of assay reagent (consisting of A and B solutions in a 50:1 ratio) was added to each 
well. The plate was sealed with a plastic film cover added and incubated for 30 min at 
37oC. Following the incubation, the absorbance was measured at 540 nm on a Tecan 
M200 plate reader. A standard curve was created by plotting absorbance values against 
BSA concentrations and a polynomial equation used to determine the concentration of 
samples. 
2.4.2. SDS-PAGE 
12% Acrylamide gels were cast between glass plates using the following 
quantities to produce two gels. 
dH2O 4.3 ml 
40% Acrylamide (37.5:1 acrylamide: 
bis-acrylamide) 
3.0 ml 
pH 6.8 Tris Page SDS buffer 2.5 ml 
10% Ammonium persulfate 350 µl 
Temed 5 µl 
 Table 2.2: Reagents for two 1.0 mm acrylamide resolving gels 
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The resolving gel was overlaid with isopropanol and allowed to polymerise. 
dH2O 4.725 ml 
40% Acrylamide (37.5:1 acrylamide: 
bis-acrylamide) 
975 µl 
pH 6.8 Tris Page SDS buffer 2.1 ml 
10% Ammonium persulfate 100 µl 
Temed 17 µl 
Table 2.3: Reagents for two 1.0 mm acrylamide stacking gels. 
The stacking gel was poured on top of the set resolving gel and a sample comb was 
inserted before allowing the gel to polymerise for 10 min.  The comb was then removed 
and each well washed out with copious amounts of distilled water. 
   
Samples volumes were equalised to the lowest concentration 20 μl with 1X RIPA buffer 
(containing protease inhibitors) before the addition of 5 μl 5X loading buffer (National 
Diagnostic). The samples were then heated at 95oC for 5 min. Samples were separated 
using either 12% polyacrylamide SDS-PAGE or precast 4-18% gradient gels (Biorad) in 
Biorad tanks filled with 1X Running buffer (88 g Glycine, 10% W/V SDS and 32 g Tris 
Base in 1 L dH2O). 20 μl of sample was loaded in each well alongside Precision Plus 
prestained protein ladder (Biorad) in the outside wells. Separation was performed at 150 
V until the dye front had reached the bottom of the glass plates. 
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2.4.3. Western Blotting  
2.4.3.1. iBlot transfer 
Proteins separated by SDS-PAGE were transferred using the iblot system (Life 
Technologies). The gel was placed on top of the nitrocellulose membrane of the iblot 
cathode. This was covered with filter paper pre-soaked in distilled water taking care to 
remove all air bubbles. The stack was completed by the addition of the anode and a 
sponge. Proteins were transferred at 23 V for 6 min. 
2.4.3.2. Biorad turbo blot transfer 
Following SDS-PAGE the gel was placed on the nitrocellulose membrane of a 
pre-prepared stack. The sandwich was assembled by the addition of the top layers and 
bubbles removed. Proteins were transferred using an appropriate programme for the 
thickness of gel. For 1.0 mm gel this was 28 V for 7 min and for 1.5 mm gels this was 
28 V for 10 min. 
2.4.3.3. Blocking and antibody incubation 
The nitrocellulose membrane was blocked in 5% (w/v) skimmed milk in TBST (8 g 
NaCl 0.2 g KCl 3 g Tris base in 1l dH2O and 0.1% Tween-20) for 1 h on a rocker 
shaker. The membrane was incubated overnight on a rocker shaker with primary 
antibody (table 2.4), diluted in blocking buffer, at 4oC. Following incubation with the 
primary antibody, the membrane was washed three times in TBST for 15 min and 
incubated with the appropriate secondary antibody (table 2.5) diluted in blocking buffer 
for 1 h at room temperature. The membrane was washed three times with TBST for 5 
min and placed in cling film. The two parts of ECL substrate (Pierce) were mixed in a 
1:1 ratio and 500 μl of the solution was added to the membrane. The excess was 
removed after a few seconds and the cling film was sealed before placing the membrane 
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either in an x-ray cassette for exposure to an x-ray film and developing with an 
automated processor (Xograph Compact X4) or imaged using a Licor scanner (Model 
no 3600) on high quality 12 min scan. 
Antibody (clone) Blocking buffer Dilution Manufacturer (Antibody 
number) 
Alix (1A12) mouse 
monoclonal 
5% milk in 
TBST 
1:200 Santa Cruz (sc-53540) 
Annexin V (C-20) goat 
polyclonal 
5% milk in 
TBST 
1:200 Santa Cruz (sc-1929) 
ADP ribosylation factor 6 
(ARF6) (3A-1) mouse 
monoclonal 
5% milk in 
TBST 
1:200 Santa Cruz (sc-7971) 
CD63 (H-193) rabbit 
polyclonal 
5% milk in 
TBST 
1:200 Santa Cruz (sc15363) 
(This antibody was 
discontinued in 2016) 
CD63 (EPR5702) rabbit 
monoclonal  
5% milk in 
TBST 
1:500 Abcam (ab134045) (This 
antibody was brought in 
2016 to replace the 
discontinued Santa Cruz 
antibody) 
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Heat shock protein 70 (HSP70) 
(3A3) mouse monoclonal 
5% milk in 
TBST 
1:200 Santa Cruz (sc-32239) 
Thrombospondin 1 (TSP1) 
(A6.1) mouse monoclonal 
5% milk in 
TBST 
1:200 Santa Cruz (sc-59887) 
Vesicle associated membrane 
protein 3 (VAMP3) (N12) goat 
polyclonal 
5% milk in 
TBST 
1:200 Santa Cruz (sc-18208) 
Alpha smooth muscle actin 
(αSMA) (IA4) mouse 
monoclonal 
5% milk and 
2.5% bovine 
serum albumin 
(BSA) in TBST 
1:500 Sigma (A2547) 
Horseradish peroxidase 
conjugated glyceraldehyde 3 
phosphate dehydrogenase 
(GAPDH) (EPR6254) rabbit 
monoclonal 
2.5% BSA in 
TBST 
1:20000 Abcam (abc181602) 
Galectin 3 binding protein 
(GAL3BP) mouse polyclonal 
2.5% BSA and 
5% milk in 
TBST 
1:500 Abcam (ab67353) 
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Major vault protein (MVP) 
(1032) Rabbit monoclonal 
2.5% BSA and 
5% milk in 
TBST 
1:1000 Abcam (ab2376) 
Eukaryotic elongation factor 2 
(EEF) (EP880Y) rabbit 
monoclonal 
2.5% BSA and 
5% milk in 
TBST 
1:10000 Abcam (ab75748) 
Integrin alpha six (ITA6) 
(EPR18124) rabbit monoclonal 
2.5% BSA and 
5% milk in 
TBST 
1:1000 Abcam (ab181551) 
Table 2.4 Details of manufacturers, dilutions and blocking buffers for all primary antibodies used 
in western blotting experiments 
Antibody Blocking buffer Dilution Manufacturer 
Anti-mouse 5% milk in TBST 1:3000 Cell Signalling 
(New England 
Biosciences) 
Anti-rabbit 5% milk in TBST 1:3000 Cell Signalling 
(New England 
Biosciences) 
Anti-goat 5% milk in TBST 1:3000 Promocell 
Table 2.5 Details of HRP conjugated secondary antibodies, blocking buffer, dilutions and 
manufacturers used in western blot experiments 
83 
 
2.4.4. iTRAQ 8 Plex 
2.4.4.1. Sample collection 
Conditioned medium was harvested from three confluent T175 flasks and EVs 
isolated by SEC. Fractions 6-9 were pooled and EVs pelleted by centrifugation at 
100,000 x g for 90 min. The pellet was then lysed in 50 µl of 1 M triethylammonium 
bicarbonate (TEAB) (Sigma), pH 8.5 with 0.05% (w/v) SDS buffer and 0.05% (v/v) 
Triton x 100 detergent on ice for 20 min. Samples were centrifuged at 10,000 x g for 20 
min at 4oC and protein concentration was determined by BCA assay. 
 
2.4.4.2. Isobaric tag labelling 
Samples were normalised to the lowest concentration in 25 µl TEAB buffer. 
Following this reduction of cysteine residues was carried out by addition of 2.5 µl 50 
mM tris (2-carboxyethyl) phosphine. After vortexing and briefly pulsing the samples in 
a microfuge they were incubated at 60oC for one hour to break any disulphide bonds in 
the proteins. To prevent them from reforming, the samples were allowed to cool to room 
temperature before alkylation with 1.25 µl of methyl methanethiosulphonate and 
incubation for 10 min at room temperature. Tryptic digestion was carried out by adding 
0.25 μg of porcine trypsin to the samples and overnight incubation at 37oC. Samples 
were then labelled with iTRAQ reagents (ABSciex) as follows B22 with 117, D35 in 
two technical replicates with 118 and 119, and H357 with 121. The labelled samples 
were then combined, vacuum evaporated and stored at -20oC. 
 
2.4.4.3. High resolution hydrophilic interaction chromatography (HILIC) 
Initial fractionation was carried out by Hypercarb™ separation on a Dionex 
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UltiMate 3000 Autosampler linked to a flow manager and pump system (Thermo 
Scientific, UK). Samples were re-suspended in 120 µL Buffer A (3% ACN, 0.1% TFA) 
and loaded onto a Hypercarb™ Porous Graphitic Carbon LC reversed phase analytical 
column (Cat no. 35003-052130, ThermoFisher Scientific, UK) with the following 
dimensions, 50 mm length, 2.1 mm diameter, particle size of 3 µm and a 250 Å pore 
size. The flow rate for loading and gradient separation was 0.2 mL/min. A gradient was 
established using Buffer A and Buffer B (97% ACN, 0.1% TFA) in the following 
proportions 0% B (0-5 minutes), 0-5% B (5-6 minutes), 5-35% B (6-51 minutes), 35-
45% B (51-56 minutes), 45-90% B (56-61 minutes), 90% B (61-66 minutes) followed 
by re-equilibration at 0% B. Peptide fractions were dried by centrifugal evaporation 
using a Scanvac vacuum centrifuge (Labogene, Denmark) connected to a Vacuubrand 
Vacuum Pump (Vacuubrand, Germany). The fractions were then recombined into 6 
samples to run on the LC-MS/MS. 
 
2.4.4.4. Reverse phase liquid chromatography (RPLC) and liquid 
chromatography tandem mass spectrometry (LC MS/MS) mass 
spectrometric analysis 
LC MS/MS was performed by nano-flow liquid chromatography (U3000 
RSLCnano, Thermo Scientific) coupled to a hybrid quadrupole-orbitrap mass 
spectrometer (Q Exactive HF, Thermo Scientific).  iTRAQ labelled-peptides were 
separated on an Easy-Spray C18 column (75 µm x 50 cm) using a 2-step gradient from 
97% solvent A (0.1% formic acid in water) to 10% solvent B (0.08% formic acid in 
80% acetronitrile) over 5 min then 10% to 50% B over 75 min at 300 nL/min. The mass 
spectrometer was used in data dependent acquisition mode with 10 product ion scans 
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(resolution 15000, automatic gain control 54, maximum injection time 20 ms, isolation 
window 1.2 Da, normalised collision energy 32, intensity threshold 2.55) per full MS 
scan (resolution 60000, automatic gain control 36, maximum injection time 100 ms).  
 
2.4.4.5. Protein identification and relative quantification 
iTRAQ ratios used for relative quantification were determined by applying an in-
house data analysis pipeline (Ow et al., 2009). Firstly, the raw data was converted to 
generic MGF peaklists via the mascot.dll embedded script (version 1.6 release no. 25) 
in Analyst QS v. 1.1 (Applied Biosystems, Sciex; Matrix Science) with the option of 
averaging the MS/MS spectra removed. The spectra charge deconvolution was disabled 
around the iTRAQ reporter region (113−119 and 121 m/z). Centroided data were 
interrogated for identifications using an in-house Phenyx algorithm cluster (binary 
version 2.6; Genebio Geneva) at the ChELSI Institute, University of Sheffield. The 8-
plex data were interrogated using the latest UniProt Human database with the following 
modifications set 8-plex iTRAQ mass shifts (+304 Da, K and N-term), methylthiol (+46 
Da, C) and oxidation of methionine (+16 Da, M).  
Stringent mass tolerances of 0.4 Da on both MS and MS/MS were used along with 
peptide level filters of a z-score of 5.0 and a p-value significance of 0.0001 to filter the 
hits. Phenyx protein scores were set using a total z-score of 20. MS/MS peptides that 
met these criteria were then used as the basis for calculations. In order to confirm 
relative quantification, the iTRAQ reporter intensities for these peptides were 
referenced directly to the centroided data provided in the MGF peaklists. Appropriate 
isotopic and median corrections were applied to the reporter ions intensities to 
compensate for systematic errors in the sample loading. Students tests with Bonferroni's 
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multiple test correction was performed on the corrected values to compare between the 
different vesicle sources.  
 
2.4.5. Label free spectrometry 
2.4.5.1. Sample collection 
Conditioned medium was harvested from three confluent T175 flasks and EVs 
isolated by SEC. Fractions 6-9 were pooled and EVs pelleted by centrifugation at 
100,000 x g for 90 min. The pellet was then resuspended in 50 µl of 50 mM ammonium 
bicarbonate buffer prepared with HPLC grade water (Thermofisher) containing 0.1% 
RapiGest (Waters). Sample protein concentration was determined by BCA assay. 
 
2.4.5.2. Preparation of samples 
Samples were normalised to the lowest concentration in 25 µl 50 mM ammonium 
bicarbonate buffer. Following this reduction of cysteine residues was carried out by 
addition of 2.5 µl 50 mM tris (2-carboxyethyl) phosphine. After vortexing and briefly 
pulsing the samples in a microfuge they were incubated at 60oC for one hour, to break 
any disulphide bonds in the proteins. To prevent them from reforming the samples were 
allowed to cool to room temperature before alkylation with 1.25 µl of methyl 
methanethiosulphonate and incubation for 10 min at room temperature. Tryptic digest 
was carried out using sequencing grade trypsin (Promega) which was resuspended in 
HPLC grade 50 mM ammonium bicarbonate and diluted to an 8 ng/µl working solution. 
Each sample had 5 µl of this solution added to give a final ratio of trypsin to protein of 
1:50 (for these samples this was 40 ng of trypsin to 2000 ng of protein). Samples were 
incubated with the trypsin overnight at 37oC. 
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2.4.5.3. RPLC and mass spectrometric analysis 
Samples were run using a reverse phase chromatography column with a 2 µm 
particle size giving pores of 100 Å. The column was run with a flow rate of 0.3µl/min 
increasing the concentration of buffer B 80% Acetonitrile, 0.1% v/v formic acid in 
water from 3% to 90% of the column volume. This creates a potential retention time of 
between 5 and 105 min for proteins on the column. Fractions were analysed 
individually using a 105-minute data dependent acquisition (DDA) method on a 
QExactive HF. The full MS scan was from 375-1500 m/z was acquired in the Orbitrap 
at a resolution of 120,000 in profile mode. Subsequent fragmentation was Top 10 in the 
HCD cell, with detection of ions in the Orbitrap using centroid mode, resolution 30,000. 
The following MS method parameters were used: MS1, Automatic Gain Control (AGC) 
target 16 with a maximum injection time (IT) of 60 ms. MS2, Automatic Gain Control 
(AGC) target 15, maximum injection time (IT) of 60 ms and isolation window 2 Da. The 
intensity threshold was 3.34, normalized collision energy 27, charge exclusion was set to 
unassigned, 1, exclude isotopes was on, apex trigger deactivated. The peptide match 
setting was preferred with dynamic exclusion of 20 seconds. 
 
2.4.5.4. Processing data 
Initial data processing was carried out by MaxQuant v1.5.3.30. Samples were 
aligned against a human protein database. The following group specific parameters were 
used: Type Standard Multiplicity 1 no labels. Trypsin digestion and label free analysis 
were selected. Using the global parameters, the methylthio addition was added to allow 
for the changes caused to the protein structure by the reduction and alkylation reactions 
detailed in the processing steps. Following this processing with MaxQuant data was 
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imported into Perseus v1.5.2.6 for further analysis. Once imported into Perseus 
contaminants were removed from the list of samples, technical replicates were 
combined, and the label free values converted to a Log2x score. 
 
2.5.  RNA extraction and analysis 
2.5.1. miRCURY RNA extraction kit 
RNA was extracted from cells and EVs using the miRCURY RNA extraction kit 
(Exiqon). Cells or EV pellets were resuspended in 350 µl of lysis buffer and incubated 
at room temperature for 5 min. The lysate was then transferred to an RNAse free 
microcentrifuge tube to which 200 µl of 100% ethanol was added. The tube was 
vortexed for 10 seconds and the lysate/ethanol mixture was added to a spin column. 
Lysate was centrifuged through the column at 3,500 x g for 1 min and the flow through 
discarded. The column was then treated with 10 µl of DNase1 in 70 µl of DTT buffer 
(Qiagen). The DNase and buffer mixture were applied directly to the membrane and left 
for 15 min at room temperature. Following DNase treatment, the column was washed 
three times with 400 µl of wash buffer and centrifuged for 1 min at 14,000 x g. After the 
final wash the column was centrifuged for 2 min at 14,000 x g to dry the filter. The 
column was then placed into an elution tube and 50 µl of elution buffer added directly 
to the filter. RNA was eluted by centrifugation for 2 min at 200 x g and then 1 min at 
14,000 x g. Extracted RNA was typically quantified on a NanoDrop spectrophotometer 
(Nanodrop 1000, Thermoscientific) and stored at -80oC.  
 
2.5.2. Measuring of RNA concentration using Agilent Bioanalyzer 
Prior to small RNA sequencing analysis RNA concentration was determined by 
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Bioanalyzer (Agilent). Reagents were allowed to equilibrate to room temperature for 30 
min, 9 µl of gel dye mix was added to the Picochip and the plunger depressed for 60 s 
before being released. 9 µl of RNA conditioning solution and 5 µl of marker were added 
to the appropriate wells. 1 µl of ladder and sample were added to the appropriate wells 
and the chip inserted into the instrument. 
 
2.5.3. Small RNA sequencing 
EVs were purified by SEC and RNA extracted using the miRCURY kit.  RNA 
samples were submitted to Edinburgh Universities Clinical Research Facility for small 
RNA sequencing. The RNA samples were analysed by Agilent Bioanalyzer using the 
RNA 6000 Pico kit to assess the quality and integrity of total RNA and then quantified 
using a Qubit 2.0 fluorometer and the Qubit RNA HS assay kit. These processes enabled 
a standardised amount of RNA to be prepared for each sample. RNA was hybridized 
and ligated before being reverse transcribed into cDNA. The cDNA was purified using 
magnetic beads and then amplified with appropriate Ion torrent adaptors and barcodes 
for 18 cycles of PCR before being purified. The library yields were quantified and 
assessed for quality using the Qubit 2.0 fluorimeter and a Bioanalyzer running the 
appropriate DNA kits. Libraries were combined in equimolar amounts for template 
preparation before sequencing on the Ion Proton instrument with a P1 v3 chip. 
Additionally, a smallRNA analysis plug in was run, this aligns microRNA reads against 
databases of known mature miRNA and unmapped reads against the whole genome to 
identify other RNA molecules. 
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2.5.4. Quantitive real-time PCR 
2.5.4.1. TaqMan qPCR 
2.5.4.1.1. cDNA Synthesis 
cDNA was prepared from extracted RNA using a TaqMan reverse transcription kit 
(Applied Bioscience). Reverse transcription master mix was first assembled on ice (0.15 
µl of 100mM dNTPs, 1.00 µl MultiScribe™ Reverse Transcriptase 50 U/µl, 1.50 µl 10x 
Reverse Transcription Buffer, 0.19 µl RNase Inhibitor 20 U/µl and 4.16µl Nuclease free 
water.) This was then combined with between 1 and 10 ng of RNA in a 7 µl:5 µl ratio in 
a PCR tube for each reaction, 3 µl of 5X RT primer was then added to the tube before a 
5 min incubation on ice. Samples were then treated to the following programme in a 
thermal cycler: 30 min at 16oC, 30 min at 42oC, and 5 min at 85oC. The cDNA produced 
was stored at -20oC prior to being used for qPCR. 
 
2.5.4.1.2. Preamplification of RNA samples 
Because some of the sequences were present in very low quantities a 
preamplification work flow (Applied Biosystems) was used with some of the miRNA 
sequencing validation PCRs. The first step was a Megaplex™ RT reaction, for each 
sample 0.8µl of 10X Megaplex™ RT primers, 0.2 µl 100 mM dNTPS, 1.5 µl of 50 U/µl 
Multiscribe™ Reverse transcriptase, 0.8 µl 10X RT buffer, 0.9µl of 25mM MgCl2, 0.1µl 
of 20U/µl RNase inhibitor and 0.2µl of nuclease free water was combined in an RNase 
free tube. The tubes were inverted and 4.5µl of the master mix added to 3 µl of 
normalised RNA for each sample. Tubes were incubated on ice for 5 min before being 
run with the following programme in a PCR machine, 40 cycles of 16oC for 2 min 42oC 
for 1 minute and 50oC for 1 second. Samples were incubated at 85oC for 5 min. 
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Immediately following the RT reaction samples were prepared for the pre-amplification 
step. For each sample 12.5 µl of 2X PreAmp master mix was combined with 2.5 µl of 
10x PreAmp primers and 7.5 µl of nuclease free water. The primers used were the 
Human Pool A Megaplex™ RT primers. After inverting the tubes and 5 min incubation 
on ice the RT reaction was run in a PCR machine with the following settings 95oC for 
10 min 55oC for 2 min and 72oC for 2 min. Followed by 12 cycles of 95oC for 15 
seconds and 60oC for 4 min, 10 min incubation at 99.9oC was used to inactivate the 
enzyme. Samples were stored at -20oC prior to use in qPCR reactions. 
 
2.5.4.1.3. qPCR 
cDNA samples were analysed using a TaqMan RTqPCR kit (Life Technologies). 
Sufficient master mix was assembled to allow for each sample and a non-cDNA 
containing control to be run in duplicate. Master mix was assembled using the following 
proportions per well: 0.5 µl TaqMan Small RNA assay 20x (table 2.6), containing the 
primers and fluorescent probes specific for sequence of the species required), 5µl of 
TaqMan universal PCR Master mix II (2x) (with no Uracil-N-glycosylase(UNG)) and 
4µl of nuclease free water. 0.5 µl of cDNA was then added to 9.5µl of master mix per 
well of 96 well qPCR plate for each reaction. 
 
After the addition of the cDNA the plate was sealed and briefly centrifuged for 2 
min at 1000 x g (Sorval Legend XT) before loading into the qPCR machine (7900 HT 
Fast Real Time PCR system). Plates were then run with the following programme using 
the FAM fluorophore and a standard run mode: 2 min at 50oC to ensure no UNG 
activity, 10 min at 95oC to activate the polymerase enzyme and the 40 cycles of 95oC 
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for 15 seconds to denature the strands and 60oC for 60 seconds to extend and anneal the 
strands. 
Target Thermo fisher assay ID 
Let-7a-5p 000377 
miR-199a-3p 002304 
miR-29b-3p 000413 
Table 2.6 ID numbers for TaqMan small RNA assays used to validate IonTorrent sequencing data 
2.5.4.2. Sybr Green qPCR 
2.5.4.2.1. cDNA Synthesis 
cDNA was prepared from extracted RNA using a High capacity reverse 
transcription kit (Applied Bioscience). Reverse transcription master mix was first 
assembled on ice (0.8µl of 100mM dNTPs, 1.00µl MultiScribe™ Reverse Transcriptase 
50 U/µl, 2.0 µl 10x Reverse Transcription Buffer, 1.0µl RNase Inhibitor 20 U/µl 2.0μl 
10x RT random primers and 3.2µl Nuclease free water.) This was then combined with 
between 1 and 10 ng of RNA in a 10 µl:5µl ratio in a PCR tube for each reaction. 
Samples were then treated to the following programme in a thermal cycler: 10 min at 
25oC, 120 min at 37oC, and 5 min at 85oC. The cDNA produced was stored at -20oC 
prior to being used for qPCR. 
2.5.4.2.2. qPCR 
cDNA samples were analysed using a SYBR Green RTqPCR kit (Life 
Technologies). Sufficient master mix was assembled to allow for each sample and a 
non-cDNA containing control to be run in duplicate. Master Mix was assembled using 
the following proportions per well: 0.25 µl of forward primer and 0.25 µl of reverse 
primer 5 µl of SYBR Green universal PCR Master Mix II (2x) and 4 µl of nuclease free 
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water. 0.5µl of cDNA was then added to 9.5 µl of master mix per well of 96 well qPCR 
plate for each reaction. Primers listed in table 2.7. 
After the addition of the cDNA the plate was sealed and briefly centrifuged for 2 
min at 1000 x g (Sorval Legend XT) before loading into the qPCR machine (7900 HT 
Fast Real Time PCR system). Plates were then run with the following programme 95oC 
for 10 min and then 40 cycles of 95oC for 10 seconds to denature the strands and 60oC 
for 15 seconds to extend and 72oC for 20 seconds to anneal the strands and acquire the 
signal. 
Primer  Sequence 
U6 Forward 5’ CTCGCTTCGGCAGCACA 3’ 
U6 Reverse 5’ AACGTTCACGAATTTGCGT 3’ 
αSMA Forward 5’ GAAGAAGAGGACAGCATG 3’ 
αSMA Reverse 5’ TCCCATTCCCACCATCAC 3’ 
Table 2.7 List of SYBR green primer sequences for U6 as a house keeping control and αSMA. All 
primers were ordered from Sigma Aldrich.  
2.6. Cell treatments and assays  
2.6.1. Fluorescent imaging of EV mediated RNA transfer 
2.6.2. Staining of extracellular EVs 
EVs were extracted from the culture medium of cell lines as described previously 
(section 2.3.4) and resuspended in 300 μl of PBS. The resuspended exosomes were 
treated with two different stains using the following method. Cyto RNASelect (Life 
Technologies) was used to stain EV RNA, this cell permeable dye binds nucleic acids 
but fluoresces strongly when bound to RNA with an absorption/emission maxima 
490/530 nm, however when bound to DNA only emits weak fluorescence. A 1 mM 
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working solution was made up in dimethyl sulfoxide (DMSO) and 1μl of this added to 
the EVs for a final concentration of 0.1 mM. A cell permeable far red 5-
Carboxyfluorescein diacetate succinimidyl ester isomer (Life Technologies), which 
binds covalently to primary amines in membrane proteins, was used to stain the 
exosome membranes. The powder was rehydrated in 200 μl of DMSO to make a 1 mM 
working solution and 1 μl of this was added to the RNA stained vesicle solution. The 
stained exosome solutions were wrapped in foil to protect them from light and 
incubated at 37oC for 30 min. Following this excess or unincorporated dye was removed 
using a MW 3000 exosome spin column (Life Technologies). The column was first 
rehydrated by the addition of 650 μl of PBS and a 15 min room temperature incubation, 
before the addition of sample to the column it was centrifuged for 2 min at 750 x g to 
remove any remaining interstitial fluid. Samples were loaded on the column and treated 
to a second spin to remove the excess dye. Vehicle controls were prepared by treating a 
300 μl aliquot of PBS to the same protocol. 
 
2.6.3. Cell treatment, fixing and mounting 
Cells were plated on sterile coverslips in a 24 well plate using 20,000 cells in 
vesicle free media. These cells were left to adhere overnight before the addition of the 
stained EVs. After this addition the cells were left for 1 hour in an incubator to allow 
uptake of the EVs. Following this the media was removed and cells washed twice with 
PBS. The washed cells were fixed in 4% paraformaldehyde (PFA) for 10 min after 
which the PBS was removed and the cover slips washed again in PBS. Slips were 
mounted on clean glass slides using 8 μl of ProLong Gold Antifade with DAPI (Life 
Technologies) per cover slip and left to dry overnight. Completed slides were then 
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imaged with a Zeiss Axioplan 2 fluorescence microscope. 
 
2.6.4. Proliferation and viability assays 
2.6.4.1. Cell seeding density optimisation  
In order to optimise the seeding of cells in 96 well microplates for growth 
experiments cells were seeded in wells of a 96 well plate at varying densities alongside 
appropriate blanks in 90 µl of media. Cells were allowed to grow for 24 48 and 72 h. At 
each time point cells were imaged again and then 10 µl of presto blue added and left to 
incubate for an hour protected from light. Wells were then read using a Fluorstar plate 
reader with absorbance at 570 nm. Following this the presto blue containing medium 
was removed and replaced with fresh medium. The absorbance values were normalised 
and then used to indicate the growth of the cells. 
 
2.6.4.2. Live/dead cell staining  
Cells were seeded at values determined by the density optimisation experiments in 
triplicate in black walled clear bottom 96 well plates (Corning) in serum free media. 
After serum starving for 24 h the media on the wells to be treated with EVs or a vehicle 
control was replaced with the appropriate media supplemented with 2% serum to 
minimise any growth promoting impact from the medium. The cells were then treated 
with either 1000, 5000, 10000 or 200000 EVs per cell or the same volume of vesicle 
free PBS per well for 24 and 48 h. The maximum ratio of 20000 EVs per cell cells was 
determined from reverse calculating the number of EVs to cells used in the fluorescent 
imaging of uptake experiments. Appropriate controls were prepared using phenol red 
free DMEM supplemented with 10% FBS and by using cells treated with 70% methanol 
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for 30 min to give wells where all or nearly all of the cells were alive or dead. Relative 
numbers of live and dead cells were determined using a Life Technologies live dead 
staining kit. This kit comprises of ethidium homodimer- 1 (EthD-1), which enters cells 
via the damaged membranes of dead cells and undergoes a 40-fold enhancement of 
fluorescence when bound to nucleic acids, and calcein AM which is retained by live 
cells and converted to the intensely fluorescent calcein by intracellular esterases.  
 
After optimising dye concentration, cell number and incubation times. A solution 
of 4 µm EthD-1 and 2 µm calcein AM was assembled from the supplied stock solutions; 
the media on the cells was replaced with 100 µl of sterile PBS and a 100 µl of the dual 
stain solution was added to each well for 30 min. The plate was then read on a Tecan 
M200 plate reader at 485/530 nm and 530/615 nm excitation/emission. Fluorescence 
values were used to calculate the relative number of live and dead cells compared to the 
control wells. 
 
2.6.4.3. BRDU ELISA  
Changes in cell proliferation following treatment with EVs was assessed using a 
BRDU ELISA kit (Roche) this kit incorporates a labelled derivative of thymidine into 
DNA during proliferation which can then be detected by an antibody conjugated to an 
enzyme with a substrate that can produce a coloured product. Cells were seeded at 
values determined by optimisation experiments in triplicate with both a blank and 
background wells in a 96 well plate and left to adhere overnight. The cells were then 
changed to 100 µl serum free media overnight and treated with 20000 EVs/cell from the 
four cancer cell lines or the same volume of serum free medium the following morning. 
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Treated cells were left to incubate for 48 h, at which point they were treated with 10 µl 
of BRDU labelling solution and the plate wrapped in foil to protect it from light and 
returned to the incubator for 4 h. After 4 h the media was removed by tapping the plate 
on top of a pad of paper towels. Cells were then fixed by the addition of 200 µl of 
fixdenat to the wells and incubation for 30 min at room temperature. During this 
incubation anti-BRDU-POD was diluted 1:100 in antibody dilution solution. The 
fixative was removed by tapping off in the same was as before. Wells were then treated 
with 100 µl of the anti-BRDU solution for 90 min at room temperature. After which 
time the solution was removed and the wells washed three times with 1XPBS following 
the final wash step 100 µl of substrate solution was added to the wells and left to 
develop for 15 min. After 15 min 25 μl of 1M H2SO4 was added to each well and the 
absorbance measured using a Fluorstar plate reader at a wavelength of 450nm. 
 
2.6.5. Fibroblast activation 
2.6.5.1. Treatment of fibroblasts 
Fibroblasts were seeded at either 8000 per well in a 24 well plate or 250000 cells 
per well in a six well plate they were then serum starved for 24 h to synchronize the 
cells and prevent activating effects from the serum. After 24 h they were treated with 
either 20000 EVs from a cancer cell line 5 ng/ml TGFβ1 (R&D Systems UK) or the 
same volume of serum free medium. Protein and RNA was harvested and used for 
western blots or qPCR with αSMA antibodies or TaqMan primers. 
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2.6.5.2. Imaging fibroblast activation by immunofluorescence staining of 
alpha smooth muscle actin (αSMA)  
Eight thousand fibroblasts were seeded onto a sterile cover slip in a well of a 24 
well plate and allowed to adhere overnight. The cells were then serum starved for 24 h 
to minimise any impact of the serum before treatment with twenty thousand EVs per 
cell from one of the cancer cell lines for a further 24 h. After vesicle treatment the media 
was removed, and the cells were fixed by the addition of 100% methanol for 20 min at 
room temperature. The cells were then permeabilized by washing with 4 mM sodium 
deoxycholate before incubating them in 1 ml of sodium deoxycholate for 10 min at 
room temperature. This buffer was then removed before the addition of 1 ml blocking 
buffer of 2.5% BSA in 1x PBS, the plate was placed on a rocker at room temperature for 
1 hour. Following this incubation, a FITC conjugated antibody for αSMA (mouse 
monoclonal antibody to αSMA (IA4) Sigma) was diluted 1 in 1000 in blocking buffer 
and added to the wells, the plate was wrapped in foil to protect the antibody from light 
and returned to the shaker for an hour. Finally, the cover slips were washed three times 
in PBS and mounted using prolong gold Antifade mounting medium (Life 
Technologies) which was left to cure for at least 24 h before being imaged using a Zeiss 
Axioplan fluorescent microscope.  
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3. Optimisation of methods for purifying and storing EVs from the culture medium of 
oral cancer cell lines 
 
3.1. Introduction 
Cell culture media are routinely supplemented with foetal bovine serum (FBS) 
and whilst this acts as a good source of growth factors and nutrients allowing the cells 
to be maintained in vitro, it also introduces animal-derived contaminants that must be 
considered during experimental design. In the case of experiments involving EVs, FBS 
is a source of unwanted bovine EVs, which could interfere with downstream analysis of 
cell culture-derived EVs. Two methods papers (Théry et al., 2006 and Witwer et al., 
2013) stressed the necessity of either using EV depleted serum, or serum-free conditions 
if the cells could be grown without serum, when harvesting EVs from cell culture 
media. Recent studies have demonstrated how important this depletion step is when 
performing analysis of RNA contents of EVs as some RNA found in FBS is 
evolutionarily conserved and is indistinguishable from human transcripts (Shelke et al., 
2014; Wei et al., 2016). Depleting the serum of EVs is particularly important when 
working with cell lines like the ones used in this project which cannot be grown in 
serum-free conditions without affecting cell viability. 
  
Depleting serum of contaminating EVs can be performed by centrifugation of 
either the serum or the medium containing the serum at 100,000 x g for at least 18 h 
(Hill et al., 2013). Alternatively, EV-depleted serum can be purchased commercially. A 
recent article has raised considerable concerns that existing protocols for EV depletion 
are not sufficient to prevent contamination with bovine RNA species. The authors go as 
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far as to suggest some early findings that were considered breakthroughs in the field, 
including some of their own work, could in fact just be the results of persisting bovine 
contamination in culture as most bovine miRNA are 100% identical to their human 
homologs because of a high degree of conservation among mammals (Tosar et al., 
2017). The authors have also identified several other possible sources of this 
contamination, including growth factors, extraction kit spin columns and ambiguous 
mapping. This is a particular problem with miR-1246 miR-4448, miR-3960, miR-1248, 
miR-1290, miR-574-5p and miR-644b-5p, these species are similar or identical to 
regions within ncRNA like RNU2. The suggestion being that the quantitation of these 
miRNA is affected by the presence of fragments of the longer ncRNA within the library 
(Tosar et al., 2017).  The article concludes with the bleak tone that while current EV 
depletion approaches may not be good enough, the standard to which we should aspire, 
completely RNA free culture, is beyond our ability to achieve at this time. 
  
 EV purification has traditionally been achieved by serial centrifugation of either 
culture media or biofluids. There are numerous subtle variations on this methodology in 
the literature with additions of wash and filtration steps. Since the early 2000s 
biotechnology companies have begun to produce precipitation reagents aimed at 
reducing the time taken to harvest EVs. Work by Clayton and Webber (2013) elegantly 
demonstrated the extent of contamination with co-precipitated proteins when using 
different extraction techniques. The contamination was highest when using a 
precipitation reagent and lowest when using sucrose density gradient centrifugation. In 
2014 a paper was published demonstrating that size exclusion chromatography could be 
used to purify EVs from platelets (Böing et al., 2014). The same group went on to work 
with Izon to develop the qEV column, a column of Sepharose CL2b with a top and 
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bottom bed support and a bed depth of 10 cm. Using these columns, it is possible to 
separate EVs from soluble proteins. The columns are also used to process samples with 
large starting volumes of biofluid or culture medium. 
  
Literature searches indicate no firm consensus from the field on methods for the 
storage of EVs. A recent International Society for Extracellular Vesicles (ISEV) position 
paper stresses the importance of selecting appropriate storage buffers to prevent pH 
changes during storage and freeze thawing cycles (Lener et al., 2015). It also mentions 
that EV integrity is preserved better at -20oC and -80oC than at 4oC. However, it only 
cites 4 different publications (Kalra et al., 2013; Lener et al., 2015; Lőrincz et al., 2014; 
Sokolova et al., 2011) as evidence for this, indicating just how little published evidence 
there is for appropriate storage protocols. 
 
3.2. Aims and objectives 
The aims of this chapter were to determine the most appropriate techniques for the 
purification of EVs produced by oral cancer cells for use in our laboratory. Once 
optimised these protocols would be used to produce EV samples for all experimental 
work performed as part of this PhD. During this optimisation, methods for depleting 
FBS of bovine EVs were compared along with different methods for purifying EVs 
from both low and high volumes of starting material. As future experiments would 
possibly require the long-term storage of EVs the impact of freeze-thawing stored EVs 
was also assessed. 
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3.3. Depletion of bovine EVs from FBS 
3.3.1. Centrifugation for 18 hours at 100,000 x g removes bovine EVs 
from FBS.  
The particle counts of commercially available EV-free serum and EV-depleted 
serum made in house were compared to undepleted serum to determine which method 
was most effective. EV-depleted serum was purchased from SBI (catalogue number 
EXO-FBS-50A-1) and used to make a standard DMEM culture medium (DMEM 
supplemented with 10% (v/v) FBS, 1% (v/v) L-Glutamine and 1% (v/v) 
Penicillin/Streptomycin). FBS purchased from Gibco was centrifuged at 100,000 x g for 
18 h before being filter sterilised with a 0.22 µm filter and used to supplement DMEM 
culture medium with the same additives. To compare the success of EV depletion 
methods samples were analysed by TRPS using an NP100 nanopore (qNano, Izon).  
 
Both the commercial serum and the in-house EV-depleted serum show a reduction 
of particle counts from 8.5x109 to 1.4x109 and 1.65x109 respectively (figure 3.1). 
Interestingly neither method reduces the particle count to zero. There was no significant 
difference in particle counts between the commercially purchased serum and the serum 
depleted of EVs in house. All the samples exhibit similar size profiles (figure 3.2) with 
the majority of EVs below 100 nm in diameter. There are a few larger particles detected 
in the EV-depleted serum containing samples, particularly those depleted in house 
(figure 3.2 B&C), possibly as a result of aggregation occurring during the depletion 
techniques. As the qNano is not capable of determining the identity of particles passing 
through the nanopore, electron microscopy was used to visualise the particles present in 
the media. 
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Overnight centrifugation at 100000 x g reduces serum particle count 
 
 
Figure 3.1 Particle concentrations of tissue culture DMEM made with FBS from three 
different sources. Unprocessed serum, EV free serum purchased from SBI Biosciences and serum 
depleted in house by 100,000 x g centrifugation overnight (18 h). The serum was diluted to a final 
concentration of 10% (v/v) in DMEM used for tissue culture. Supplemented DMEM was diluted 1 
in 5 with filtered PBS containing 0.03% Tween-20 and run through a 0.22 μm centrifugal filter 
unit. Samples were then analysed by TRPS using an NP100 nanopore. The in-house and the SBI 
EV free serum were both seen to have significantly fewer particles when tested using a One-way 
Anova with Tukeys multiple test correction. n=2 technical replicates error bars representing SEM. 
**** = P <0.0001. 
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Size distribution profiles of bovine vesicles in DMEM  
 
 
Figure 3.2 Size distribution profiles of tissue culture DMEM made with FBS from three 
different sources. Unprocessed serum (A), EV free serum purchased from SBI Biosciences (B) and 
serum depleted in house by 100,000 x g centrifugation overnight (18 h) (C). The serum was 
diluted 1 in 10 with DMEM used for tissue culture, the DMEM plus FBS was then diluted 1 in 5 
with filtered PBS containing 0.03% Tween 20 and run through a 220 μm centrifugal filter unit. 
Samples were then analysed using an NP100 nanopore on Izons qNano. EVs are predominantly 
smaller than 100 nm in size for all three types of serum. Where the serum depleted in house was 
used, a few larger objects are detected around the 200 nm mark. n=2 technical replicates error bars 
representing SEM. 
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Overnight centrifugation at 100000 x g removes EV like structures from DMEM 
 
 
 
Figure 3.3 TEM images of DMEM supplemented with different serum types negatively 
stained with uranyl formate. DMEM made with undepleted serum (image A) at low magnification 
several clusters of vesicle like structures can be observed (marked with arrows). Image B is at a 
higher magnification and shows one of these clusters can be seen in the centre of the image 
comprised of multiple EVs. DMEM made with SBI Biosciences serum (Image C) and serum 
depleted of EVs in house (Image D) lack the clusters of small EVs observed in the DMEM with 
unprocessed serum but a few larger (60-80 nm) vesicle like structures are observed (marked with 
arrows) which is consistent with both the different particle concentrations and size distribution 
profiles seen with qNano. Representative images from 2 experiments. 
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As expected from the particle concentrations seen with the qNano, EVs are readily 
visible in the DMEM supplemented with unprocessed serum even at low magnifications 
(figure 3.3 A & B). These EVs appear to be quite small (less than 100 nm in size) and 
cluster together in large clumps which are distinctly visible at lower magnification. This 
is again consistent with the size profiles observed by the qNano, and the presence of the 
clusters indicates the capability of these EVs to aggregate even when they have not been 
subjected to the g forces experienced during the depletion steps. The large dense black 
structure seen in image A are salt crystals formed during the staining process. Images of 
DMEM containing the depleted sera do not show the clusters of small EVs present in 
the unprocessed samples (figure 3.3 C& D). There are a few larger vesicle like 
structures present which are around 80 nm in size in the serum depleted in house. This 
is consistent with the size distribution data from the qNano which showed 80 nm to be 
the modal size of particles in this sample. Similar structures were found in the SBI 
serum albeit slightly smaller in size which is again consistent with the data from the 
qNano. As depleting the serum of EVs in house was similarly efficient to the methods 
used by SBI biosciences this method was used for future experiments. 
 
3.4. Comparison of EV purification methods 
Three different EV purification methods were compared in order to determine 
which was the most efficient in our hands: ExoQuick reagent (SBI), a serial 
centrifugation method from Théry et al (referred to as the Théry method) (Théry et al., 
2006) and a method with a filtration step from a paper published in 2007 (referred to as 
the Valadi method) (Valadi et al., 2007). The two serial centrifugation methods or 
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derivatives of them are widely used in the literature to purify EVs from cell culture 
media and using Clayton and Webber’s particle to protein ratio measurement for purity 
have been shown to produce pure EVs with low protein contamination (Webber and 
Clayton, 2013). 
 
3.4.1. High protein concentrations are seen in pellets produced by 
ExoQuick reagent 
EV pellets produced by each of the extraction techniques were initially analysed 
by a BCA assay to determine the protein concentration (figure 3.4). The protein yields 
for the precipitation reagent are between two and three-fold higher than those seen for 
the serial centrifugation techniques potentially indicating a large quantity of co-
precipitated protein impurities in this preparation. It is also interesting that the protein 
yields were more variable in extractions carried out using this reagent than either of the 
two centrifugation protocols tested. The Valadi method produces a lower yield of 
protein than the Théry method, but because this method utilises a filtration step 
excluding anything above 220 nm in size from the sample, it would suggest that the 
difference between the two is still contaminating proteins rather than EV proteins.  
 
 
 
 
 
 
 
108 
 
 
Serial centrifugation protocols produce lower protein yields than precipitation 
reagents 
 
 
Figure 3.4 Protein concentration of vesicle pellets from three different vesicle purification 
techniques. Conditioned medium from confluent H357 cells was treated to one of three different 
extraction techniques and the final pellet resuspended in 1x RIPA buffer containing protease 
inhibitors. A BCA assay was used to determine the protein concentration of the resulting 
suspension. Protein concentration is around two-fold higher in the lysate produced by the 
ExoQuick method than in those produced by the serial centrifugation methods. Lysates produced 
by the Valadi method have marginally less protein in them than those produced by the Théry 
method. n=2 biological replicates error bars representing SEM. Results were non-significant with 
both a Student’s Test and One-way Anova with Tukeys multiple test correction. 
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3.4.2. Detection of EV markers in pellets from different extraction 
techniques  
To determine if the protein detected by the BCA assay was from lysed EVs, or just 
precipitated during the extraction, protein from the different extractions was normalised 
to the sample with the lowest concentration and 5 µg loaded into a well of a 12% 
polyacrylamide/SDS gel alongside 5 µg of protein lysate from whole cells. After 
transferring to a nitrocellulose membrane samples were treated with a panel of 
antibodies for proteins which had previously been detected in different EVs to 
determine which were present in the EVs purified by our techniques (Akers et al., 
2013). 
Antibody Marker for Reference 
CD63 Exosomes Escola et al., 1998 
HSP70 Exosomes Greening et al., 2015 
ALIX Exosomes Lässer et al., 2012 
TSP1 Apoptotic Bodies van Engeland et al., 1998 
ANNEXIN V Apoptotic Bodies van Engeland et al., 1998 
VAMP3 Micro-vesicles Muralidharan-Chari et al., 2009 
ARF6 Micro-vesicles Muralidharan-Chari et al., 2009 
Table 3.1 List of antibodies used on pellets purified by the extraction techniques. The antibodies 
are markers for the three major subclasses of EVs identified in the literature. These were used to 
determine which previously identified markers were present on EVs purified from these cells using our 
protocol. 
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 EVs purified by all methods are positive for CD63 and TSP1 but not HSP70 
 
Figure 3.5 Detection of vesicle markers in pellets produced by three vesicle extraction 
techniques. Conditioned media was treated to one of three different extraction techniques and the 
final pellet resuspended in 1x RIPA buffer containing protease inhibitors. Whole cell lysate was 
produced by lysing 500000 H357 cells in 1x RIPA buffer and protease inhibitors. Following a 
BCA assay 5 µg of protein was run per lane of 12% acrylamide gel before transferring to a 
nitrocellulose membrane. Antibodies were diluted at 1:200 in 5% milk in TBST and incubated 
overnight at 4oC. Secondary antibodies were used at 1:3000 in 5% milk in TBST and incubated for 
1 hour. Bands for CD63 were in both the cells and in EVs purified by all extraction methods. TSP1 
was in the EVs purified by all of the extraction methods but was not detected in the whole cell 
lysates. The reverse was seen for HSP70. Representative blot from 2 experiments. 
 
 
 
 
 
 
111 
 
Only three antibodies from the panel produced visible bands in the vesicle and 
cell samples these were HSP70 which was detectable only in the cells, TSP1 which was 
only detected in the EVs and CD63 which was detected in the both cells and EVs 
(figure 3.5). CD63 is a tetraspanin protein commonly referred to as a marker for 
exosomes and can be heavily glycosylated. The glycosylation most likely accounts the 
multiple bands seen for this protein, the ExoQuick method purifies samples with a 
greater proportion of the heavy form of the protein than the serial centrifugation 
approaches. The detection of CD63 in these samples would suggest that EVs are being 
successfully purified from the conditioned medium of H357 cells with these techniques. 
 
 TSP1 is thought of as a marker of apoptotic bodies and microvesicles. A double 
band was observed for TSP1 in the ExoQuick purified samples the second of which is 
approximately double the weight of the first. However, there is no record in the 
literature of multiple forms or dimers of this protein occurring, it would also be unlikely 
that a dimer would remain intact in the denaturing conditions of the SDS gel. The 
second band is close to the interface between the stacking and the resolving gels 
suggesting the upper band could be contaminants stuck in the stacking gel. Because of 
this uncertainty over the markers and the higher yields of protein generated using this 
method no further work was done using the ExoQuick reagent. HSP70 was detected in 
the cell lysates but not in the EVs purified by any of the methods suggesting it is 
unsuitable as a marker for EVs purified from these cells with these methods. 
Additionally, because CD63 was detectable in both the serial centrifugation methods but 
the Valadi method produced the lower protein yield, suggesting the filtration step 
reduced contamination, a hybrid final protocol was used in subsequent experiments (see 
section 2.3.4). 
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3.4.2.1. Wash step reduces protein concentration but doesn’t remove EV 
markers 
Clayton and Webber’s work illustrated the efficacy of a wash step in further 
reducing protein contamination of EV samples (Webber and Clayton, 2013). Before 
adding one to our own protocol, media from three confluent T75 flasks of H357s were 
treated to the purification protocol detailed in section 2.3.4 both with and without a 
wash step the resultant pellets were lysed and BCA assays run to compare the final 
protein concentration. The wash step reduced the protein concentration in the sample 
from 4.3 mg/ml to 0.5 mg/ml whilst still retaining the band for CD63 indicating the 
presence of EVs in the sample (figure 3.6), interestingly the wash step appears to 
remove the larger form of CD63 seen in the unwashed sample suggesting that this is a 
co-precipitated contaminant of the extraction. On the strength of this evidence a single 
90 min wash step was added to the combined protocol for subsequent use. 
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Wash step reduces protein concentration but doesn’t remove CD63 band 
 
 
Figure 3.6 Effect of introducing a wash step on protein yield and detection of EV markers 
in pellet produced by final hybrid protocol. Conditioned medium was treated to the final extraction 
protocol. Three preparations were resuspended in 1x RIPA buffer containing protease inhibitors 
following the first 100,000 x g step. Three separate preparations were treated to a wash step using 
1 ml of PBS and spun for 90 min at 100,000 x g the pellet was then resuspended in 100 ul of 1x 
RIPA buffer containing protease inhibitors. BCA assays were performed on the lysates. Protein 
concentration is reduced significantly by the wash step as determined by a two tailed unpaired 
students t test. 10 µg of EV lysate from the wash step was run on a 12% acrylamide gel and probed 
with CD63 primary antibody overnight after transferring to a nitrocellulose membrane. Following 
treatment with a HRP conjugated secondary antibody bands were detected in both the unwashed 
and the washed samples indicating the presence of CD63 in the pellet, representative blot from 3 
experiments. n=3 biological replicates error bars representing SEM * = P <0.05 students T-test 
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3.4.3. Size exclusion chromatography can be used to purify vesicles 
from large starting volumes of culture media 
Because of the limited capacity of our ultracentrifuge rotor an alternative method 
would be required for processing volumes of conditioned media above 30 ml. Such 
large volumes would be required for generating the yields of EV protein and RNA 
necessary for proteomic and transcriptomic analysis of their contents. Conditioned 
media from 3 confluent T175s of each of the cancer cells lines was concentrated from 
60 ml to >1 ml using a Vivaspin 100 kDa MW cut off column and the concentrated 
media loaded on to a column of 15 ml Sepharose CL2B that had been allowed to settle 
under gravity for at least four hours. This gave a bed depth of 10 cm, the same depth 
used by the commercial columns. Twelve 0.5 ml fractions were taken from the column 
and the fractions used for a BCA assay to determine protein concentration and run 
through a NP150 nanopore on the qNano using appropriate stretch voltages and 
pressure settings to determine particle counts. Comparison of the particle count and the 
protein concentration of each fraction was used to generate an elution profile for the 
home-made columns. EVs eluted between fractions 4 and 9 in all cell lines peaking at 
fraction 8, the majority of the protein was eluted in fraction 12 indicating a good 
separation between EVs and protein is achieved by the column (figure 3.7). 
 
 
 
 
 
 
 
115 
 
 
EV’s elute at fractions 4-9 on homemade SEC column with protein eluting at 
fractions 10-12 
 
 
Figure 3.7 Elution profile of homemade Sepharose column. 60 ml of conditioned media 
was cleared of dead cells and cell debris before being concentrated down to >1 ml in volume using 
a 100 kDa MW cut off filter unit. The concentrated media was applied to the top of a fresh 
Sepharose CL2B column with a bed volume of 10 ml. Twelve 0.5 ml fractions were collected 
using PBS with 0.03% Tween 20. Fractions collected were analysed for protein concentration 
using a BCA assay and vesicle number using a qNano TRPS instrument with an NP150 nanopore. 
The combined data from four different cell lines was used to create a combined elution profile for 
the home-made columns. EVs are in fractions four through nine, with the peak being fraction 
eight. The majority of the protein elutes from the column in fractions ten to twelve. n=4 biological 
replicates error bars representing SEM. 
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3.5. Storage of EVs 
3.5.1. Intact vesicles are seen by TEM after freezing at -20oC 
Because of the long duration of the intended experiments in this project EVs 
would have to be stored regularly. With this in mind EVs from the same serial 
centrifugation preparation were used to prepare grids for TEM before and after freezing 
to -20oC and thawing on ice to determine if this had any impact on the integrity of the 
EVs. Under electron microscopy intact EVs are seen both before and after the freeze 
thaw cycle strongly suggesting this does no damage to the EVs structural integrity 
(figure 3.8). The EVs in both images have similar size ranges (80-150 nm) but do 
exhibit subtly different morphologies, with those that have been frozen showing a more 
compressed shape. However, it is uncertain if this is caused by the freezing, or as is 
more likely the fixation. Similar shapes have been seen by other groups using protocols 
that contain a fixation step, this morphology is however missing when EVs are fixed 
using cryo EM techniques. 
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Freezing to -20oC and thawing on ice has no impact on EV morphology 
 
 
Figure 3.8 Transmission electron microscopy of EVs before and after freezing. EVs were 
extracted from the culture medium of confluent H357 cells using serial centrifugation and 
resuspended in PBS. The final suspension was split into two fractions and one of these was frozen 
at -20oC and thawed on ice. Both were then fixed in 2% paraformaldehyde and then adsorbed on to 
formvar coated EM grids and negatively stained using uranyl acetate and uranyl oxalate before 
imaging with a Tecani Spirit G2 microscope. EVs (marked by arrows) were clearly visible both 
before (left hand image) and after (right hand image) freeze thawing with intact membrane 
structures and similar sizes. Representative images from 3 experiments. 
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3.5.2. Freezing to -20oC and thawing on ice has no impact on EV 
samples particle count 
Alongside TEM samples were prepared in a similar fashion and used for analysis 
with the qNano. Samples split into two 50 μl fractions, one of which was frozen at -
20oC before thawing on ice. Samples were diluted 1 in 10 and ran through an NP100 
nanopore with appropriate stretch, voltage and pressure settings. The particle counts 
seen by the qNano were very similar before and after the freeze thawing suggesting that 
there is no damage caused to the EVs during the freeze thawing cycles (figure 3.9). 
There is however a difference in the size distribution profiles of the particles (figure 
3.10). Before freezing the mode size is 110 – 120 nm but after a freeze thaw cycle this 
has shifted to 70-90 nm. Taken together this evidence suggests that EVs can be stored at 
-20oC and thawed on ice without a loss of structural integrity or a reduction in numbers. 
Where required EVs would be stored at -20oC in future experiments but with care taken 
to minimise the number of freeze thaw cycles a sample was subjected to. 
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Freezing to -20oC and thawing on ice has no impact on EV sample particle count 
 
 
Figure 3.9 Particle counts of EV samples pre and post freezing. EVs were extracted from 
the culture medium of confluent OSCC cells using serial centrifugation and resuspended in PBS 
with 0.03% Tween 20. This final suspension was split into two fractions one of these was frozen at 
-20oC and thawed on ice. Both fractions were then run through the qNano using an NP100 
nanopore with appropriate settings. Particle counts were determined against CPC100B calibration 
beads. The freeze thaw cycle has no detectable impact on the number of particles in the sample 
difference was non-significant when tested with a student’s T-test. n=4 biological replicates error 
bars representing SEM 
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Freezing to -20oC and thawing on ice slightly alters EV particle distribution 
 
 
Figure 3.10 Size distribution profiles of EV samples pre and post freezing. EVs were 
extracted from the culture medium of confluent OSCC cells using serial centrifugation and 
resuspended in PBS with 0.03% Tween 20. This final suspension was split into two fractions one 
of these was frozen at -20oC and thawed on ice. Both fractions were then run through the qNano 
using an NP100 nanopore with appropriate settings. Size distribution profiles were created using 
the data from the qNano. The freeze thawing process is shown to have shifted the size distribution 
with more smaller particles detected. This could be due to the breakup of vesicle aggregates into 
single EVs during the freeze thawing. n=4 biological replicates error bars representing SEM. 
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3.6. Discussion  
In this chapter overnight centrifugation has been shown to deplete FBS of bovine 
EVs comparably to commercially depleted serum with around 75% of the EVs present 
in undepleted FBS removed by both protocols which is consistent with data from other 
groups (Shelke et al., 2014). Two different protocols for extracting EVs from both large 
and small volumes of conditioned media have been developed from a combination of 
established methods used by other groups. Antibodies for a range of proteins which 
have previously been detected in EVs were used to determine which markers were 
present in our EVs with whole cell lysate included as a control. Of this panel of 
antibodies only CD63 and TSP1 were present in our EVs. CD63 is widely reported to be 
a marker of EVs in the literature and is heavily glycosylated. Its expected weight is 26 
kDa but is seen in all our samples to be present in two bands one at 50 kDa a second at 
75 kDa potentially caused by variable glycosylation, that similar bands were in the 
whole cell lysate and in the vesicle samples suggests this glycosylation is a feature of 
the oral cancer from which this cell line was established. TSP1 has been considered as a 
marker of apoptotic bodies its presence in EVs purified by all three techniques suggests 
either that there is some contamination with apoptotic bodies, which is unlikely as these 
cells were grown in normal culture conditions and this protein was not detected in the 
cells, or it is present on other vesicle classes as suggested by entries in the database 
Exocarta (Chan et al., 2015). 
 
EVs produced from these methods have been determined to have a reasonable 
degree of purity by methods available to us in the laboratory. Unfortunately, a direct 
comparison with the particle protein ratios determined by Clayton and Webber was not 
possible with this data for two reasons. Firstly, experiments were performed in my first 
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year prior to the arrival of the qNano in our laboratory. Secondly Clayton and Webber 
used a Nanosight instrument for the determination of particle count in their samples, 
whilst the two instruments perform the same function the different technologies used 
mean the particle counts are not easily comparable. The late arrival of the qNano in our 
laboratory also prevented a more detailed comparison of the three extraction techniques 
in terms of particles purified being carried out. As using protein concentration alone is 
inadequate to quantify the EVs it is still possible that the ExoQuick reagent was 
purifying more particles than the serial centrifugation methods. The elution profile of 
our homemade columns was similar to that published by Izon and their collaborators 
(Böing et al., 2014) with EV elution peaking at fractions 7 and 8.  
  
Storage of EVs was also assessed using a combination of methods and EVs were 
seen to remain intact via TEM after freezing to -20oC and thawing whilst TRPS shows 
no reduction in the number of particles in the sample. There were however differences 
in the size profile of the EVs before and after freezing. These shifts are possibly caused 
by dissociation of aggregated EVs during the freeze thawing, this would also explain 
the marginally increased particle counts following freeze thawing. The qNano is not 
able to distinguish clusters of EVs as individual particles and it will instead see them as 
a single larger particle. EVs were seen to cluster together under TEM, which may be 
caused by the final centrifugation step of the extraction process, but there was no 
consistent or quantifiable decrease in size of the EVs seen under TEM post freeze 
thawing. Another possibility is that some precipitation of the phosphate salts has 
occurred during the thawing process giving rise to small particles detectable by the 
qNano. This data compliments that published in previous papers, whilst our work hasn’t 
touched on multiple freeze thaw cycles (Sokolova et al., 2011) or functional assays of 
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the EVs (Kalra et al., 2013) it has combined TEM and TRPS which will show any 
changes in pure particle number more accurately than the paper published in 2014 
(Lőrincz et al., 2014), this combination of techniques has not previously been used in 
this context.  
For experiments in subsequent chapters, all culture media required to be EV free 
will be supplemented with FBS treated with a 100,000 x g centrifugation overnight to 
remove bovine EVs as described in this chapter. The final serial centrifugation 
developed in this chapter (figure 3.11) will be used routinely for work performed in 
other chapters with vesicles stored at -20oC in appropriate buffers for downstream 
experiments for future use. For generating the EV to produce sufficient RNA and 
protein for the next generation sequencing and mass spectrometry the size exclusion 
protocol developed in this chapter will be used instead of the serial centrifugation 
protocol.  
3.6.1. Future work 
Further work for this chapter should begin by confirming the functional integrity 
of EVs pre and post freezing. This would rely on the identification of a functional trait 
of the EVs which could be robustly quantified such as delivery of a particular protein or 
RNA. Work should also be done to study the effect of multiple freeze thaw cycles on 
EV numbers size and activity. It would also be instructive to perform a more in-depth 
comparison of the EVs purified from the different extraction techniques. This should 
include average diameters, size ranges, protein and RNA contents as well as functional 
activity. An alternative direction to take this research would be to follow the lead of 
other groups in the literature and perform parallel experiments on the products of the 
10000 x g and 100,000 x g pellets of the serial centrifugation process. 
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Final workflow 
Figure 3.11 Schematic outlining routine workflow for EV purification which will be used for future 
chapters. Volume of starting medium will determine the choice of purification technique with 
volumes larger than 24 ml purified by size exclusion. The choice of resuspension buffer and storage 
will depend on intended downstream experiments with the purified EVs. 
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4. Characterisation of EVs produced by oral cancer cells 
4.1. Introduction 
Oral cancer, like other solid tumours, progresses through a defined process of 
tumourigenesis from dysplasia to carcinoma and finally, potentially, metastasis. To date 
there is a dearth of studies that explore how tumourigenesis effects EV production, 
although it is often speculated that circulating EVs in biofluids could be used as 
prognostic markers for disease progression as discussed in this review (Torrano et al., 
2016). A study using an inducible mouse embryonic fibroblast model identified an 
interesting change upon the induction of an oncogenic transformation. The number of 
EVs released remained similar but the EVs released from the transformed cells 
contained a signalling protein (Kreger et al., 2016). This protein, focal adhesion kinase, 
allowed the EVs to promote the survival of untransformed fibroblasts and enhance their 
proliferation under anchorage independent conditions. This indicates a change in EV 
signalling caused directly by the induction of tumourigenesis. 
  
However, this model has its limitations the induction of tumourigenesis is 
artificial and simplified by comparison to a real tumour. A study comparing 
oligodendroglioma cells and astrocytes, an example of natural tumour progression, 
(Schiera et al., 2013) suggests that a change in vesicle production occurs as a 
mechanism for the release of a histone protein H10. However, although they were able 
to demonstrate the transformed cells released vesicles containing this protein, they were 
not able to detect a change in vesicle production. It is also known that HPV can cause an 
increase in EV production in infected cells as a mechanism for spreading viral RNA 
(Ahmed et al., 2014). Although this viral transformation of cells is relevant in the 
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progression of some oral cancers many cases are not caused by an oncolytic virus but by 
other carcinogens. 
EV production rates and size ranges can be measured using an instrument like the 
qNano or Nanosight and changes in these numbers between cancer stages can be easily 
identified. Whilst TEM has its limitations when studying EVs, particularly with regards 
to fixation induced changes in morphology, when membrane stabilising reagents are 
included in the protocol it remains a useful and accessible method for visualising the 
EVs. TEM experiments can be used to validate the size ranges observed with particle 
counting instruments alongside identifying any dramatic changes in morphology of the 
EVs. Thanks to databases like Exocarta and the work of numerous groups within the 
field there are a wide variety of protein markers for EVs that can help to distinguish the 
origin and status of the vesicle. 
 
4.2. Aims and objectives 
The aims of this chapter were to use the protocols developed in the previous 
chapter to isolate EVs from the culture media of oral cancer cell lines representing 
different stages of the disease. The physical properties of these EVs were characterised 
by a combination of TEM and TRPS to determine the size ranges and rates of 
production for the different cell lines. The Agilent Bioanalyzer and western blotting 
were used to identify RNA populations present in and any protein markers carried by 
the EVs produced. 
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4.3. EVs are produced by oral cancer cells representing different stages of 
tumourigenesis 
Four cell lines were assembled representing various stages of oral cancer 
progression from the same primary site. D20 is a cell line established from a 
leukoplakia (a white lesion of the oral mucosa) situated on the lateral tongue of a 50-
year-old non-smoking male and which was found to be immortal after over a hundred 
passages. This cell line is representative of an early stage of the tumourigenic process in 
oral cancer and progressed into a carcinoma within five years in this patient. D35 is a 
cell line established from an erythroleukoplakia (a red and white non-homogenous 
lesion of the oral mucosa) situated on the lateral tongue of 68-year-old male smoker and 
which was found to be immortal after over a hundred passages. This cell line represents 
a more severe dysplasia which is in the process of acquiring the mutations that will see 
it progress into a carcinoma and progressed to a carcinoma in situ shortly after the cell 
line was established. H357 is a cell line established from squamous cell carcinoma of 
the tongue from a 74-year-old male patient who smoked between the age of 17 and 20. 
The carcinoma was a STNMP stage 1, well differentiated, node negative tumour. 
Finally, B22 is a cell line established from the lymph node metastasis of an 88-year-old 
male smokers cancer of the tongue. The tumour was stage four well differentiated with 
invasion of multiple nodes. This cell line represents a local metastatic deposit of the 
lymph nodes. 
 
To determine if EVs were being produced by these cell lines the conditioned 
media was subjected to the purification protocol developed in the previous chapter and 
the resulting sample adsorbed on to a TEM grid. Vesicle like structures can be clearly 
seen under the electron microscope (figure 4.1). For the mild dysplasia on the left (D20; 
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figure 4.1A) multiple EVs can be seen with a clearly defined outer membrane and an 
electron sparse lumen. These EVs range between 50 and 120 nm in size and are not 
observed to cluster. On the right (figure 4.1B) a single vesicle can be seen in the centre 
of the image, this is a larger vesicle, 150 nm in size, with a more electron dense cytosol 
than the EVs of the left-hand image, although this may be an artefact of the staining.  
 
For EVs from the severe dysplastic cells (D35; figure 4.1C&D) similar sizes were 
observed (around 150 nm) and have very clearly defined membrane bilayers. In the left-
hand image (figure 4.1C) there is some evidence of the 3D shape of the vesicle with a 
concave depression in the centre. Those in the right-hand image are more 2D in nature 
(figure 4.1D) indicating the variability of the fixation process. This image is the only 
one which shows evidence of a classic lipid bilayer like structure to the membrane, the 
other images do show some internal membrane like structure, but this is more central 
and possibly artefactual in nature.  
 
Similar morphological variation was seen in the EVs from the carcinoma cell line 
(H357; figure 4.1E&F) however unlike the severe dysplasia derived EVs they were 
observed most frequently in clusters like those seen in the centre of both images. 
Smaller clusters were also observed in the EVs produced by the metastatic deposit cell 
line (B22; figure 4.1G) although the EVs are a similar size to those seen from other cell 
types. The vesicle in the centre of the right hand (figure 4.1H) image displays an 
unusual morphology not seen in the EVs produced by other cell types. This vesicle is 
around 160 nm in size and has an extremely electron dense region within the lumen 
suggesting the presence of more complex lipid or protein structures. 
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EVs purified from OSCC culture media medium exhibit different morphologies 
under TEM  
  
Figure 4.1 TEM of EVs released by oral cancer cell lines from different stages of oral cancer. 
From mild dysplasia (A&B), severe dysplasia (C&D) a non-metastatic carcinoma (E&F) and cells 
from a metastatic deposit (G&H). Conditioned media from oral cancer cells was treated to the 
serial centrifugation protocol as previously described. The resultant sample was adsorbed onto a 
formvar coated 200 mesh TEM grid and negatively stained with uranyl acetate and uranyl oxalate. 
Vesicle like structures (marked with arrows) are clearly visible in all images ranging from 50-200 
nm in size. Representative images from 2 experiments. 
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EVs produced by OSCC have similar size distribution profiles 
 
 
 
Figure 4.2 Size distribution profiles of EVs produced by oral cancer cell lines from different 
stages of oral cancer. From mild dysplasia (A), severe dysplasia (B) a non-metastatic carcinoma 
(C) and cells from a metastatic deposit (D). EVs were extracted from the culture medium of 
500000 cancer cells using the protocol developed in the previous chapter as far as the filtration 
step to minimise the loss of EVs during the higher speed spins and get as close to the total EVs 
produced for this cell line as possible. Samples were run through an NP100 nanopore using 
appropriate stretch voltage and pressure settings and the data used to generate a size distribution 
profile. Detected EVs range in size from 60-210 nm with the modal size being 90-110 nm. n=3 
biological replicates error bars representing SEM. 
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Alongside the electron microscopy conditioned culture media was prepared 
to use for TRPS analysis with the qNano to quantify the production of EVs by 
these cell lines using methods detailed in 2.3.6. The size distribution profiles 
(figure 4.2) generated were consistent with the sizes seen under TEM, with a 
marked similarity for all the cell lines EVs, only the metastatic cells (figure 4.2 D) 
produced EVs with a marginally larger modal size of 100-110 nm as opposed to 
90-100 nm for the other cell lines. The data acquired shows that EVs from the 
different cell lines used in this project share similar physical properties. They are 
similar in size with only EVs from the carcinoma cells showing a slightly different 
size profile in that it has no EVs smaller than 70 nm and a larger modal size of 
100-109 nm. Because of the physical characteristics selected for by the extraction 
protocol it was expected that the EVs would share similar size ranges with very 
few particles around the 200 nm mark thanks to the filtration step. Interestingly 
when the mean diameter of the EVs is compared (figure 4.3) a trend of increasing 
size with cancer stage is observed with the mean diameter increasing from 99-126 
nm. EVs from the metastatic deposit cells were seen to be significantly larger than 
those of the severe dysplastic cells with a one-way Anova using Tukeys multiple 
test correction.  
 
Images from the TEM grids show that EVs also share similar morphological 
properties. In general, the EVs show a well-defined outer membrane which is 
electron dense with a lumen that is electron poor. There are a few exceptions to 
this, notably where only a single EV is in the image frame, where the lumen is 
extremely electron rich. This would normally indicate a large quantity of lipids 
which stain well with these negative stains, but it is likely to also be an artefact of 
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the staining or the software trying to normalise the staining against the 
background with a small area of well stained grid in frame. 
 
4.4. Comparison of production rates of EVs from different stages of oral cancer 
The same samples that were used to generate the size distribution profiles for each 
of the cell line-derived EVs were also used to generate production figures per cell in 24 
hours (figure 4.4). The rates of EV production were consistent for 3 of the cell lines, the 
mild dysplastic, the carcinoma and metastatic cells produced around 1500 EVs per cell 
in 24 hours but the severe dysplastic cells produced more than double that at around 
4000 per cell in 24 hours. This difference was statistically significant by a one-way 
Anova with Tukeys multiple correction test. 
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Average sizes of EVs produced by OSCC cells 
 
 
Figure 4.3 Mean diameter of EVs purified from the conditioned media of confluent OSCC cells 
by serial centrifugation. The EVs were resuspended in PBST before diluting 1in10 and running 
through a 0.22 µm centrifugal filter cartridge and measuring on an NP100 nanopore with 
appropriate stretch voltage and pressure settings. Values were compared to CPC100b calibration 
beads and the mean diameter calculated. General trend suggests and increase in average size with 
cancer stage, only the difference between the D35 (severe dysplastic) cell EVs and the B22 
(metastatic deposit) cell EVs was seen to be significant by one-way Anova with Tukeys multiple 
test correction. Error bars representing SEM for n=3 biological repeats. * = P < 0.05. 
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Severe dysplastic cells produce double the EVs in 24 h 
 
 
Figure 4.4 EV production rates of oral cancer cell lines. EVs were extracted from the 
culture medium of 500000 cells of each of the cell lines using the protocol developed in the 
previous chapter as far as the filtration step to minimise the loss of EVs during the higher speed 
spins and get as close to the total EVs produced for this cell line as possible. Samples were run 
through an NP100 nanopore using appropriate stretch voltage and pressure settings and the 
concentration of the samples used to generate a production figure per cell in a 24 period. The 
production was seen to be consistent with around 1500 EVs produced per cell in 24 hours for all 
bar the severe dysplastic cells where it is nearly 4000 EVs per cell in 24 hours. This difference was 
shown to be significant (p=>0.05) by a one-way Anova with Tukeys multiple correction test. n=3 
biological replicates error bars representing SEM. 
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4.5. RNA can be purified from EVs produced by oral cancer cells 
The Bioanalyzer (Agilent) was able to detect RNA in EVs produced by each of 
the oral cancer cell lines (figure 4.5). The bulk of the detected RNA falls between 
around 25 and 200 nucleotides, this spans the size ranges of miRNA and some smaller 
mRNA species, the RNA types most commonly associated with EVs. The mild 
dysplastic EVs show a peak of 20 FU at around 1000 nucleotides; the instrument has 
labelled some of this as contamination with 18s rRNA, a structural component of the 
small subunit of the eukaryotic ribosome. There are small peaks for this subclass of 
rRNA detected in each of the samples with similar small peaks for 28s rRNA present in 
EVs produced by the severe dysplastic and carcinoma cells. The severe dysplastic EVs 
contained the lowest signal for RNA, between 0-20 FU and the mild dysplastic EVs 
contained the highest, between 0-80 FU. 834.5 pg/μl and 1602.5 pg/μl of RNA was 
present in EVs purified by size exclusion chromatography from the culture media of the 
mild dysplastic and carcinoma cell lines (figure 4.6). This rises to around 6382 pg/μl 
and 4606 pg/μl in the severe dysplastic and metastatic deposit cell lines respectively 
(figure 4.6). These figures which were generated from separate biological replicates 
appear to contradict each other with the severe dysplastic vesicles having the lowest 
RNA content in the first experiments and the highest in the second. This would suggest 
that the protocols used to harvest RNA from the EVs have a poor repeatability.  
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EVs from OSCC contain high numbers of RNA between 25 and 200 nucleotides 
long 
 
 
Figure 4.5 Bioanalyzer profiles of RNA isolated from EVs produced by oral cancer cells from 
different stages of oral cancer using size exclusion chromatography. A) Mild dysplasia, B) Severe 
dysplasia, C) a non-metastatic carcinoma and a metastatic deposit D). Fractions 4-9 were pooled 
and centrifuged at 100,000 x g for 90 min. The pellet was treated with the miRCURY miRNA 
isolation kit and run on a total RNA Picochip. All samples show a similar output with a large peak 
between 25 and 200 nucleotides representing miRNA and other small RNA species. Only the EVs 
from the mild dysplastic (A) cells contain substantial numbers of the larger RNA species shown by 
the peak at 1000 nucleotides. There is some contamination with rRNA in each sample with peaks 
for the 18s and 28s rRNA in all the samples. Outputs are representative from 2 experiments. 
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EVs from severe dysplastic and metastatic deposit cells contain double the RNA 
of EVs from mild dysplastic and carcinoma cells 
 
 
Figure 4.6 RNA yields from EVs produced by oral cancer cells purified using size exclusion 
chromatography. Fractions 4-9 were pooled and centrifuged at 100,000 x g for 90 min. The pellet 
was treated with the miRCURY miRNA isolation kit and run on a total RNA Picochip. RNA yields 
were expressed in pg/μl, yields from the D20 and H357 cell derived EVs were consistently around 
1000 pg/μl with much more variability in yield of the EVs from D35 and B22 cells. D35 cell 
derived EVs have the highest yield of the four cell lines. n=2 biological replicates error bars 
representing SEM. Results were non-significant with both a Student’s T test and One-way Anova 
with Tukeys multiple test correction. 
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4.6. Protein markers of oral cancer extracellular EVs 
EVs are frequently characterised by particular protein markers to determine their 
origin within the cells, either MVBs or the plasma membrane, and subsequently attempt 
to identify the vesicle sub class to which they belong. The same antibodies used in the 
previous chapter with the addition of GM130 a golgi body marker, the presence of 
which would indicate cellular contamination, CD81 and tumour susceptibility protein 
101 (TSG101) which are markers used in other studies of small EVs (Kowal et al., 
2016). Protein lysates from both the producing cell and their EVs were analysed by 
western blot using the antibodies listed below (table 4.1). Bands were detected for 
CD63 TSP1 GM130 Alix and TSG101 (figure 4.7). No bands were detected for HSP70, 
Annexin V, VAMP3, ARF6 or CD81 in any of the samples. This could be due to them 
not being present or not present in sufficient quantities for detection with antibodies in 
these cells and their EVs. Something which could be confirmed by the use of a positive 
control for these proteins. 
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Antibody Marker for  Citation 
CD63 (Abcam antibody) Exosomes Escola et al., 1998 
HSP70 Exosomes Greening et al., 2015 
ALIX Exosomes Lässer et al., 2012 
TSP1 Apoptotic Bodies van Engeland et al., 1998 
ANNEXIN V Apoptotic Bodies van Engeland et al., 1998 
VAMP3 Micro-vesicles Muralidharan-Chari et al., 2009 
ARF6 Micro-vesicles Muralidharan-Chari et al., 2009 
CD81 Exosomes Lässer et al., 2012 
TSG101 Exosomes Lässer et al., 2012 
GM130 Golgi body Lässer et al., 2012 
Table 4.1 Table of antibodies used in this chapter to characterise the EVs produced by oral cancer cells 
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OSCC EVs are positive for TSP1 CD63 and Alix but negative for GM130 
Figure 4.7 Western blots of vesicle markers present in the EVs purified from the conditioned 
media of oral cancer cells alongside the lysate of the producing cells. Whole cell lysate was 
produced from each of the cancer cell lines as previously described. EVs were purified using size 
exclusion chromatography. These were then normalised to 10 μg of protein and run on a 12% 
acrylamide gel. After transferring to a nitrocellulose membrane, they were blocked and incubated 
overnight with the primary antibodies. Blots were developed by incubation with appropriate HRP 
conjugated secondary antibodies and then exposed to ECL substrate and X-ray film and developed 
on a Xograph X4. No bands were observed for CD81 VAMP3 ARF6 Annexin V or HSP70 in any 
of the samples. Bands were observed in all whole cell lysate (WCL) and EV lysate (EVL) samples 
for CD63 TSP1 and Alix. Bands for TSG101 were in D20 and B22 WCL and H357 EVs. GM130 
was detected in WCL of D20 D35 and B22 cells. Blots shown are representative from at least three 
experiments. 
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4.7. Discussion 
In this chapter EVs were shown to be produced by four oral cancer- or pre-cancer-
derived cell lines representative of different stages of the disease. These vesicles were 
shown to have similar size ranges by two different techniques and share similar 
morphologies when visualised via TEM. These size ranges and morphologies are 
consistent with those in many other studies. The mean measurements however do 
increase with cancer stage, something which hasn’t been reported in the literature to 
date. However, there is evidence of vesicle size increasing with reticulocyte maturation 
(Carayon et al., 2011) a process which, like tumourigenesis, leads to differently 
differentiated cells. 
 
Very little data exists on how tumour progression effects EV production, our data 
shows that the production rates for three cell lines are very consistent with only the 
severe dysplastic cells producing significantly more. Possible explanations for this lies 
in the details of this cell line, the patient from which these were established was a 
smoker whereas the other dysplastic cell line was established from a non-smoker, this 
patients disease also progressed to a carcinoma shortly after the establishment of the cell 
line. Both of these could provide a biological explanation for this observation either in 
combination or alone. However, it is worth noting that the patient donors for both the 
carcinoma and metastatic deposit cell line were smokers (although the carcinoma 
patient had only smoked between the ages of 17 and 20). This suggests that is more 
likely to be a combination of the two factors or the severity of the dysplasia alone that is 
responsible for the increased production rates. There is also a distinct difference in the 
genomic landscape of the cells. All cell lines have P53 mutations however each has a 
different mutation. The mild dysplastic cells have a G to A base change at codon 248 
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causing an arginine to glutamine amino acid change the mild dysplastic cell line has a t 
insertion at codon 200 which gives rise to a frameshift mutation. The carcinoma cell 
line also has a base change but at codon 110 from G to A, the metastatic cells exhibit a 
fourth different mutation, a 19 bp deletion. It is also possible that the increased EV 
production is an artefact caused by an accelerated doubling time of the severe dysplastic 
cells relative to the other lines in the OSCC panel, this could be tested for by comparing 
the growth rates of the cell lines in the same conditions and producing a figure for 
vesicles produced per cell per doubling time. 
 
One limitation to our data is that whilst the cell lines cover the same primary site 
they are not from the same patient. Similar work would need to be carried out in 
samples from more patients encompassing a wider variety of gender (all of our patients 
were male) age and smoking status to ensure these observations were not just caused by 
patient variability. There are two other distinct limitations in these cells as a model of 
tumour progression, first is 2D culture on plastic does not truly represent the complexity 
of the tumour with a number of cellular processes demonstrating differences when co 
culture or 3D conditions. The second is the observed immortality of the dysplastic cell 
lines which sheds doubt on how representative they are of an early stage of a tumour. 
However, whilst 3D culture would have been a more realistic representation of the 
tumour environment it would not have been possible to purify EVs from individual cells 
in the same way from a 3D culture model. 
  
 
It was the discovery that EVs could transfer RNA species between other cells 
which caused the fields rapid expansion. The majority of these papers focus either on 
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the coding mRNA or the non-coding miRNA, many of these have benefitted from the 
increasing availability of next generation sequencing technology (Jenjaroenpun et al., 
2013; Lunavat et al., 2015). Our data has shown that there is RNA present in the EVs 
produced by oral cancer cells although the variability in RNA yields between replicates 
make it difficult to make meaningful comparisons. Several groups have made use of the 
same Bioanalyzer platform used in this study to analyse vesicle RNA contents and it is 
instructive to compare their findings with ours. A group in Sweden performed 
Bioanalyzer assays on samples from whole cell RNA, microvesicles pelleted at 16500 x 
g and exosomes pelleted at 100,000 x g (Lunavat et al., 2015). Similarly, to this data 
they saw their 100,000 x g exosome pellets had an abundance of small RNA species 
between 25 and 200 nucleotides. Another group (Jenjaroenpun et al., 2013) has 
performed similar experiments comparing the outputs from breast cancer cells and the 
EVs they produced, their EVs exhibited similar profiles to ours with large peaks for the 
smaller nucleotides and small rRNA peaks, where these EVs appear to differ is they 
contain a large number of nucleotides up to 1000 nucleotides in size. The cellular RNA 
has more in common with that from the EVs purified from the 16500 x g centrifugation 
step (Lunavat et al., 2015) with large rRNA peaks which mask any signal from smaller 
rRNA species.   
 
Data from the western blots strongly suggests that our EVs, or a sizeable 
proportion of them, originate from within MVBs of the parent cells and could perhaps 
be termed exosomes. Alix is a 97 kDa adaptor protein involved in sorting cargo proteins 
in MVBs into the intraluminal vesicles. While bands for Alix were detected in all WCL 
and EVL samples, they were not at the normal size of 97 kDa but were visible at around 
the 200 kDa mark suggesting the protein is present as a dimer (figure 4.6). Alix 
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functions in the MVBs of cells as a dimer (Hurley and Odorizzi, 2012; Pires et al., 
2009) which binds to the ESCRT III component CHMP4. However, the dimer form of 
the protein should be reduced to the monomer by the loading buffer and SDS within the 
gel although it is possible that its packaging into EVs is as part of a complex with 
CHMP4 which protects it from the reducing conditions. Its presence in the vesicle 
samples strongly suggests the EVs produced by the oral cancer cells and isolated by our 
protocol originate in the MVB of the cells.  
 
CD63 is a tetraspanin protein long established as a marker of EVs (Escola et al., 
1998; Zitvogel et al., 1998) its molecular weight is normally 26 kDa. There are bands 
for this protein in all cell and EV samples on this blot (figure 4.6), however the weights 
of these bands are all over 50 kDa. The protein itself is heavily and variably 
glycosylated with three N linked glycosylation sites, cancer cells can exhibit different 
glycosylation to healthy cells (Horejsí and Vlcek, 1991; Metzelaar et al., 1991). It 
maybe that the form in these cells are very heavily glycosylated explaining the higher 
sized bands than expected. The Abcam data sheet for the antibody indicates a predicted 
range of between of between 30 and 65 kDa and suggests that the canonical weight is 
only detected in non-reducing conditions. The glycosylation of this protein in vesicles 
could be confirmed by treating with PNGase. It is still possible that the protein detected 
by this antibody is not CD63, however with the monoclonal antibody which was used in 
this chapter it is unlikely to be the case. CD63 has been shown to have a role in the 
intracellular vesicle signalling process (van Niel et al., 2011) which is why it is 
frequently used as a vesicle marker. Its detection in these EVs could indicate the 
presence of a population of vesicles arising from MVBs.  
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The absence of bands for GM130, a marker of the golgi body, in the EVs indicates 
the EVs are not contaminated with cellular debris and are unlikely to be produced by 
apoptotic processes. GM130 is a 130 kDa golgi matrix protein, the antibody for this was 
included to determine that the vesicles purified contained no cellular contaminants or 
were not themselves cellular debris. This protein was detected only in the whole cell 
lysates of D20 D35 and B22 cells but not in the EV samples from any of the cells. This 
is an important indication that the purification process is not purifying cellular 
fragments or co precipitating any cellular debris. Its absence in H357 whole cell lysate 
was unexpected but given the weak bands in other samples it may be that the signal was 
too weak to be detected in this sample. The double band in the lysate of the D35 cells is 
also unusual, whilst the protein has a splice variant it is shorter by 382 amino acids than 
the 1002 amino acid full length variant the size difference between the two isoforms 
would be expected to be bigger than that seen on the blot. This band could be explained 
by a mutated or modified form present in the D35 cells. 
 
 The EVs were also positive for the protein thrombospondin 1 (TSP1) which has 
been seen to associate with EVs isolated from the saliva of a healthy patient (Gonzalez-
Begne et al., 2009) as well as oral cancer cells (Chan et al., 2015) suggesting it is 
possibly enriched in oral cancer. TSP1 is a highly adhesive glycoprotein which binds to 
fibrinogen, fibronectin, laminin, type V collagen and integrins alpha 5 and beta 1 it has 
no transmembrane components indicating it should be present inside the EVs although 
it could also be bound to matrix associated proteins on the EV surface. The protein was 
detected in all whole cell and EV lysate samples and has been shown to have roles in 
tumourigenesis and angiogenesis both of which might be highly significant given the 
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origin of these EVs. Without a loading control however it is not possible to quantify any 
differences between the amounts present in the samples however the strength of the 
bands suggests that it is enriched in the EV samples compared to the cells.  
 
TSG101 is a 43 kDa protein which is involved with ubiquitination and can be 
recognized by the ESCRT-1 complex (Kostelansky et al., 2006; Teo et al., 2006) during 
the loading of vesicles. Its presence in so few of the samples was unexpected; it has also 
been used consistently as a vesicle marker and has been identified as being enriched in 
“light small EVs” a class of EVs they suggest can be separated from the tetraspanin 
enriched EVs purely by its physical properties (Kowal et al., 2016). Its presence in the 
H357 EVs could suggest that there is a similar subpopulation of EVs produced by these 
cells that is distinct from the CD63 positive population. It should also be noted that this 
protein is not detected in the parent cell lysate for H357 indicating it is possibly 
selectively enriched in the EVs. The bands for this protein were of similar sizes and 
intensity but it is possible that it is not expressed in the other cell lines or not expressed 
sufficiently to be detected. Alternatively, it could be expressed in a mutated form, one 
which removes its ability to negatively regulate cell growth (Morita et al., 2007) and 
which is not detectable by this antibody. 
 
Taken together this chapter indicates that EV production is a constant throughout oral 
cancer development, possibly increasing during the final stages of establishing a 
carcinoma. EVs are produced with a similar size range throughout tumourigenesis with 
an increase in mean size observed as the cells progress through tumourigenesis. The 
EVs purified by our protocol are positive for two MVB associated proteins and negative 
for a golgi marker confirming the presence of a population of EVs derived from the 
147 
 
MVB of the producing cells in the final sample. Given that the size ranges observed for 
the samples are larger than those normally associated with exosomes it is possible that 
there are potentially larger EVs derived from other pathways in the final samples. This 
would explain the mixed morphologies present under TEM, particularly the larger EVs 
observed alone with the more electron dense lumens (figure 4.1 B, C&H).  
4.7.1. Future work 
Future work for this chapter should focus initially on performing the same 
experiments in a wider range of cell lines. This should include multiple samples from 
the same tumour stages as well as samples from patients of different genders and 
smoking status. This would go someway to overcoming the studies currently 
underpowered sample size and would help to confirm if trends identified in our samples 
such as an increasing mean diameter or producing rate with cancer stage is true of oral 
cancer in general or just in the cells used in this study. The western blot experiments 
detailed in this chapter have also raised some questions that were unable to be addressed 
during the time span of the project. The CD63 antibody consistently detected bands that 
were different to the cannonical weight for the protein, the impact of glycoslyation on 
this should be tested by comparing EV samples treated with PNGase against untreated 
samples. Another approach would be to use targeted mass spectrometry for the EV 
markers used in the western blots possibly with an iTRAQ experiment comparing the 
levels of those proteins against the producing cells. As with the other experiments these 
should ideally be performed in a wider range of cells lines than the four used in this 
study. If ethical permission could be obtained it would be interesting to compare the 
results obtained in this chapter with samples from either the saliva or cells isolated from 
the biopsies of oral cancer patients.  
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5. Next generation sequencing of the miRNA contents of oral cancer EVs 
5.1. Introduction 
The discovery that EVs contained miRNA was a catalyst for the fields rapid 
expansion. These versatile nucleic acid molecules hinted at the potential for EVs to do 
more than act as cellular recycling bins. Small RNA species like miRNA have been 
shown to play roles in various cellular processes and disease states, particularly in 
cancer (Palanichamy and Rao, 2014; Yuan et al., 2014). The presence of miRNA and 
mRNA in exosomes was reported in 2006 and 2007 (Ratajczak et al., 2006; Valadi et al., 
2007). Subsequently the RNA contents of the different EV classes have been shown to 
vary (Crescitelli et al., 2013), with little or no RNA present in larger EVs pelleted at 
12,200 x g. These EVs and similar ones pelleted at medium speeds are often thought of 
as microvesicles. A paper in 2012 focusing on immune cell-derived EVs demonstrated 
that the most abundant small RNA species in the EVs were not miRNA but other less 
well studied species, namely vault RNA, Y-RNA and specific t-RNAs (Hoen et al., 
2012). Whilst these RNA species are not protein coding some of them have been 
observed to have regulatory functions in cells (Hoen et al., 2012).  
  
The RNA contents of EVs have been shown to play potentially important roles 
during tumour progression. Early in tumourigenesis cells evade normal growth 
regulation pathways and then, when they grow beyond the 2 mm diffusion limit of O2 
from the local vasculature, begin to develop their own blood supply. EVs have also been 
shown to contribute to dysregulation of normal growth controls; in an osteosarcoma 
model EVs from mesenchymal stem cells exposed to stress caused osteosarcoma cells 
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to become more resistant to apoptosis via the EV mediated transfer of miRNA which 
regulate the expression of PTK2, a versatile non-receptor tyrosine kinase with roles in 
cell cycle progression, proliferation and apoptosis (Vallabhaneni et al., 2016). EV RNA 
regulates or facilitates angiogenesis in different tumour types. In renal cancer, EVs 
increased VEGF expression at both the mRNA and protein levels by down regulating 
hepaCAM, suggesting that the EVs contain a miRNA for the hepaCAM transcript 
(Zhang et al., 2013). In myeloma, EVs carrying miR-135b promote the formation of 
endothelial tubes during hypoxic conditions (Umezu et al., 2014). Another mechanism 
is seen in leukaemia where EVs carry a range of miRNA which activate NF-κB and 
cause an increase in the induction of angiogenic markers (El-Saghir et al., 2016). 
  
Metastasis and the acquisition of drug resistance are two processes which can 
occur late in tumourigenesis and are most strongly associated with cancer becoming 
lethal. Both have been shown to be regulated by miRNA within EVs. In breast cancer 
EVs containing miR-200 family microRNA, a family that is highly dysregulated in 
cancer, were shown to transfer these miRNA to non-metastatic cells which in turn led to 
them acquiring metastatic potential (Le et al., 2014). The miR-200 family regulates 
epithelial-mesenchymal transition (D. Yuan et al., 2014), a process in which epithelial 
cells become less adherent and more capable of migration, considered a necessary part 
of the metastatic process. In a breast cancer model of docetaxel resistance one group 
showed that the transfer of miRNAs, notably miR-100 miR-222 and miR-30a, in EVs 
could facilitate this resistance (Chen et al., 2014). 
  
Because of the ease with which miRNA can be detected and identified from low 
amounts of RNA there is a significant focus on their application as biomarkers for 
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cancers. Coupled to the stability of EVs in biofluids this has led to many studies on the 
ability of EV RNA to act as biomarkers. Oral cancer is relatively unique in having a 
readily accessible biofluid that could be enriched for products produced by its 
component cells, salivary miRNA is likely to be encapsulated in EVs and there are 
already studies exploring these, miR-139a-5p and miR-31 (Duz et al., 2016; Liu et al., 
2012) are currently being proposed as salivary biomarkers for oral cancer. Next 
generation sequencing platforms, such as IonTorrent, provide a technique where the 
total RNA contents of a vesicle population can be profiled. This list of contents can then 
be interrogated to identify mediators of any observed biological effects or to track 
changes in contents with disease progression. Which could identify potential prognostic 
or diagnostic markers which can be looked for in patient samples. 
 
5.2. Aims and Objectives 
The aims of this chapter were to identify and characterize the RNA contents of the 
EVs produced by oral cancer cells. EVs were purified using size exclusion 
chromatography with pooled RNA positive fractions being spun down at 100,000 x g 
overnight. RNA extraction was carried out using the miRCURY extraction kit. Purified 
miRNA was sent to Edinburgh University for analysis on their Ion Torrent system. 
Analysis was carried out by a range of different bioinformatics techniques. Small RNA 
sequencing data was validated using TaqMan PCR 
 
5.3. Small RNA sequencing quality and species distribution 
EV samples were purified from the conditioned media of six confluent T175 
flasks per cell line using the size exclusion protocol. Following the Bioanalyzer 
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measurements of RNA concentration the samples were sent for IonTorrent sequencing. 
Different RNA species were present in the samples (figure 5.1). The largest proportion 
of the samples, between 60 and 75% in each case, is classified as “other RNA” this will 
include vault RNA, Y RNA as well as unidentified fragments. The next most abundant 
class of RNA is mRNA in all samples, with around 20-25% of the total RNA in each 
case. The remaining fraction of the samples is comprised of non-coding RNA, including 
small nuclear and nucleolar RNA as well as long non-coding RNA. The most widely 
studied type of RNA in EVs is miRNA but this class was poorly represented in all our 
samples both as the primary transcript and the mature final version account for less than 
0.5% of the total RNA in each sample. 
 
Quality control measurements from the small RNA sequencing experiment (table 
5.1) shows that a higher number of reads was gained from the RNA contained with the 
in the dysplastic cell derived EVs than the carcinoma or metastatic deposit derived EVs, 
10x106 and 9x106 respectively compared to 4x106 and 5x106. Whilst this figure varies 
the mean read length, the filtered reads and the aligned reads figures are more similar. 
With an average read length of between 20-22 base pairs for each sample and between 
2.7x106 and 4.5x106 filtered reads and between 2.5x106 and 3.9x106 aligned reads per 
vesicle samples. The trend observed in the total reads of more reads in the dysplastic 
cell derived EVs is lost when the reads are aligned. The fifth column details the 
percentage of mapped reads which for all bar the severe dysplastic derived EVs is above 
91% but in this sample drops to 58.57%. In the final three columns the miRNA contents 
of these reads are detailed, in both the D20 and the B22 EVs miRNA accounts for less 
than 0.5% of the mapped RNA reads; in the D35 and H357 samples this rises to 3.86% 
and 1.21% respectively.  
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RNA distribution in OSCC by IonTorrent sequencing shows majority of RNA are 
categorized other with miRNA being less than 0.2% in all EV types 
 
 
Figure 5.1 Distribution of RNA types within the samples sent for ion torrent sequencing. The 
largest component of the samples was classified as other RNA which includes vault RNA Y RNA 
and any unidentified fragments at around 60-75%. The next largest is mRNA with around 20-25% 
of the total RNA. 
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EV origin Total reads Mean 
read 
length 
(BP) 
Reads 
passing 
filters 
Aligned 
reads 
Percentage 
mapped 
reads 
miRNA 
reads 
Percentage 
miRNA 
reads 
miRNA 
detected 
with at 
least 10 
reads 
D20 (mild 
dysplasia) 
10,123,202 20 4,265,363 3,982,359 93.37 17,683 0.41 138 
D35 (severe 
dysplasia) 
9,983,848 21 4,502,722 2,637,110 58.57 173,994 3.86 270 
H357 
(carcinoma) 
4,390,352 22 2,743,519 2,502,136 91.20 33,216 1.21 174 
B22 
(metastasis 
5,006,112 20 3,145,916 2,882,198 91.26 14,896 0.47 132 
 
Table 5.1 Characteristics of RNA identified by IonTorrent smallRNA sequencing of EVs produced by 
oral cancer cell lines. Over 4x106 total reads were identified in each of the EV samples, of these between 
2-3x106 were successfully aligned to the human genome. The table also shows the proportion of those 
reads which were determined to be miRNA as being between 0.4 and 3.8% in each of the vesicle types. 
 
5.4.  Processing of IonTorrent data 
Following the Ion Torrent processing the number of miRNA reads ranged from 
14896-173994. To normalise for this large variation the reads score for each sample was 
converted to reads per million mapped reads. 200-300 miRNA per vesicle type were 
identified by the Ion Torrent sequencing experiments (figure 5.2). Using 10 and 100 
reads per million mapped reads does not reduce the number of miRNA significantly. 
Imposing a minimum of 1000 reads per million mapped reads as a threshold reduced 
this to less than 100 miRNAs per vesicle type. 
 
 
Following this, Euclidean clustering was used to construct a heat map for the 107 
miRNA species common to all the vesicle types. This heat map (figure 5.3) shows that 
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with respect to the miRNA contents the EVs cluster independently of tumour stage, with 
the EVs from the mild dysplastic (D20) and metastatic deposit cells (B22) showing the 
most similarity. EVs from the severe dysplastic cells were most dissimilar as they 
branch independently to any of other vesicle types, these EVs have 10-fold more 
miRNA reads than any of the other vesicle types which may contribute to this difference 
in the clustering (table 5.1). miR-23a was the most abundant miRNA in all the samples. 
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1000 RPM cut of reduces number of miRNA to around 100 per EV type 
 
 
Figure 5.2 Following Ion Torrent sequencing and mapping to miRBase between 200 and 300 
miRNA were identified for each cell line, cut of levels were imposed to remove sequences that 
weren’t frequently identified. Several of these sequences were only read between 1 and 10 times 
per million mapped reads; around half of them were read between 11-100 times per million 
mapped reads. Neither of these values represent a significant proportion of the total reads, 1000 
reads per million is often used as a cut of value in other similar studies, this cut of value reduced 
the number of miRNA sequences to between 50 and 100 more abundant sequences. 
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Euclidean heat map of OSCC RNA shows severe dysplasia and carcinoma cell 
derived vesicles have most similar contents 
 
 
Figure 5.3 Euclidean clustering was performed on those miRNA with more than 1000 reads per 
million mapped reads using Perseus. The EVs didn’t cluster by tumour stage. With the EVs of the 
mild dysplastic and metastatic deposit cells clustering together on the far right, the EVs of the 
carcinoma cells are separated from these two by one branch and on the far left are the EVs of the 
severe dysplastic cells. 
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5.5. Comparison of the miRNA contents of EVs produced by mild and severe dysplastic 
cells  
As a means of expanding on the comparisons drawn by the heat map the miRNA 
contents of the two dysplastic cell lines were compared in a volcano plot (figure 5.4). 
Very few of the miRNA are significantly detected in EVs. The majority of the miRNA 
were non-significantly detected with a p value of less than 0.05. There are only two 
distinct populations revealed by this graph, the majority of miRNA have between a 0 
and 5 log fold difference in levels between the two vesicle types which is not 
significant. Five miRNA were significantly detected in the severe dysplastic EVs, these 
include 2 members of the miR-199 and the miR-34 superfamilies of miRNA. The two 
significantly detected miRNA in the mild dysplastic EVs were miR-1307-3p and miR-
1285-1-5p the latter being the most abundant. A large group of miRNA were common to 
both samples, this group includes several members of the large let-7 superfamily along 
with miR-23a-3p and miR-27b-3p. 
  
Of those miRNA which were more abundant in the mild dysplastic EVs, both the 
3 and 5p forms of miR-1285-1 along with miR-635-3p, 590-5p and 1307-3p were 
between 5 and 10-fold more abundant in the mild dysplastic cell EVs (figure 5.5). In the 
severe dysplastic cell derived EVs further enrichment for whole families was seen as 
three members of the miR-199 family and two each of the miR-200 and miR-34 family 
are enriched albeit not all of these are significant, also enriched 10-fold in the severe 
dysplastic EVs were miR-503-5p and miR-708-5p (figure 5.5). The two members of the 
miR-34 family were the most abundant miRNA in the severe dysplastic EVs. 
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Volcano plot of miRNA in mild and severe dysplastic cell derived EVs 
 
 
 
Figure 5.4 Volcano plot of miRNA identified in EVs from mild dysplastic and severe dysplastic 
cells. The majority of the miRNA detected were detected with between 0 and 5 log fold difference in 
amounts but at non-significant levels. Only two miRNA were significantly detected in the mild dysplastic 
cell derived EVs miR-1285-1-5p and miR-1307-1-3p with five significantly detected in the severe 
dysplastic cell derived EVs including miR-199a-1-3p and miR-503-5p as well as miR-34b-5p and 34b-5p. 
p <=0.05. 
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Top 10 most differentially regulated miRNA in mild and severe dysplastic cell derived 
EVs 
 
 
Figure 5.5 Log2 fold change of the 10 most differentially abundant miRNA in the mild dysplastic 
and severe dysplastic cell derived EVs. The miR-200 miR-199 and miR-34 families are more 
abundant in the EVs of the severe dysplastic cells. 
 
 
 
 
160 
 
5.6. Comparison of the miRNA contents of EVs from non-metastatic carcinoma and 
metastatic deposit cells 
In a similar fashion to the EVs from the two dysplastic cell lines the miRNA 
contents of the non-metastatic carcinoma and the metastatic deposit were compared. As 
with the volcano plot for the EVs from the two different dysplastic cell lines the 
majority of the miRNA in the non-metastatic and metastatic cell derived EVs (figure 
5.6) have a log fold change of between 0 and 5 whilst having a non-significant 
difference between them. The only four significantly detected miRNA are all in the non-
metastatic carcinoma cell derived EVs, all of which were from the miR-200 family. The 
miR-34 and let-7 families are abundant in both vesicle types. Of the 10 most 
differentially abundant miRNA (figure 5.7) those in the metastatic deposit are all 
between 2 and 6-fold more abundant whereas those in the carcinoma exhibit fold 
changes of between 2-10-fold. In the EVs of the metastatic deposit cells miR-199a-2-3p 
was most abundant with a log fold change of 6. Also enriched in these EVs are miR-
144-3p and miR-378a-3p. The most abundant miRNA in the non-metastatic cells with a 
log fold change of 10 are the miR-200 family members miR-200a-3p miR-200b-3p and 
miR-200c-3p along with miR-41-3p. 
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Volcano plot of miRNA in non-metastatic carcinoma and metastatic deposit cell 
derived 
 
 
 
Figure 5.6 Volcano plot of miRNA identified in EVs from non-metastatic and metastatic cells. The 
majority of the miRNA detected were detected with between 0 and 5 log fold difference in amounts but at 
non-significant levels. Only four miRNA have a significant difference in abundance and all of these were 
in the non-metastatic cell derived EVs. These were the 3p forms for miR-200a miR-200b and miR-200c 
as well as miR-141-3p. p <=0.05. 
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Top 10 most differentially regulated miRNA in non-metastatic carcinoma and 
metastatic deposit cell derived EVs 
 
 
Figure 5.7 Log2 fold change of the 10 most differentially abundant miRNA in the carcinoma and 
metastatic deposit cell derived EVs. The most abundant miRNA in the metastatic deposit cell EVs 
is miR-199a-2-3p and the most abundant miRNA in the non-metastatic cell EVs are both 3p forms 
of miR-200 family members. 
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5.7. Comparison of the miRNA content of EVs from two oral dysplastic cell lines and an 
oral carcinoma cell line 
Because the cell lines used in this project originate from the same primary site it is 
appropriate to combine the miRNA content of the EVs from the two dysplastic EVs into 
one set to compare these to those detected in the carcinoma cell derived EVs using the 
same techniques as used for the other comparisons. The volcano plot in figure 5.8 is 
different from that seen with previous comparisons, a far larger number of miRNA were 
significantly abundant in the different vesicle types. In the dysplastic EVs four miRNA 
are highly significant (p= <0.0001); these are miR-34c-5p miR-34b-3p and 5p along 
with miR-199b-3p. A further four are also significant but with a higher p value these 
include miR-199a-3p and miR-34a-3p. Six miRNA are significantly abundant in the 
carcinoma cell derived EVs these include miR-200a b and c 3p.  As with the other 
comparisons a large proportion of the miRNA are common to both dysplastic cell and 
carcinoma cell derived EVs. The shared miRNA include 8 members of the let-7 family 
along with miR-29a and b 3p. In the dysplastic EVs the miR-199 and miR-34 family are 
between 4 and 14-fold more abundant than in the carcinoma EVs (figure 5.9). Similar 
enrichment of families is seen in the carcinoma cell derived EVs with three members of 
the miR-200 family between 5 and 10-fold more abundant in these EVs than in those of 
the dysplastic cells. Both miR-181a and b 5p are also slightly enriched in the carcinoma 
cell derived EVs with between 2 and 4-fold greater abundance than in the dysplastic 
EVs (figure 5.9). 
 
 
 
 
164 
 
 
 
Volcano plot of miRNA in dysplastic and carcinoma cell derived EVs 
 
 
Figure 5.8 Volcano plot of miRNA identified in EVs from dysplastic and carcinoma cells. The 
majority of the miRNA detected were detected with between 0 and 5 log fold difference in 
amounts but at non-significant levels. Large numbers of miRNA were significantly abundant in 
EVs from the dysplastic cells, the most significant were miR-34 and miR-199 family members. 
The significantly abundant miRNA in the carcinoma cell EVs include miR-200 family members. p 
<=0.05. 
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Top 10 most differentially regulated miRNA in dysplastic and carcinoma cell 
derived EVs 
 
 
Figure 5.9 Log2 fold change of the 10 most differentially abundant miRNA for the 10 most 
abundant miRNA in the dysplastic cell and carcinoma cell derived EVs. This reveals the miR-199a 
family are enriched in the dysplastic EVs and the miR-200 family members are enriched in the 
carcinoma cell derived EVs. 
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5.8. Comparison of miRNA levels and target pathways in EVs from different tumour 
stages 
Following the differential expression analysis between the vesicle types, those 
miRNAs which were common to all of the vesicle types were identified. Out of the 108 
miRNA with more than a thousand reads per million mapped reads (RPM) 44 were 
common to all four EVs types. Several of the miRNA have changing levels across the 
different tumour stages (figure 5.10), miR-181a-5p is more abundant in both carcinoma 
and metastatic cell derived EVs when compared to the dysplastic EVs with an increase 
of between 3 and 5-fold. The levels of miR-31-5p halve in carcinoma and metastatic 
cell derived EVs compared to the dysplastic cell derived EVs. Both the 3p and 5p forms 
of miR-126 are twice as abundant in the EVs of the mild dysplastic cells compared to 
the other three vesicle types, whereas miR-27a-3p is twice as abundant in the EVs of the 
severe dysplastic cells when compared to the other three types. There are several 
miRNA which are present in much higher levels in the severe dysplastic cell EVs which 
might be caused by the 10-fold higher level of detected reads in this sample. As with the 
other analyses miR-23a-3p was the most abundant in all EVs types. 
  
Using the miRBase tool DIANA the miRNA were mapped to the KEGG pathways 
in which their target proteins are found (figure 5.11). The majority of miRNA of interest 
are predicted to target multiple pathways, all bar three of the pathways are represented 
by at least 50 miRNA in all of the vesicle types. Because of the similar numbers of 
miRNA representing each pathway it is difficult to determine if there are any variations 
in the distribution. Among the pathways targeted by the miRNA in EVs are the MAPK, 
PI3K-AKT and WNT signalling pathways as well as focal adhesion and regulation of 
actin cytoskeleton. As expected the pathways all appear to be more heavily represented 
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in the EVs of the severe dysplastic cells however there are 15 more miRNA with over 
1000 RPM in these EVs than any of the other vesicle types with 85 miRNA, those of 
the mild dysplasia had 70 the carcinoma 63 and the metastatic deposit cells 68. Putting 
these numbers alongside those seen in the graph reveals that for all the pathways bar 
fatty acid synthesis over 60% of the miRNA present in the EVs target that pathway. 
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Abundance of detected miRNA varies with EV type 
 
Figure 5.10 Comparison of the abundance of the miRNA common to all EVs types. 108 miRNA 
with more than 1000 reads per million mapped reads (RPM) were filtered to find those common to 
all of the vesicle types. Forty-four miRNA were present in EVs from each of the tumour stages, the 
amounts of several miRNA vary with tumour stage notably miR181a-5p. 
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Kegg pathway analysis of EV miRNA contents reveals no significant changes 
 
Figure 5.11 KEGG pathways represented by the 44 shared miRNA. Shared miRNA with over 
1000 RPM were entered into the DIANA miRNA database to identify the KEGG pathways 
represented. The database search reveals that the majority of miRNA target several pathways with 
most of the pathways being represented by over 50% of the miRNA over 1000 RPM. 
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5.9. Validation of IonTorrent sequencing data 
5.9.1. Selection of targets 
In order to validate the IonTorrent data, qPCR was employed to examine the 
abundance of target miRNA sequences in whole cell RNA preparations and EV samples. 
Candidates were selected for one of two characteristics. Firstly, sequences were selected 
which had high and consistent abundance in all samples and would therefore have a 
high likelihood of being detected by qPCR in both EVs and cells. Secondly, some 
sequences were selected which were not consistently abundant in all the samples, 
detection of similar patterns of abundance by qPCR would indicate that the patterns 
seen by sequencing were valid. Detection of these candidates in both EV and cell 
samples would indicate that the IonTorrent experiments had identified sequences 
successfully in all of our EV samples. Both let-7a and miR-29 have high abundance in 
each of the samples however miR-29 has higher abundance in the severe dysplastic cell 
derived EVs (figure 5.12) detection of this sequence via qPCR in both EVs and WCL 
would indicate the IonTorrent had both detected the correct miRNA and had detected 
any patterns of variation of miRNA between EV samples successfully. miR-199 was 
only present in the severe dysplastic cell derived EVs and would also act to confirm any 
indications of variance seen in the IonTorrent data. 
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Let-7a miR-199a-3p and miR-29a-3p are suitable validation candidates 
 
Figure 5.12 To select suitable targets to validate the ion torrent sequencing reads per million 
mapped reads for different miRNA sequences was compared for each of the EV samples. This 
figure details the RPM for three putative validation candidates. Let-7a-5p and miR-29a-3p were 
selected because they were seen to be abundant in all the samples, in the case of miR-29a-3p there 
was also a difference in abundance seen by ion torrent with the severe dysplastic vesicles 
containing several fold more reads of this species. miR-199a-3p was selected as it was only 
abundant in the severe dysplastic samples. Detection of these 3 miRNA in similar proportions with 
qPCR would confirm both the patterns seen with ion torrent and the miRNA identified. n =1 
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5.9.2. Validation by qPCR 
Following the qPCR, the raw cycle numbers (figure 5.13) show that the EVs of all 
the cancer cell lines contain the miRNA let-7a-5p (figure 5.13 A) and miR-29a-3p 
(figure 5.13 C) as was shown in the Ion Torrent data, however the same enrichment of 
miR-29a-3p in the severe dysplastic EVs which was observed in the sequencing 
experiment was not seen in the qPCR. This could suggest that this variation is a 
technical variation and might not have been present in subsequent sequencing 
experiments. Both of the miR-29a and let-7a were present in the producing cells of 
these vesicle types. In the case of let-7a it was detected 6/7 cycles earlier in the cell 
samples than in the vesicle samples (figure 5.13 A) when ΔCT values were calculated 
for the samples (figure 5.13 D) the miRNA was significantly more abundant in the cells 
as opposed to the EVs in each of the cancer cell lines. Although there was substantial 
variation between the replicates the general trend demonstrates a significant reduction in 
the amounts of this miRNA in EVs relative to the producing cells. 
  
 In the case of miR29a (figure 5.13 F) the miRNA varied considerably in terms of 
relative abundance. In the mild dysplastic cells miR-29a was marginally more abundant 
(but with no statistical significance) in the EVs, this abundance increases in the severe 
dysplastic EVs to around 1-fold more abundant. In the carcinoma cells however, this 
trend is reversed, and the miRNA is significantly more abundant in the cells than in the 
EVs compared to the other samples. The trend reverses a second time in the metastatic 
deposit cells where the miRNA is some 900-fold more abundant in the EVs than 
compared to the cells. miR-199a was selected as is it was only present in the EVs of the 
severe dysplastic cells. Using qPCR (figure 5.13 B) it was seen to be significantly more 
abundant in both the severe dysplastic cells and the EVs when compared to the cells and 
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EVs of the mild dysplasia, the carcinoma and the cells of the metastatic deposit, 
however it was also present in the EVs of the metastatic deposit although at a much 
higher cycle number. When the relative abundance was calculated (figure 5.13 E) this 
miRNA was 4-fold more abundant in the EVs of the severe dysplastic cells and 8-fold 
more abundant in the EVs of the metastatic deposit cells when compared to their 
respective cells. 
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Presence of all three validation candidates is confirmed by qPCR 
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Figure 5.13 RNA extracted from the oral cancer cell lines and their respective EVs using the 
miRCURY kit was normalized to 10ng in 5μl and converted into cDNA before being used for qPCR with 
TaqMan Probes for let-7a-5p miR-199a-3p and miR-29a-3p. A, B and C show the qPCR cycle numbers at 
which the signal intensities crossed a threshold of 0.05 for let-7a miR-199a and miR-29a. Both let-7a and 
miR-29a are detected in the cells and EVs of all samples. miR-199 is in the EVs and cells of the severe 
dysplastic cells and was present in the EVs of the metastatic deposit but not in the cells. D, E and F show 
the corresponding ΔCT values indicating the relative abundance of the miRNA sequences in the EVs 
compared to their respective cells. let-7a is significantly more abundant in the cells of all the oral cancer 
lines, miR-199a is less abundant in the mild dysplastic and carcinoma EVs. For miR-29a the miRNA is 
marginally more abundant in the EVs of the mild and severe dysplasia. In the carcinoma cells the miRNA 
is more abundant than in the EVs whereas in the EVs of the metastatic deposit the miRNA is 900 times 
more abundant than in the originating cells. n=3 biological replicates error bars representing SEM. One-
way Anova with Tukeys multiple corrections were used to compare between variables * = p>0.05 ***= 
p>0.001 ****= >0.0001.
176 
 
5.10. Discussion 
It was the discovery that EVs could transfer RNA species between other cells 
which caused the fields rapid expansion. The majority of these papers focus either on 
the coding mRNA or the non-coding miRNA, many of these have benefitted from the 
increasing availability of next generation sequencing technology (Jenjaroenpun et al., 
2013; Lunavat et al., 2015). Several groups have made use of the different technologies 
to compare the RNA contents of EVs and producing cells. A group working on breast 
cancer cell lines showed the EVs purified at 100,000 x g contained large peaks for Y-
RNA and tRNA and lower levels of other small RNA. This was very different to the 
distribution of small RNA observed in the parent cell (Tosar et al., 2015). Breast cancer 
cells small RNA is predominantly miRNA whereas the vesicle small RNA is only 
0.26% miRNA with the majority being tRNA or 5’ tRNA halves, something observed in 
EVs from a non-malignant cell line too (Tosar et al., 2015). 
  
This strongly suggests that either the large rRNA peaks observed in EVs purified 
at lower speeds are cellular in origin introduced by the difference in formation pathways 
or they are cellular fragments co-precipitated with the EVs at this speed. The proportion 
of miRNA they observed in the vesicle small RNA samples is consistent with that 
observed in our experiments where less than 0.5% of the small RNA was miRNA 
species in each of the cell lines. Given the number of papers that focus on the miRNA 
contents of EVs the low proportion of the total small RNA peak represented by miRNA 
sequences was unexpected. However, our data did not see a similarly large proportion of 
tRNA fragmented or otherwise, the largest proportion of our small RNA was 
categorized as “other”, although this may be due to software differences. This segment 
177 
 
covers a large number of poorly studied RNA types including vault RNA and Y-RNA 
which are not coding sequences. All samples were treated to rRNA depletion as part of 
the work flow, despite this step the severe dysplastic EVs show a large amount of rRNA 
suggesting either a problem with this step or an abnormally large amount of rRNA in 
this cell line as has recently been reported in HEK293T cells (Memet et al., 2017 and 
Eckenfelder et al., 2017). It is also worth noting that RNA purified from urine EVs 
contain 12% rRNA after an Illumina sequencing experiment with a similar rRNA 
depletion step (Koppers-Lalic et al., 2016). 
 
One of the reasons for performing this kind of experiment is to enable changes in 
the miRNA contents of the EVs with tumour stage to be explored in detail. Although 
hierarchical clustering did show that the miRNA contents are varying with the vesicle 
source the clustering observed was independent of cancer stage. The EVs from the 
severe dysplastic cells have the most varied miRNA contents when compared to the 
other EVs types with the mild dysplastic and metastatic deposit cell vesicle being most 
similar. Where this data is only produced from a single biological replicate, any issues 
caused by the differences in the number of reads and the difference in the number of 
miRNA with over 1000 reads per million in the difference vesicle sources are unable to 
be corrected for. It is possible that the differences observed in the clustering are 
impacted by the severe dysplastic EVs having the highest number of miRNA reads and 
the lowest percentage of mapped reads. The lack of biological replicates is also 
responsible for the low number of miRNA above the significance threshold in the 
volcano plots. It is worth noting that the largest number of significantly enriched 
miRNA were seen in the volcano plot which compared the contents of two dysplastic 
cell derived EVs, which created the effect of replicates, with those of the carcinoma 
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cells. Despite this however there were some miRNA identified as being significantly 
enriched in the EVs of the mild dysplastic cells miR-1285-1-5p and miR-1307-1-3p. 
miR-1285 has not previously been detected in EVs but database searches reveal it 
functions as a tumour suppressor (Hidaka et al., 2012; Huang et al., 2017). miR-1307 
has been detected in EVs of colorectal cancer cell lines (Ji et al., 2014) and patient 
plasma (Huang et al., 2013) two papers from this year show this miRNA to be involved 
in chemo resistance (Chen et al., 2017) and promoting proliferation in tumour cells (Qiu 
and Dou, 2017). The enrichment of these miRNA in the EVs of the mild dysplastic cells 
would suggest that they are removing a tumour suppressor from the dysplastic cells and 
encouraging their proliferation in a bid to drive tumourigenesis. 
  
A larger number of miRNA were significantly enriched in the EVs of the severe 
dysplastic cells these included members of the miR-199 and miR-34 families both of 
which have been seen in EVs from plasma (Huang et al., 2013), miR-199 has been seen 
to be anti-tumourigenic, inhibiting invasion and migration in head and neck cancer in a 
recent publication (Koshizuka et al., 2017). The miR-34 family is a well-studied group 
of miRNA that are also seen to be tumour suppressing via SIRT1(Yamakuchi et al., 
2008). The enrichment of tumour suppressive miRNA in the EVs of this cell line is 
interesting when placed in context of the patient data, shortly after the establishment of 
this cell line the patients dysplasia progressed to a carcinoma. Indeed, comparing the 
contents of the dysplastic EVs with those of the carcinoma cells reveals that these 
tumour suppressing miRNAs are absent in the carcinoma cells EVs and if a similar 
pattern of enrichment was observed in EVs from other oral dysplasia and carcinoma cell 
it could be said that the release of EVs constitutes an important part of tumourigenesis. 
However, it would be instructive to determine if blocking the release of EVs prevents 
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tumourigenesis in an animal model. When comparing the miRNA contents of the EVs 
from the two different dysplastic vesicle types and those of the carcinoma EVs the miR-
34 family RNAs were enriched in the severe dysplastic cell EVs this family but were 
not present in the other vesicle types from later stages of cancer possibly suggesting that 
its removal from the cell is something that is necessary for continued progression 
through tumourigenesis. 
  
Although there appears to be an enrichment of tumour suppressing miRNA in the 
severe dysplastic EVs there is a group of miRNA which are common to both vesicle 
types which comprises several of the let-7 superfamily of miRNA this well 
characterised group of miRNA has been seen in various vesicle types and is considered 
to be tumour suppressing. Another common miRNA is miR-27b-3p which has been 
detected in colorectal cancer EVs (Ji et al., 2014) but is a pro-tumourigenic miRNA in 
contrast to some of the others (Lánczky et al., 2016). The most abundant miRNA in all 
the vesicle types is miR-23a which is a tumour suppressor in osteosarcoma (He et al., 
2014) and has been detected in in EVs from colorectal cancer cells and patient plasma. 
Because there exist within the shared miRNA both tumour suppressing and oncogenic 
miRNA it is difficult to assign a particular role to the EVs from either of these tumour 
stages. Some of these miRNAs are present in all vesicle types both in the sequencing 
experiments and by qPCR, the let-7 family is known to be differentially regulated in 
many cancers (Shell et al., 2007) and its abundance has been linked to the 
differentiation state of the producing cell. In our study the levels of this miRNA family 
were reasonably consistent across the different vesicle types suggesting that any 
variation in abundance with differentiation doesn’t extend to the contents of the EVs. 
The fact similar miRNA are seen to be in all the vesicle types is something that should 
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be explored further, it would be valuable to see if the same miRNA are also common to 
EVs of healthy cells of the oral cavity such as fibroblasts and keratinocytes or if their 
presence is as a result of an enrichment that occurs as part of tumourigenesis. 
  
Only four miRNA were significantly enriched when comparing between the non-
metastatic cell and metastatic cell derived EVs and all of them were in the non-
metastatic cell derived EVs. Three of these four miRNA belong to the miR-200 
superfamily, which in addition to having been detected in the EVs of colorectal cancer 
cells and patient plasma is also found in melanoma cells (Lunavat et al., 2015). When 
comparing between the vesicle contents of the dysplastic and carcinoma cell derived 
this family of miRNA are three of the seven miRNA enriched in the carcinoma cell 
EVs. This family is heavily implicated in cancer and there are papers showing that 
miR200a miR-200b and miR-200c function as tumour suppressors which inhibits 
invasion and metastasis (Damiano et al., 2017; Xu et al., 2016). The fact it is 
significantly enriched in the non-metastatic carcinoma EVs, but not present above the 
1000 RPM threshold in any other vesicle types, potentially suggests that again their 
removal from the cell is something that must occur for metastasis to happen. It is worth 
noting however that a paper from 2009 (Dykxhoorn et al., 2009) shows that the miR-
200 family promotes rather than inhibiting metastasis albeit its positive effect is exerted 
on a later stage of the process. The hypothesis linking removal of the miR-200 from the 
cells in EVs to metastasis may not stand up to testing. This duality of function observed 
in the literature for one miRNA family does highlight some of the challenges when 
attempting bioinformatic analysis of miRNA sequencing data. 
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The data presented here identifies several miRNA whose abundance varies 
between the EVs produced by the cells of different cancer stages. One of these miRNA 
is miR-181a-5p which appears to decrease in the severe dysplastic cell derived EVs 
relative to those of the mild dysplasia, but in the EVs produced by the carcinoma and 
metastatic deposit cells the levels of this miRNA increase dramatically. A search of 
Exocarta reveals that this miRNA has previously been detected in colorectal cancer cell 
EVs (Ji et al., 2014) and patient plasma (Huang et al., 2013). In several papers it has 
been shown to function as a tumour suppressor (Shi et al., 2017) which is under the 
control of TGFβ (Neel and Lebrun, 2013). Perhaps more significantly however a paper 
from 2011 reveals that this miRNA is upregulated in OSCC cells which developed from 
leukoplakia and its over expression is correlated with lymph node metastasis vascular 
invasion and poor survival (Yang et al., 2011) which given its previously reported 
function as a tumour suppressor is unexpected. The group also reported that ectopically 
over expressing this miRNA caused an increase in the invasion and migration of OSCC 
cells. In this respect miR-181a is similar to the miR-200 family in that there is evidence 
indicating it can act as both a tumour suppressor and as a tumour promoter, in the case 
of the miR-200 family it appears that the miRNA acts on different stages of the 
metastatic process with different effects, it is possible that the miR-181 family behaves 
in a similar way. The findings of this paper are reflected in the data presented in this 
chapter, with the EVs from the carcinoma cells having greater levels of this miRNA that 
those which originate from the leukoplakia, the levels of the miRNA in the producing 
cells should be determined in order to see if the cell line data is consistent with that 
from clinical samples and if there are any differences with in the enrichment between 
the EVs and their producing cells. 
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Some miRNA have different levels in the EVs from the dysplastic cells as 
opposed to the carcinoma and metastatic deposit cells. In the dysplastic cell EVs miR-
31-5p, which has been seen in EVs from colorectal cancer cells and patient plasma is 
twice as abundant compared to those of the carcinoma and metastatic deposit cells, this 
miRNA has been well studied in oral cancer, it has been shown to be upregulated in oral 
cancer tissue samples (Yan et al., 2017) a mouse model of tongue carcinogenesis 
showed that miR-31 was one of the first miRNA to appear in the saliva of the mice 
suggesting that it could be in salivary EVs (Kao et al., 2015) another paper which 
focused on the formation of leukoplakia identified the 3p form of this miRNA as one of 
the miRNA upregulated during the formation of leukoplakia (Xiao et al., 2012), miR-31 
has also been proposed as a biomarker of cancers of the tongue (Liu et al., 2012). Again, 
the findings presented in this chapter seem to be consistent with the published data in 
that the miRNA levels in the EVs match what has been reported in tissue or cells 
however the levels of miR-31-5p should be checked in the producing cells to determine 
if the levels are consistent with those reported in the literature and with those in the cell 
lines.  
A second miRNA is miR-126 which has been detected in the same colorectal 
cancer cell and patient plasma studies as the other miRNA. This miRNA is twice as 
abundant in the EVs of the mild dysplastic cells and in oral cancer this miRNA is 
tumour suppressive (Han et al., 2016; Yang et al., 2014),  so as with other miRNA its 
enrichment in the EVs of the dysplastic cells could be contributing to the progression of 
oral cancer. Conversely miR-27a-3p is significantly more abundant in the EVs of the 
severe dysplastic cells compared to the other vesicle types, this miRNA is oncogenic in 
breast cancer (Guttilla and White, 2009; Li et al., 2010) with links to proliferation. 
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Four miRNA species were mentioned in the introduction as being currently under 
study as biomarkers for oral cancer. The first of these miR-21 and miR-1245 have been 
detected in EVs from the serum of oesophageal cancer patients, neither of these were 
detected above the 1000 RPM cut of in our study, which is likely to be because of the 
different cellular origin, the epithelium found on the tongue is different from that found 
in the oesophagus. The second two miR-31 and miR-139 have not previously been 
detected in EVs either in saliva or from oral cancer cells, but were detected in our study, 
miR-139 was in the EVs of the mild dysplastic cells and miR-31 was present in all 
vesicle types but enriched in the EVs from both dysplastic cell lines. Our findings 
would suggest that at least some of the miRNA for these two-species detected in saliva 
is enclosed within EVs, the proportion of the salivary miR-139 and miR-31 which is in 
EVs could be easily determined using qPCR experiments on RNA extracted from whole 
saliva and on salivary EVs from patients. 
  
Alongside these one on one comparisons, KEGG pathways analysis of the miRNA 
was performed using the DIANA tool and miRBase. The outputs from this tool reveal 
just how multifunctional the miRNA contents of these EVs are. Unfortunately, this 
makes it difficult to draw any conclusions as to the EVs functions let alone changes in 
function with tumour stage. With the exception of fatty acid metabolism, each of the 
pathways is represented by around 80% of the miRNA in the EVs. It is possible that the 
EVs purified by this protocol are from different populations each with a distinct miRNA 
population, if this were the case it could offer some explanation for this difficult to 
interpret pathway data. If there were multiple populations with distinct miRNA contents 
and therefore affected pathways this could be masked by viewing the miRNA data for 
all the EVs. There are several interesting pathways targeted by the miRNA in these EVs, 
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including those that regulate adhesion and the regulation of the cytoskeleton, both of 
which are influential in metastasis. A missing piece of this jigsaw is the copy number of 
miRNA per vesicle in the literature this value has been speculated to be significantly 
lower than 1 copy number per vesicle (Chevillet et al., 2014), should similar numbers be 
observed in our EVs it would indicate one of two things, either random packaging or 
miRNA into the EVs or that multiple populations are purified. In either case it would 
limit any conclusions that could be drawn from further exploration of the pathway data. 
  
The validation experiments performed using TaqMan qPCR primers showed that 
as in the RNA sequencing experiments the miRNAs, miR-29a-3p and let-7a-5p were 
present in all of the vesicle samples, these miRNAs were also present in the cells that 
produced these EVs, it also confirmed the pattern observed in the RNA sequencing 
where miR-199a-3p was only present in the EVs of the severe dysplastic cells which 
would suggest that other patterns in the data are reliable observations. There were a few 
differences seen by qPCR however. Firstly, miR-199a was also detected in the EVs of 
the metastatic deposit cells although the high cycle  represents the fact it was below the 
1000 rpm cut of in the sequencing data. Secondly miR-29a was seen by RNA 
sequencing to have a much higher abundance in the EVs of the severe dysplasia 
however by qPCR there was little variation in the cycle number at which the miRNA 
was detected in any of the samples with the carcinoma EVs and metastatic deposit cells 
having the highest cycle numbers indicating the lowest levels, but this difference was 
only marginal. It is possible that these variations were only observed via RNA 
sequencing because of technical variation and would not have been detected in 
subsequent experiments whereas the qPCR was performed from three different 
biological samples. Whilst the RNA was normalised prior to running the Ion Torrent, the 
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number of different reads per sample indicates that there was considerable variability in 
the quality of the samples which could also account for this variation. The consistent 
similarity between the results from the two different techniques gives some confidence 
to the conclusions drawn from the Ion Torrent data. 
  
Let-7a-5p was one of the core miRNA species common to all the EVs types, 
calculating the ΔCT values reveals that this miRNA is actually more abundant in the 
originating cell. The Let-7 family of miRNA is commonly enriched in cancer and its 
presence in significantly lower levels in the EVs suggests it is not being actively 
packaged into these EVs. The substantial variation observed between biological 
replicates does not mask the overall difference pattern which is a reduction of between 
100 and 1000-fold of the miRNA in the EVs. Let-7a-5p is an evolutionarily conserved 
miRNA and if it were being actively packaged into the EVs the ΔCT values would be 
expected to be closer together. Research has shown that the levels of Let-7 family 
miRNA could be of prognostic value in cancer, (Shell et al., 2007) with this in mind the 
amounts of Let-7a-5p should be compared in healthy oral squamous cells to the 
cancerous cells as our qPCR experiments give no indication as to differences in the 
abundance of this miRNA in the different cancer stages. The information gained from 
this experiment could give some biological context to the significant difference in the 
abundance of this miRNA in the EVs and cancer cells. It is possible that the miRNA is 
deliberately maintained in the cells as opposed to being packaged into the EVs, however 
this wouldn’t fit with documented evidence detailing the Let-7 family as being tumour 
suppressive (Lee and Dutta, 2007). 
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 miR-199a-3p was selected as a validation candidate as it was only present in EVs 
from the severe dysplastic EVs, calculating ΔCT values shows that there is a fourfold 
increase in the levels of the miRNA in the EVs relative to the severe dysplastic cells. 
This miRNA was also enriched in the EVs of the metastatic deposit cells, although this 
ΔCT value was calculated from replicates with extremely high cycle numbers and 
should be viewed with caution. Evidence in the literature shows that this miRNA is 
heavily implicated in the acquisition of the invasive and migratory behaviours necessary 
for migration (Deng et al., 2017; Koshizuka et al., 2017) and it is possible that its 
release in the EVs of this cell line enabled it to obtain those phenotypes. However, this 
miRNA was not detected in the other cell lines, this suggests two possibilities, firstly 
that this mechanism is not occurring in every case of oral cancer or secondly that this 
miRNA is not alone in driving the acquisition of these behaviours. 
  
As with Let-7a-5p, miR-29a-3p was one of the core RNA shared by all the vesicle 
types in the sequencing data. qPCR showed that it was consistently present in all the 
cancer cells and the EVs they produced, it was also detected at a similar cycle number 
for all the cells and EVs, between 28-32, however these small variations in cycle 
number did indicate that the abundance of the miRNA in the EVs and the cells is not 
consistent. Whilst the abundance of the miRNA in the EVs relative to the cells steadily 
increases with the severity of the dysplasia, for the carcinoma this miRNA is more 
abundant in the cells than the EVs. The inverse of which is seen in the metastatic 
deposit cells where an 800-fold increase relative to the producing cells is observed. This 
is an extreme change in relative abundance when compared to the other cell and vesicle 
pairs, unfortunately without a suitable internal control this cannot be correlated to an 
increase in this miRNA in the cells or in the EVs. Unfortunately, we were unable to 
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establish a similar control for the vesicle samples which prevents robust comparisons 
between the miRNA levels of the different vesicle types in the same way. 
  
 As is common with many miRNA there are conflicting reports in the literature as 
to its role in cancers, some articles report that it is anti-tumour in gastric cancer cells (L. 
Chen et al., 2014) and pancreatic cancer cells (Tréhoux et al., 2015) whereas in 
colorectal cancer it promoted metastasis (Tang et al., 2014) and in breast cancer it 
promoted proliferation of tumour cells (Pei et al., 2016). It is possible that the function 
of the miRNA switches at some stage during tumour progression which would explain 
the change in distribution of miR29a between cells and EVs at the different stages. The 
additional information and questions raised by the comparison of the miRNA of the 
cells and the producing EVs demonstrates the importance of doing this with the other 
candidates identified during the analysis of the Ion Torrent data. 
5.10.1.  Future work 
This chapter hints that the field (ourselves included) should shift some of the 
focus on the miRNA contents of the EVs to the more abundant types of other small 
RNA present in these EVs. The Ion Torrent data was validated by confirming the 
expression of three miRNA candidates in the EVs and the corresponding cell lines the 
consistency of the results with two different techniques gives a reasonable confidence to 
the Ion Torrent data. Although limited in scope the Ion Torrent sequencing has provided 
some interesting options for further experimentation. The miRNA that appear to be 
differentially abundant in the EVs from the different tumour stages all merit further 
exploration, although there is one notable caveat that should be addressed. The amounts 
of RNA used for sequencing and for the qPCR were not normalised against the number 
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of EVs in part due to the technical difficulties of doing so. Because of this it would be 
valuable to perform experiments using PCR-based approaches on the RNA isolated 
from a known number of EVs to determine the copy number of the RNA species per 
vesicle. This would ensure that any changes observed in miRNA abundance were not 
caused by a different number of EVs being used to produce the miRNA, these 
experiments would be reliant on the identifying suitable controls however.  
 
If possible additional biological replicates of the IonTorrent sequencing should be 
performed, although an alternative approach would be to use a TILDA microarray or 
qPCR for a wider array of targets. Once this has been resolved the of these miRNA 
should be confirmed in the cell lines that produced the EVs used in these experiments 
along with other cells from the same stages as well as healthy keratinocytes to enable a 
wider and more reliable comparison to be drawn. If ethical permission could be 
obtained, then these targets could also be validated in EVs produced from cells 
extracted from patient biopsies or EV from patient saliva. Ectopic over expression and 
knockdown of the miRNA should be used to determine what phenotypic effects delivery 
of these species could have on surrounding cells of the TME. Given the number of 
miRNA that are linked to invasion and metastasis found in our EVs it would be 
interesting to establish a model using transwell or scratch assays to determine the effects 
on both cancerous cells, which would implicate these miRNA in metastasis, and 
immune cells or fibroblasts which would implicate these miRNA in the establishment of 
the TME.  
 
Considering the findings in this chapter that miRNA represent a very small 
proportion of the total RNA in the EVs, it would perhaps be most valuable to perform a 
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similar range of experiments on other less well studied RNA species in the EVs. Y-RNA 
and tRNA have both been identified in similar studies, although normally non-coding 
their apparent enrichment in EVs suggests a biological role which is yet to be 
uncovered. 
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6. Proteomic analysis of the contents of oral cancer cell EVs 
6.1. Introduction 
Vesicles are formed by the cell as a method of membrane protein recycling or as 
part of a mechanism receptor internalisation. EVs were first identified by tracking 
transferrin receptor recycling (Johnstone et al., 1987). The membrane contents of EVs 
are particularly significant for vesicles that form via inwards invagination of the 
intraluminal membrane in MVBs. Because the membrane undergoes two inversions 
during their biogenesis any membrane proteins are presented in their active 
configuration when released from the cell. This is important for trastuzumab resistance 
(Ciravolo et al., 2012) as EVs are released bearing active forms of the decoy receptor 
which bind drug molecules preventing them from binding the tumour cells. Non-
membrane proteins have also been detected in EVs, including proteins such as survivin 
(Khan et al., 2011), which is released during times of stress from the cell, or misfolded 
proteins in the case of Alzheimer’s disease (Saman et al., 2012). In cancer, these 
proteins have been shown to have multiple functions: they can be oncogenic forms of 
proteins (Al-Nedawi et al., 2008), transporter proteins that aid in drug resistance (Chen 
et al., 2014), or they can be ligands that can kill immune cells (Lundholm et al., 2014).  
 
Proteins contained within or on EVs form one of two of the major bioactive 
groups of molecules within EVs. With the increasing body of evidence for the selective 
packaging of proteins into EVs, the comparison of vesicle protein contents between 
those produced by diseased and healthy cells or patients has become an increasingly 
important step in studying diseases like cancer (Moon et al., 2016). As EVs yield a 
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small amount of protein the sensitivity of mass spectrometry techniques makes them 
valuable, enabling the identification of large numbers of proteins from a minimal 
amount of protein. This is particularly useful when applied to patient samples like 
saliva, a study by a group from Brazil has used label free analysis of salivary vesicle 
protein from healthy and unhealthy patients (Winck et al., 2015). From only 2 μg of 
vesicle protein 247 different proteins were identified post processing using a HPLC-MS 
system. Label free mass spectrometry assumes that the ion signal detected by the 
instrument correlates in a linear fashion with the proteins concentration, the machine 
relies on spectral counting or spectral peak intensities to determine this. Spectral 
counting works on the principle that peptides that are more abundant will be selected for 
fragmentation more often and will therefore produce spectra of a greater intensity. This 
contrasts to iTRAQ which is an isobaric labelling technique where all proteins in a 
sample are labelled with small molecular tags which produce fragments of a 
characteristic mass enabling the different samples to be compared. Two recent papers 
have made use of iTRAQ tagging to analyse vesicle proteins in both prostate cancer 
using urine samples from healthy and unhealthy patients (Fujita et al., 2017), and 
malignant mesothelioma using cancerous and primary mesothelial cells (Creaney et al., 
2017). 
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6.2. Aims and Objectives 
The aims of this chapter were to use mass spectrometry to profile the protein 
contents of EVs from cell lines representing the different stages of oral cancer. Detected 
proteins were analysed using a variety of bioinformatics tools enabling us to identify 
any changes in vesicle contents with tumour progression. GO analysis tools were used 
to provide details on the subcellular origin and pathways identified proteins belong to. 
This information provided details on the potential biological effect of EVs on receptor 
cells enabling future experiments to be designed. The mass spectrometry data was 
validated by western blotting for suitable candidates identified by the mass 
spectrometry. These validation experiments were carried out with whole cell lysates as 
well as vesicle lysates to enable comparison of relative abundance between the EVs and 
their parent cells. 
 
6.3. iTRAQ mass spectrometry of EV contents 
EVs were purified from the media of multiple confluent T175 flasks conditioned 
for 72 hours per cell line using size exclusion chromatography. The vesicle containing 
fractions were pooled and pelleted at 100,000 x g. This pellet was lysed using 0.1 M 
TEAB buffer containing 0.1% SDS and samples analysed by iTRAQ 8 plex. Protein 
yields were too low from the mild dysplastic cell (D20) EVs and so this sample was 
excluded from the iTRAQ experiment. As the samples for this experiment were 
allocated four of the eight iTRAQ tags available (with the other four being used for 
another user’s experiments), the severe dysplastic vesicle sample was loaded in 
duplicate. Following the iTRAQ run the differential abundance of the proteins was 
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determined for the EVs from the dysplastic and carcinoma cells and between the non-
metastatic and the metastatic cell derived EVs. Immediately evident is that despite the 
effort to separate these EVs from the protein and create pure samples there is 
contamination with serum proteins in these samples. Once the bovine proteins are 
removed there are 6 proteins decreased in the severe dysplastic EVs and 5 that are 
increased when compared to the carcinoma cell derived EVs (table 6.1). No proteins 
have significant differences in abundance when the most stringent statistical filters were 
used. If the multiple test corrections are removed however, then several proteins are 
decreased in the dysplastic EVs (table 6.2); histone 2 b (H2B), elongation factor 2 (EF2) 
histone 3.2 (H3.2) and nidogen-1 a basement membrane protein. Only 1 protein is 
significantly increased (p=<0.01) in the dysplastic EVs; splicing factor, proline- and 
glutamine-rich (100 kDa DNA-pairing protein). 
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Protein name Fold change in 
severe 
dysplastic 
vesicles relative 
to carcinoma 
vesicles 
Number of 
quantifications 
Number of 
unique peptides 
Species 
Alpha-1B-
glycoprotein 
0.75 14 1 Bos taurus 
Histone H2B 0.7 13 2 Homo sapiens 
V-type proton 
ATPase catalytic 
subunit A 
(Fragment) 
0.7 4 1 Homo sapiens 
Alpha-2-HS-
glycoprotein 
(Asialofetuin) 
(Fetuin-A) 
0.75 53 3 Bos taurus 
Beta-2-
glycoprotein 1 
(Apolipoprotein H) 
(Apo-H) 
0.65 5 1 Bos taurus 
IGK protein 0.7 6 2 Bos taurus 
Bifunctional 
glutamate/proline-
-tRNA ligase 
(Fragment) 
0.55 2 1 Homo sapiens 
Elongation factor 
2 (EF-2) 
0.6 13 3 Homo sapiens 
Serotransferrin 0.65 3 1 Bos taurus 
Histone H3.2 
(Histone H3/m) 
(Histone H3/o) 
0.4 22 2 Homo sapiens 
Nidogen-1 (NID-1) 
(Entactin) 
0.4 5 1 Homo sapiens 
Table 6.1 Proteins downregulated in the EVs of the severe dysplastic cells by iTRAQ (two replicates) 
compared to the carcinoma cell derived EVs (single replicate). p values were determined using a student’s 
t-test with several correction options to give varying levels of stringency. Proteins in italics have a p value 
of 0.01. Those in normal script have a p value of 0.05. The large number of bovine proteins present 
indicates the samples are still contaminated with serum proteins. Number of quantifications and unique 
peptides are included as a measure of quality control, proteins with a high number of quantifications are 
unique peptides are likely to be present as a complete protein and are abundant within the sample. 
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Protein name Fold change 
in severe 
dysplastic 
vesicles 
relative to 
carcinoma 
vesicles 
Number of 
quantifications 
Number of 
unique 
peptides 
Species 
Collagen alpha-
2(I) chain 
6.35 2 1 Homo 
sapiens 
Uncharacterized 
protein 
KIAA0408 
(Fragment) 
1.9 2 1 Homo 
sapiens 
Splicing factor, 
proline- and 
glutamine-rich 
(100 kDa DNA-
pairing protein) 
1.3 3 1 Homo 
sapiens 
60S ribosomal 
protein L8 
1.2 3 1 Homo 
sapiens 
Fibrinogen 
alpha chain 
1.2 8 3 Bos taurus 
Inter-alpha-
trypsin inhibitor 
HC2 component 
homolog 
(Fragment) 
1.15 9 4 Bos taurus 
Calmodulin 1.25 4 1 Homo 
sapiens 
Table 6.2 Proteins upregulated in the EVs of the severe dysplastic cells by iTRAQ (two replicates) 
compared to the carcinoma cell derived EVs (single replicate). p values were determined using a student’s 
t-test with several correction options to give varying levels of stringency. Proteins in italics have a p value 
of 0.01. Those in normal script have a p value of 0.05. The large number of bovine proteins present 
indicates the samples are still contaminated with serum proteins. Number of quantifications and unique 
peptides are included as a measure of quality control, proteins with a high number of quantifications are 
unique peptides are likely to be present as a complete protein and are abundant within the sample. 
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Protein name Fold change in 
metastatic 
deposit vesicles 
relative to 
carcinoma 
vesicles 
Number of 
quantifications 
Number of 
unique peptides 
Species 
Transforming 
growth factor-
beta-induced 
protein ig-h3 
(Fragment) 
9.4 2 1 Homo Sapiens 
Fibronectin (FN) 7.5 4 1 Homo sapiens 
Immunoglobulin 
superfamily 
member 8 
(Fragment) 
5.3 3 1 Homo sapiens 
Major vault 
protein (MVP) 
(Lung resistance-
related protein) 
2.3 9 1 Homo sapiens 
Elongation factor 
2 (EF-2) 
2.0 13 3 Homo sapiens 
Inter-alpha-trypsin 
inhibitor heavy 
chain H3  
1.8  17 5 Bos taurus 
Nidogen-1 (NID-1) 
(Entactin) 
1.8 5 1 Bos taurus 
Apolipoprotein E 
(Fragment) 
1.8 4 1 Homo sapiens 
Alpha-1,4 glucan 
phosphorylase (EC 
2.4.1.1) 
1.8 4 1 Homo sapiens 
Collagen alpha-2 
(I) chain 
1.7 2 1 Homo sapiens 
? 1.6 2 1 ? 
Inter-alpha-trypsin 
inhibitor 
1.6 9 4 Bos taurus 
Fibrinogen alpha 
chain 
1.6 3 1 Homo sapiens 
Protein AMBP 1.6 4 1 Bos taurus 
Charged 
multivesicular 
body protein 1b 
1.6 2 1 Homo sapiens 
Thrombospondin-
4 
1.5 5 1 Homo sapiens 
Fibrinogen alpha 
chain 
1.4 8 3 Bos taurus 
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Coatomer subunit 
gamma-2 
1.3 2 1 Homo sapiens 
Galectin-3-
binding protein 
(Fragment) 
1.3 22 2 Homo sapiens 
Heat shock 
protein HSP 90-
beta 
1.3 2 1 Homo sapiens 
Galectin-7 1.2 8 1 Homo sapiens 
Complement 
component C7 
1.2 4 1 Bos taurus 
Chromobox 
protein homolog 3 
(HECH) 
1.2 3 1 Homo sapiens 
Pre-mRNA-
processing factor 
19 (Fragment) 
1.2 2 1 Homo sapiens 
Table 6.3 Proteins upregulated in the EVs of the metastatic deposit compared to the EVs of the carcinoma 
cells by iTRAQ. p values were determined using a student’s t-test with several correction options to give 
varying levels of stringency. Proteins in bold have a p value of 0.05 with multiple corrections applied. 
Proteins in italics have a p value of 0.01 and those in normal script have a p value of 0.05 but no multiple 
corrections are applied. The large number of bovine proteins present indicates the samples are still 
contaminated with serum proteins. Number of quantifications and unique peptides are included as a 
measure of quality control, proteins with a high number of quantifications are unique peptides are likely 
to be present as a complete protein and are abundant within the sample. 
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Protein name Fold change in 
metastatic 
deposit vesicles 
relative to 
carcinoma 
vesicles 
Number of 
quantifications 
Number of 
unique 
peptides 
Species 
Aminoacyl tRNA 
synthase complex-
interacting 
multifunctional 
protein 2 0.9 2 1 Homo sapiens  
Apolipoprotein A-II 
(Apo-AII)  0.9 2 1 Bos taurus  
Integrin beta-4 
(GP150) (CD antigen 
CD104) 0.9 4 2 Homo sapiens  
Histone H2B 0.9 34 1 Homo sapiens  
Regulator of 
nonsense 
transcripts 2 0.9 2 1 Homo sapiens  
Deoxyuridine 5'-
triphosphate 
nucleotidohydrolase 0.9 4 1 Homo sapiens  
Protein RCC2 (RCC1-
like protein TD-60)  0.9 5 1 Homo sapiens  
Histone H1.3 
(Histone H1c) 
(Histone H1s-2) 0.8 3 2 Homo sapiens  
Cofilin-1 (Fragment) 0.8 5 1 Homo sapiens  
Beta-2-glycoprotein 
1 (Apolipoprotein H) 0.8 5 1 Bos taurus  
Alpha-fetoprotein 0.7 3 2 Bos taurus  
Fructose-
bisphosphate 
aldolase A 
(Fragment) 0.7 4 1 Homo sapiens  
Serotransferrin  0.7 3 1 Bos taurus  
Laminin subunit 
gamma-2 a) 0.7 2 2 Homo sapiens  
Alpha-2-HS-
glycoprotein 
(Asialofetuin) 
(Fetuin-A) 0.7 53 3 Bos taurus  
Alpha-1B-
glycoprotein (Alpha-
1-B glycoprotein) 0.6 14 1 Bos taurus  
Integrin alpha-6  0.6 15 3 Homo sapiens  
Mutant myocilin 
(Myocilin) 0.6 3 1 Homo sapiens  
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Table 6.4 Proteins downregulated in the EVs of the metastatic deposit compared to the EVs of the 
carcinoma cells by iTRAQ. p values were determined using a student’s t-test with several correction 
options to give varying levels of stringency. Proteins in bold have a p value of 0.05 with multiple 
corrections applied. Proteins in italics have a p value of 0.01 and those in normal script have a p value of 
0.05 but no multiple corrections are applied. but no multiple corrections are applied. The large number of 
bovine proteins present indicates the samples are still contaminated with serum proteins. Number of 
quantifications and unique peptides are included as a measure of quality control, proteins with a high 
number of quantifications are unique peptides are likely to be present as a complete protein and are 
abundant within the sample. 
 
Much like the comparison between the dysplastic cell EVs and those of the 
carcinoma cells the comparison between the non-metastatic and metastatic cell EVs 
(table 6.3 and 6.4) is heavily contaminated with bovine serum components like 
fibrinogen α chain. This is unexpected as any serum contamination would be expected 
to be consistent across all EV samples. There are two proteins which show a statistically 
significant difference in abundance even with the most robust stringency settings: EF2 
and galectin-3-binding protein are both increased in metastatic cell-derived EVs, 
although the latter was only identified as a fragment of the main protein (table 6.3). If 
the multiple test correction is removed more proteins have significantly different 
abundances. The structural proteins fibrinogen α chain (the human version), nidogen-1, 
fibronectin and collagen α 2 (I) chain are all enriched in the metastatic EVs along with 
major vault protein and thrombospondin 4. Integrins α 6 and β 4 and H2B are decreased 
in the metastatic cell EVs compared to the non-metastatic cell EVs (table 6.4). EF2, 
major vault protein, the galectin-3-binding protein and integrin α 6 were all selected for 
validation with western blotting as they were enriched in one or two vesicle sources and 
in the case of EF2 were seen in multiple samples. However, given the contamination 
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with bovine proteins and having inadequate amounts of protein to run all of our 
samples, the decision was taken to repeat these experiments using label free mass 
spectrometry. This had two advantages over iTRAQ, firstly it could be run with a lower 
amount of protein, and secondly it would enable us to generate a list of all proteins 
detected as opposed to just the differential intensities of the tagged proteins. 
 
6.4. Label free mass spectrometry of oral cancer EV contents 
6.4.1. Mass spectrometry data processing 
EVs were purified from the conditioned media of three confluent T175 flasks per 
cell line using SEC. Multiple preparations were pooled to give sufficient protein for 
analyses by reverse phase HPLC-MS. Samples were reduced, alkylated and then 
digested using trypsin. A 105 min data dependent acquisition on an Orbitrap Velos 
instrument yielded 1054 identified proteins following processing of the raw data with 
MaxQuant. The data was then subjected to post processing in Perseus (figure 6.1A). 
Removal of the contaminants identified by MaxQuant reduced the number of proteins to 
910. These contaminants included keratin and glucose-6-phosphate isomerase, which 
are often detected in very high quantities in samples masking other signals. 
  
The data was subsequently screened for quality by removing proteins with a low 
number of unique peptides; proteins with a razor and unique peptide score of less than 2 
were removed leaving 376 proteins. With so few unique peptides detected these matches 
could not be viewed with the same reliability as those with a greater number of unique 
peptides. Razor peptides are those peptides assigned by the software to a protein on the 
principle of Occam's razor. Therefore, if the razor peptide is unique it can only match 
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with a single protein group. If it is not unique it will only be a razor peptide for the 
protein group with the largest number of peptides. Finally, statistics were used to 
identify those proteins with significant differences in abundance between different 
samples using a multiway Anova test with appropriate corrections, which gave 194 
proteins common to the EVs from all cell lines with a p value of <0.05. The distribution 
of these proteins however wasn’t even across the different cell lines (figure 6.1B), 
ranging from between 18 and 177 proteins detected within the EVs from the cell lines. 
Twice the number of proteins were detected in the EV sample isolated from the 
carcinoma cell line than in any other sample. 
 
6.4.2. Comparison of protein contents of oral cancer EVs 
As part of the data processing in Perseus a heatmap was created using Euclidean 
clustering (figure 6.2). This clustering produced an unexpected result where the EVs 
from the carcinoma cells (H357) clustered independently from the other three vesicle 
types, which were clustered from left to right in order of increasing cancer stage. The 
heat map also places the EVs from the severe dysplastic cells and the metastatic deposit 
in a separate branch from those of the mild dysplastic EVs. A core of proteins is 
common to all vesicle types with smaller sections that are unique to one or two of the 
types. The heat map also shows that a number of proteins were only detected in one of 
the two technical replicates, which were subsequently removed from the data processing 
by the statistical tests. 
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Work flow for post processing of label free mass spectrometry data and range in protein 
number with EV type 
 
 
Figure 6.1 A) Workflow detailing data processing carried out in Perseus and the corresponding 
reduction in protein number achieved by the steps taken. B) Shows the variability in number of 
significantly detected proteins between the different cell lines. Data produced from n=2 technical 
replicates which were merged to allow statistical tests to be used. 
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Protein contents of OSCC EVs do not cluster by tumour stage 
 
Figure 6.2 Following label free MS protein hits were mapped using MaxQuant and the resulting 
data imported into Perseus where identified contamination and poorly identified peptides were 
removed. A Euclidean heat map of 376 oral cancer cell vesicle proteins with a razor + unique 
peptide score =>2 was produced. This shows the technical replicates of the mass spectrometry runs 
clustering together but also indicates the vesicles from the carcinoma cells cluster distinctly from 
those of the other cell lines which cluster from left to right in order of increasing cancer stage. Red 
coloured proteins are those with the highest abundance. n=2 technical replicates. 
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Following data processing in Perseus, gene ontology analysis was performed 
using the Panther database. The first characteristic compared was the molecular function 
of the proteins (figure 6.3). The most common protein type observed were binding 
proteins, which accounted for between 40-65% of the identified proteins. Catalytic 
proteins were more abundant in the EVs produced by the carcinoma cells (H357) and 
metastatic cells (B22). The EVs from the severe dysplastic cells lacked proteins with 
translation regulator or signal transduction activity, possibly caused by the lower 
number of proteins detected in these EVs in comparison to the other stages. These 
protein classes are highest in the mild dysplastic cell EVs. 
 
The distribution of cellular origins was reasonably consistent across the vesicle 
types (figure 6.4). A large proportion of the proteins originate from the extracellular 
region in all vesicle types, although this is seen to decrease to around 10% in carcinoma 
cells. However, there is also a significant proportion of proteins that are classified as 
cell parts, perhaps suggesting the presence of contaminants from cell debris. Again, a 
difference is observed in the severe dysplastic cell EVs with a decrease in the proportion 
of proteins derived from organelles to under 10% which are around 15-20% of the 
proteins in the other samples. All vesicle types have between 8-25% of proteins derived 
from organelles, upon further analysis (figure 6.5) the majority of these proteins were 
from the nucleus in all sources except for the severe dysplastic EVs where the only 
proteins present were cytoskeletal in origin. Further exploration of the cell part category 
(figure 6.6) indicates the majority of proteins for all the vesicle types are intracellular or 
plasma membrane in origin with few belonging to the nuclear outer membrane ER 
membrane network in the mild dysplastic and carcinoma derived EVs. 
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Binding and catalytic proteins are most abundant in OSCC EVs 
Figure 6.3 GO molecular function results for 194 statistically significant proteins purified from 
the conditioned media of confluent flasks of cell lines from different stages of oral cancer. A) mild 
dysplasia, B) severe dysplasia, C) a non-metastatic carcinoma and D) a metastatic deposit. Proteins 
were analysed by reverse phase HPLC coupled to label free mass spectroscopy, detected peptides 
were quantified and identified using MaxQuant before clean up and post processing with Perseus. 
Statistically significant proteins were run through the Panther Gene Ontology databases, with the 
above graphs detailing the distribution of molecular roles for the proteins detected. The majority of 
the proteins for all vesicle types were binding proteins with large numbers also involved in 
catalysis. n=2 technical replicates. 
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EV proteins are predominately cell part of extracellular region in origin 
Figure 6.4 GO cellular component results for 194 statistically significant proteins purified from 
the conditioned media of confluent flasks of cell lines from different stages of oral cancer. A) mild 
dysplasia, B) severe dysplasia, C) a non-metastatic carcinoma and D) a metastatic deposit. Proteins 
were analysed by reverse phase HPLC coupled to label free mass spectroscopy, detected peptides 
were quantified and identified using MaxQuant before clean up and post processing with Perseus. 
Statistically significant proteins were run through the Panther Gene Ontology databases, with the 
above graphs detailing the distribution of cellular origins for the proteins detected. For all cell 
types large numbers of proteins were from the extracellular region which is expected. There were 
also large numbers of proteins with origins in organelles, extracellular matrix or cellular parts. n=2 
technical replicates. 
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EV proteins from organelles are predominantly from nucleus or cytoskeleton in 
origin 
 
Figure 6.5 GO organelle results for 194 statistically significant proteins purified from the 
conditioned media of confluent flasks of cell lines from different stages of oral cancer. A) mild 
dysplasia, B) severe dysplasia, C) a non-metastatic carcinoma and D) a metastatic deposit. Proteins 
were analysed by reverse phase HPLC coupled to label free mass spectroscopy, detected peptides 
were quantified and identified using MaxQuant before clean up and post processing with Perseus. 
Statistically significant proteins were run through the Panther Gene Ontology databases, with the 
above graphs detailing the distribution of organelle origins for the proteins detected. The largest 
group of proteins is from the nucleus for all sources except the severe dysplastic cell derived EVs 
(B). n=2 technical replicates. 
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EV proteins from cell parts are predominantly intracellular or plasma membrane in 
origin 
 
Figure 6.6 GO Cell part results for 194 statistically significant proteins purified from the 
conditioned media of confluent flasks of cell lines from different stages of oral cancer. A) mild 
dysplasia, B) severe dysplasia, C) a non-metastatic carcinoma and D) a metastatic deposit. Proteins 
were analysed by reverse phase HPLC coupled to label free mass spectroscopy, detected peptides 
were quantified and identified using MaxQuant before clean up and post processing with Perseus. 
Statistically significant proteins were run through the Panther Gene Ontology databases, with the 
above graphs detailing the distribution of cell part origins for the proteins detected. Proteins are 
predominantly intracellular or plasma membrane in origin for all samples with a few belonging to 
the nuclear outer membrane ER membrane network in the mild dysplastic (A) and carcinoma 
derived EVs (C). n=2 technical replicates. 
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Nucleic acid binding is the most common function of OSCC EV proteins 
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Figure 6.7 GO Protein class results for 194 statistically significant proteins purified from the 
conditioned media of confluent flasks of cell lines from different stages of oral cancer. A) mild 
dysplasia, B) severe dysplasia, C) a non-metastatic carcinoma and D) a metastatic deposit. Proteins 
were analysed by reverse phase HPLC coupled to label free mass spectroscopy, detected peptides 
were quantified and identified using MaxQuant before clean up and post processing with Perseus. 
Statistically significant proteins were run through the Panther Gene Ontology databases, with the 
above graphs detailing protein classes for the proteins detected. Large numbers of nucleic acid 
binding proteins are all samples, along with cytoskeletal and matrix proteins. EVs from the 
carcinoma cells have a wider range of protein classes within them in comparison to other vesicle 
types. n=2 technical replicates. 
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Analysis of the protein class reveals more variation than for the protein origin and 
molecular function (figure 6.7). Consistent with the large number of proteins identified 
as being from the nucleus, there are large numbers of nucleic acid binding proteins in all 
samples. However, these are not transcription factors which are listed as a separate 
category and are far less abundant in all samples. There are also large numbers of 
cytoskeletal and matrix proteins in all samples. As is expected, cell adhesion proteins 
are present in all samples and account for ~4-5% of the proteins in each sample. Given 
the expected origin of some of these EVs is the intraluminal vesicles of MVBs, the 
presence of membrane traffic proteins in all bar the severe dysplastic vesicle type is 
expected. There is variation in the number of protein classes across the samples, which 
is likely to be due to the variation in number of proteins detected across the samples. 
There are several enzyme classes in the different samples, including isomerases, 
transferases, hydrolases and lyases. Ligases only appear in the carcinoma cell EVs 
(figure 6.7 C), as do transmembrane receptor regulator and adaptor proteins. With the 
exception of the severe dysplastic cell EVs (figure 6.7 B) immune system proteins are 
seen in all the EVs, as are chaperone proteins. Calcium binding proteins appear to be 
unique to the metastatic deposit EVs (figure 6.7 D) which in turn lack any transfer or 
carrier proteins. 
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6.4.3. Comparing the protein contents of EVs from mild and severe 
dysplastic cells 
The advantage of using discovery proteomics approaches is it allows the entire 
protein contents of EVs from the different cell lines to be compared at once using 
bioinformatics tools. The two dysplastic cell lines used in this project represent differing 
severity of pre-malignant oral lesions, which may be reflected in the vesicle contents of 
these cells. Comparison of the fold changes in abundance and the p values of the 
proteins detected in mild and severe dysplastic cell derived EVs (figure 6.8 and 6.9) 
reveals three distinct populations of proteins that were significant. A group of four 
proteins that are unique to the severe dysplastic EVs are phosphate & actin regulator 3, 
tumour necrosis factor inducible gene 6 protein and collagens α 1 and 2 (V) chain. A 
large group of proteins are significantly detected and common to both vesicle types 
including fibronectin, several histone proteins and collagen α 3 (VI) chain. By far the 
largest group is unique to the mild dysplastic cell derived EVs. Two of those with the 
highest significance values are another collagen in this case α-1 XII chain and guanine 
nucleotide binding protein G(i) subunit α-2.  
 
A core group of proteins is seen to be common to both EV types, including several 
histone proteins, thrombospondin 1 which was detected by western blots in previous 
experiments, and proteins like fibronectin. The laminin subunit proteins are all unique to 
the EVs from the mild dysplastic cells (>20 fold more abundant), as are several 
chaperone proteins including HSP90. Interestingly, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), which is commonly used as a loading control for western 
blots, was only detected in the mild dysplastic EVs illustrating the difficulty in finding 
loading controls for vesicle western blots. The 10 proteins with the largest changes in 
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the mild dysplastic EVs all have fold changes in excess of 20, whereas only 7 of the top 
10 changes in the severe dysplastic EVs are above 3-fold. This is because the majority 
of the proteins are more abundant in the mild dysplastic EVs (figure 6.9). In the severe 
dysplastic EVs phosphate actin regulator 3 saw the largest difference in abundance 
being 25-fold more abundant in the severe dysplastic EVs. Also listed are the five 
chains of collagen α-1 and 2 both of which are over 20-fold more abundant in the severe 
dysplastic EVs. 
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Largest population of EVs is enriched in mild dysplastic cell derived EVs 
compared to severe dysplastic cell derived EVs 
 
 
Figure 6.8 Volcano plot comparing the filtered proteins from the EVs of mild and severe 
dysplastic cells. Significance was set at p=>0.05 in Perseus, very few of the filtered proteins were 
below this line. Three distinct populations of proteins can be seen on the graph. A small group of 
proteins are significantly detected and are unique to the severe dysplastic EVs seen on the far left 
of the graph. A second population is common to both vesicle types, the largest population is unique 
to the mild dysplastic EVs. n=2 technical replicates. 
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Top 10 differentially abundant proteins in mild and severe dysplastic cell derived EVs 
 
 
Figure 6.9 Fold change in abundance of the 10 most differentially abundant proteins in mild and 
severe dysplastic cell derived EVs purified from the conditioned media of confluent T175 flasks. 
More proteins were identified in the mild dysplastic EVs than those of the severe dysplastic cells. 
A group of proteins including several histone proteins were common to both vesicle types. Several 
laminin subunits were present in the mild dysplastic EVs but not present in those from the severe 
dysplasia derived EVs. n=2 technical replicates. 
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6.4.4. Comparison of the protein contents of EVs from non-metastatic 
carcinoma and metastatic deposit cells 
Another valuable comparison to make is between the contents of the carcinoma 
cell derived EVs and those of the metastatic deposit cells. The cells of the metastatic 
deposit despite originating from the same anatomical site will likely exhibit many 
changes from those of the primary carcinoma. As with the comparison between the EVs 
of the two dysplastic cell types, comparison of the fold changes in abundance and the p 
values of the proteins detected in carcinoma and metastatic deposit cell derived EVs 
(figure 6.10 and 6.11) show three distinct populations of proteins. Ten proteins were 
significantly increased in the EVs from the metastatic deposit cells including the (I) 
chains of both collagen α 1 and α 2 along with extracellular matrix proteins fibulin 2 
and emilin 2 (figure 6.10 and 6.11). Nespirin 1, a nuclear membrane cytoskeletal protein 
with key roles in cellular movement, was 23-fold more abundant in EVs from metastatic 
deposit cells. A group of proteins are significantly detected and similarly present in each 
of the groups including histone H3, collagen α 3 (VI) chain, fibronectin, actin and 
thrombospondin 4.  
 
158 proteins with increased abundance were detected in the non-metastatic 
carcinoma cell derived EVs, which includes syndecan 4 (SDC4), the HLA class 
compatibility antigen A and the lipolysis stimulated lipoprotein receptor being among 
the most significantly detected of this group (appendix 3). Agrin is abundant in both 
EVs from the carcinoma cells and mild dysplastic cells this is a proteoglycan with three 
potential attachment points for heperan sulphate in its structure.   
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A group of proteins were common to both of the vesicle types, many of these were 
also present in the carcinoma cell derived EVs. Including subunits of histones H2, 3 and 
4 along with collagen α 3 (VI) chain and thrombospondin 4. Many of these proteins are 
cytoskeletal in nature with fibronectin, tubulin β chain and clatherin heavy chain units. 
Thrombospondin 1 and major vault protein are marginally more abundant in the EVs 
from the non-metastatic cells whereas the versican core protein is slightly enriched in 
the metastatic deposit cell derived EVs. Among the interesting proteins enriched in the 
non-metastatic carcinoma cells is integrin β4 which is 26-fold more abundant in these 
EVs, which is consistent with the iTRAQ dataset. Another interesting protein enriched 
in the EVs from the non-metastatic carcinoma cells, is the transferrin receptor protein 1, 
which is the protein through which EVs were first identified (Appendix 3). 
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Largest population of EVs is enriched in non-metastatic carcinoma cell derived 
EVs compared to metastatic deposit cell derived EVs 
 
 
Figure 6.10 Volcano plot comparing the filtered proteins from the EVs of non-metastatic cells 
with those of the metastatic deposit cells. Significance was set at p=>0.05 in Perseus. Very few 
proteins were seen to be below this threshold. Three distinct populations of proteins can be seen on 
the graph. A small group of 10 proteins are significantly detected and are unique to the metastatic 
deposit cell EVs seen on the far left of the graph. A second population is common to both types or 
marginally more abundant in the EVs from the non-metastatic carcinoma cells. The largest group 
of proteins is most abundant in the non-metastatic carcinoma cell derived EVs. n=2 technical 
replicates. 
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Top 10 differentially abundant proteins in non-metastatic carcinoma and metastatic 
deposit cell derived EVs 
 
Figure 6.11 Fold change in abundance of the 10 most differentially abundant proteins in non-
metastatic carcinoma and metastatic cell derived EVs purified from the conditioned media of 
confluent t175 flasks. More proteins are present in the non-metastatic carcinoma cell derived EVs 
than those of the metastatic deposit cells these include several laminin subunits, agrin and an EGF-
like repeat and discoidin I-like domain-containing protein 3. A group of proteins including several 
histone proteins and extracellular matrix proteins are common to both vesicle types. A smaller 
group of proteins including some collagen α chain units are enriched in the metastatic deposit cell 
derived EVs. n=2 technical replicates. 
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6.4.5. Comparison of the protein contents of EVs from two oral 
dysplastic cell lines with those of oral carcinoma 
Because the cell lines used in this study originate from the same primary site it is 
appropriate to combine the protein content of the EVs from the two-dysplastic cell 
derived EVs into one dataset to compare with those detected in the carcinoma cell 
derived EVs. This allows for the identification of any changes in vesicle protein content 
as a result of a dysplasia progressing into carcinoma. Strikingly most of the proteins 
detected (69) were more abundant in the carcinoma cell EVs. Among the most 
differentially abundant and significantly detected proteins were SDC4, the HLA class 
compatibility antigen A and the lipolysis stimulated lipoprotein receptor (figure 6.12). 
There is a shared group of 20 proteins present in EVs from dysplastic and carcinoma 
cells including fibronectin and histones 2A and 2B. The third population visible is 4 
proteins that are more abundant in the carcinoma cell derived EVs but were not detected 
in significant amounts, including R-Ras 2 and the 40s ribosomal protein s16. The most 
abundant protein in the carcinoma EVs is the EGF like and discoidin 1 like domain 
containing protein 3 which is 30-fold more abundant in these EVs. Laminin subunit 
proteins are also highly abundant as is integrin α 6, a protein with implications in oral 
cancer (Garzino-Demo et al., 1998). Thrombospondin 4 is also more abundant in 
carcinoma EVs whereas thrombospondin 1 is present in similar levels in each of the 
vesicle types.  
 
A common set of proteins was observed including both histone H2 and H3 
subunits as well as the proteins laminin and fibronectin. The latter was marginally more 
abundant in the dysplastic cell derived EVs. Histone H2E was one of the most abundant 
proteins in the carcinoma EVs as is a laminin subunit β2, which is one of the subunits 
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not present in the mild dysplastic EVs. Plotting the log fold change of the 10 most 
differentially abundant proteins in each sample (figure 6.13) shows how the majority of 
proteins are enriched in the carcinoma EVs with only 3 being enriched in the dysplastic 
cell derived EVs. These are fibronectin lactadherin and collagen α 3 (VI) chain all of 
which are between 1 and 3-fold more abundant in these EVs. There are 7 proteins that 
are less than 5-fold enriched in the carcinoma cell derived EVs including four histone 
proteins as well as a heat shock protein. The 10 proteins most differentially abundant in 
the carcinoma cell EVs are over 25-fold more abundant in these EVs and include a 
receptor tyrosine kinase, fatty acid synthetase and the HLA class 1 histocompatibility 
antigen. 
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Majority of proteins enriched in carcinoma cell derived EVs compared to dysplastic cell 
derived EVs 
 
 
Figure 6.12 Volcano plot comparing the filtered proteins from the EVs of dysplastic cells with 
those of carcinoma cells. Significance was set at p=>0.05 in Perseus, there were many proteins 
seen to be on or below this line predominantly with greater abundance in the carcinoma samples. 
Three distinct populations of proteins can be seen on the graph. A very large group of proteins are 
significantly detected and are unique to the carcinoma cell EVs seen on the far left of the graph. A 
second population is more abundant in the carcinoma EVs but not detected at significant levels, a 
small group of proteins is common to the two vesicle classes and significantly detected. n=2 
technical replicates. 
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Top 10 differentially abundant proteins carcinoma and dysplastic cell derived EVs 
 
 
Figure 6.13 Fold change in abundance of the 10 most differentially abundant proteins in dysplastic 
and carcinoma cell derived EVs purified from the conditioned media of confluent T175 flasks. 
More proteins are present in the carcinoma cell derived EVs than those of the dysplastic cells. A 
group of proteins including several histone proteins are common to both vesicle types. An EGF 
like and discoidin 1 like domain containing protein 3 is highly abundant in the carcinoma cell EVs 
but is absent in the dysplastic cell EVs. n=2 technical replicates. 
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6.5. Validation of mass spectrometry data 
In order to validate these data proteins were selected as candidates for western 
blotting in both cell and vesicle protein lysates. Candidates were selected that were 
detected in all samples as well as those which were enriched in individual samples. As 
previously mentioned, antibodies had initially been selected to validate the iTRAQ 
dataset. In order to determine if they would also be suitable for validation of the label 
free data, the label free intensities scores and the sequence coverage of these proteins 
were examined (table 6.5). Thrombospondin 1 had high scores in all samples and had 
been shown to be present in vesicle samples during previous experiments (figure 4.6). 
Major vault protein similarly had high scores in all samples bar one of the replicates for 
D35, which may be due to instrumentation error. EF2 was present in all bar the D35 
replicates and along with L-galectin 3 binding protein (LGAL3BP), which is present in 
both D20 and H357 replicates, would enable the trends observed by the mass 
spectrometer to be confirmed.  
 
Also considered was the percentage coverage, which is the percentage of the total 
protein sequence covered by the peptides detected by the instrument. The higher the 
percentage coverage score the more likely that antibody binding epitopes for these 
proteins would be present in the EVs meaning they were more likely to be successfully 
validated by western blot. The majority of these were above 25%, the exception being 
integrin α 6 which is 18.7%. As thrombospondin-1 had both high label free intensities in 
all samples and a comparable sequence coverage to EF2 it was added to the validation 
panel to further increase the reliability of the screen. Western blots were carried out on 
whole cell lysates as well as their respective vesicle samples to compare the abundance 
of the target proteins in the EVs against that of their parent cell. Thrombospondin 1 was 
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detected in all of the EV samples as well as the cells from which they originate (figure 
6.14). EF2 was detectable in all samples except for H357 EVs and B22 cell lysate. This 
is inconsistent with mass spectrometry data by which it was detected in both of these 
EV types but not in the EVs of the D35 cells, which along with its producing cells were 
seen to contain the protein by western blot. Major vault protein, which was detected in 
all of the vesicle samples by mass spectrometry, was only detectable in the D20 cell 
lysates and EVs, and the B22 cell lysate by western blotting (figure 6.14). Strangely 
LGAL3BP which was seen by mass spectrometry to be abundant in the D20 and H357 
EVs was detected in the D20 EVs but not in the H357 EVs by western blot. It was 
however in the B22 EVs, albeit with significantly lower abundance than in the D20 
EVs. Integrin α 6 however was not detected in any of the samples by western blot, 
possibly because of its low sequence coverage not including any antibody epitopes. 
  
 
 D20.1 D20.2 D35.1 D35.2 H357.
1 
H357.
2 
B22.1 B22.2 
Elongation factor 2 
(27.6%) 
24.5 24.4 0 0 26.5 26.2 0 21.3 
Integrin alpha 6 
(18.7%) 
0 0 0 0 25.5 25.5 0 0 
Major vault protein 
(45.5%) 
26.2 26.8 0 22.6 26.4 26.5 21.8 23.3 
Thrombospondin 1 
(26.6%) 
28 28.3 24.1 24 29.6 29.7 26.1 25.5 
L-galectin 3 binding 
protein (38.1%) 
25.6 25.7 0 0 26.3 26.3 0 0 
Table 6.5 Log 2x of the label free intensity scores for the selected validation candidates. Thrombospondin 
1 and major vault protein were selected because they are present in all samples, L-galectin 3 binding 
protein integrin α 6 and elongation factor 2 were selected as they were present in 1 2 and 3 of the samples 
respectively. Percentage value in brackets is the percentage of the total peptide sequence covered by the 
peptides detected. n=2 technical replicates. 
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Validation of label free mass spectrometry by western blot confirms presence of 
some candidates 
 
 
Figure 6.14 Validation of mass spectrometry data by western blotting. EVs were purified from the 
culture media of confluent oral cancer cell lines using size exclusion chromatography. Fractions 6-
9 were pooled and pelleted at 100,000 x g for 90 min before lysing in 1xRIPA buffer with protease 
inhibitors. Protein lysate was produced from 250000 cells of each line. Protein from all samples 
was normalised and 10μg loaded per sample in a 12% acrylamide gel. Following transfer to a 
nitrocellulose membrane samples were blocked and incubated with primary antibodies overnight. 
Blots were imaged by incubation with a secondary antibody conjugated with HRP before treating 
with a chemiluminescent substrate and exposing to X ray film and developing with a Xograph X4 
compact. Thrombospondin 1 is present in all cell lysate and EV samples. Major vault protein was 
detectable only in the cell and EV lysates of the D20 cells and the whole cell lysate of B22 cells. 
Elongation factor 2 was present in all bar H357 and B22 EVs with LGAL3BP detected in both 
D20 and B22 EVs. Western blots representative from a minimum of 2 experiments 
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6.6. Oral cancer EVs are enriched in proteins from oral cancer associated pathways 
Along with identifying any changes in protein contents across the EVs of the 
different cancer stages another reason for performing proteomic experiments was to 
identify possible functional roles the EVs could have. Using the Panther GO database 
tool the significantly detected proteins were matched to pathways (figure 6.15). Several 
of these are of importance in cancer. Most abundant is the integrin pathway with 
inflammatory and cytoskeletal regulation proteins also present in large amounts. There 
are small numbers of proteins involved in the angiogenic, apoptotic and DNA 
replication pathways along with a few protein signalling pathways including P35 P38 
MAPK fibroblast growth factor and EGF factor pathway. Because of the number of 
pathways present in this data set it is very difficult to observe any fluctuations in the 
distribution of pathways across the tumour stages.  
 
Focusing on those pathways with the most implication in cancer (figure 6.16), 
shows that two of the pathways, the angiogenic and DNA replication are only present in 
one of the vesicle types. The angiogenic pathway is only present in carcinoma EVs and 
the DNA replication pathway in the metastatic deposit cell derived EVs. Only the 
pathways for apoptosis, cytoskeletal, regulation, inflammation, integrin and P53 are 
represented in all vesicle types. The EGF and FGF pathways have no proteins in the 
EVs from the severe dysplastic cells and neither the severe dysplastic cells nor the 
metastatic cells produce EVs containing P38 and MAPK pathway proteins. Because of 
the variation in the number of proteins detected in the different samples it is difficult to 
determine however if any of these pathways are increasing or decreasing in 
representation across the different stages. 
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Integrin signalling, and other pathways are most abundantly represented in OSCC EV 
proteins 
 
Figure 6. 15 Protein pathways represented in the protein content of oral cancer cell derived EVs. 
Following label free mass spectrometry of EV proteins from four oral cancer cell lines the data 
was pooled and EV proteins with statistically significant label free intensities and a razor and 
unique peptide score of =>2 were entered into the Panther database and the GO pathways returned. 
While the majority of pathways were labelled as “other”, integrin signalling and cytoskeletal 
regulation pathways are seen to be the most abundant. n=2 technical replicates. 
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Integrin signalling, inflammation, apoptosis and cytoskeletal regulation pathways 
all represented in OSCC EVs 
 
 
Figure 6.16 Oral cancer EV proteins with statistically significant label free intensities and a razor 
and unique peptide score of =>2 were entered into the Panther database and the GO pathways 
returned. The percentage of total proteins for each of the pathways was calculated. n=2 technical 
replicates. 
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6.7. Discussion 
An unexpected outcome of this chapter was the comparison of iTRAQ and label 
free mass spectrometry techniques for the analysis of EV protein contents. 
Unfortunately, the biggest finding from the iTRAQ data was that the samples were 
contaminated with bovine serum proteins despite the multiple processing steps and the 
great care taken to remove all protein contaminations. In hindsight, these experiments 
were performed in the wrong order. Label free mass spectrometry should have been 
performed first to identify targets that appeared to be differentially packaged into the 
EV types, this could then have been confirmed using iTRAQ. Even allowing for the 
limitations of the data output the iTRAQ data did identify several proteins which were 
subsequently identified by the label free experiments, including all the validation 
candidates and several histone proteins. 
 
However, differences in abundance seen via iTRAQ were not seen in the label 
free results and vice versa. Label free mass spectrometry is not without its drawbacks as 
each sample must be run individually causing a large increase in the required instrument 
time for experiments and necessitating careful cleaning of the system between each 
sample. iTRAQ however enables a degree of multiplexing reducing the instrument time 
required, which is desirable, but this is what presents limitations when working with 
EVs. EV contents are known to exhibit a degree of heterogeneity, something which will 
be particularly true when working with patient samples. Because iTRAQ outputs the 
comparative amounts of the protein between the samples, the heterogeneity of EVs 
means that some proteins that are not present in all samples could be missed. Although 
there are studies which have successfully used iTRAQ to study EVs these are only 
comparing protein contents of EVs between two states, healthy and cancerous cells or 
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individuals which are more suitable for iTRAQ than our more ambitious study with its 
four different cell lines from different stages of oral cancer. 
 
Label free mass spectrometry was able to identify 376 proteins within EVs from 
the different oral cancer cell lines of which 194 were present in statistically significant 
quantities. The number of detected proteins varied considerably between the producing 
cell lines from 18-155, this is however unlikely to be entirely caused by any biological 
variation but will almost certainly be caused in part by technical variation. Ideally the 
mass spectrometry itself would have been carried out in replicate but this was not 
possible, however because samples were pooled to generate enough material to run the 
analysis this will have introduced a degree of biological variation into the dataset. The 
heat map produced during the processing indicates one of the problems introduced by 
the range in protein number observed in the samples. The carcinoma cell EVs have over 
double the number of proteins of the next highest EV type, which could explain why it 
is clustered distinctly from the other EV types, it is also interesting how many of the 
proteins are only detected in one of the technical replicates for the mass spectrometry 
run. It was expected that the EVs would cluster by cancer stage, which is seen for three 
of the four EV types and it is possible that had the H357 EVs had a smaller number of 
proteins associated with them they would have conformed to this pattern. 
 
Gene ontology (GO) tools were used to give a further insight into the proteins 
present within the EVs, firstly the molecular function was compared, this indicated that 
the distribution of functions across the EVs was largely similar with the majority of 
them in all cases being binding proteins. This would suggest that they are largely 
membrane-bound proteins which was shown not to be the case when the cellular origin 
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of these proteins was explored with the majority in all samples being classified as 
originating from cell parts. The GO tools suggest that there is an increase in the 
proportion of catalytic proteins in the carcinoma cell derived EVs and a lack of 
translation regulator and signal transduction proteins in the severe dysplastic EVs. This 
should however be viewed with some caution given these two samples are at the 
extreme ranges of the number of proteins seen in our samples and the proportions 
maybe affected by this. With the exception of the EVs from the severe dysplastic cells a 
similar distribution with respect to cellular origin is seen in all samples, although the 
carcinoma cell derived EVs saw fewer proteins from the extracellular spaces, with both 
cell parts and organelles being the largest groups. On closer examination of the cellular 
origin the of the proteins they were predominantly nuclear and intracellular which is 
unexpected. Given the origin of at least some of these EVs will be from the outer 
membrane and others would be from MVBs it was expected that the more proteins 
would be extracellular and of lysosomal origin. 
 
A study from a group in Brazil performed mass spectrometry on salivary EVs 
from oral cancer patients (Winck et al., 2015), their data indicates similarly high levels 
of binding proteins, with a large amount of the proteins originating from cell parts, and 
much like our data this was predominantly intracellular, however the majority of their 
proteins were classified as extracellular region in origin. This is the only paper 
published in English that has used mass spectrometry to analyse the protein content of 
oral cancer EVs. The similarities between their data and ours end with the protein class 
however, none of the proteins they detected in the salivary EVs were characterised as 
nucleic acid binding which was the most abundant class of proteins present in our EVs. 
Whilst these comparisons are interesting it is important to consider that the EVs isolated 
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from a patient's saliva will have been produced by more than one cell type whereas ours 
are produced by a single cell type. Taken together this data shows a stronger than 
expected similarity between the contents of our EVs with very similar distributions of 
protein origin and function. The prevalence of proteins originating in the nucleus and 
with nucleic acid binding abilities suggests that these EVs are enriched in proteins like 
transcription factors, which has been seen in large oncosomes with AKT1 (Minciacchi 
et al., 2017) in prostate cancer and also in HEK293 cell derived EVs which carry 14-3-3 
and β-catenin (Dovrat et al., 2014). Our data shows many of the 14-3-3 family proteins 
are actually in our carcinoma EVs with a few of the proteins detected in the mild 
dysplastic and metastatic cell derived vesicle. There are however none of them in the 
severe dysplastic cell derived EVs. Such variation in protein content is one of the major 
reasons for performing proteomic analysis of the vesicle contents.  
 
Comparisons between the vesicle proteins of the cell lines indicates that there is a 
group of proteins common to all the vesicle types, it would be valuable to determine if 
these proteins are also common to EVs produced by non-cancerous cells. Included in 
these proteins are histone proteins, whilst the presence of histones does not necessarily 
indicate the presence of genomic DNA this is something that should be tested. During 
the RNA extraction protocols the columns are treated with DNase, but this was done 
more as a precaution than because of any suspicion of DNA being present. There are 
currently very few papers that explore the DNA contents of EV, genomic DNA has been 
detected in in EVs produced by various cancer cell lines (Lázaro-Ibáñez et al., 2014) 
and (Montermini et al., 2015) but also in those found in patient plasma (Cai et al., 
2013). These papers do suggest that this DNA can have functional effects and is capable 
of being actively transcribed. It would be simple to determine if the histones are 
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associated with DNA by use of immune affinity techniques. 
 
Comparing the proteins compositions also raises the possibility that the different 
collagen α chain subunits are differentially distributed between the vesicle types, with α 
1 (V) and (XVII) chain being enriched in the mild dysplasia and α 1 and 2 (V) chain 
enriched in the severe dysplasia EVs, α 3 (VI) chain common to all types α 2 (IV) chain 
enriched in the carcinoma and α 1 and 2 (X) chain enriched in the metastatic EVs. 
Because the collagen chains will share some sequence commonality there is a degree of 
uncertainty in the ability of the mass spectrometer to accurately determine between the 
different chains if they are present in small quantities, so these findings would need to 
be confirmed using western blotting before being pursued further. The experiments 
should also be performed in a larger panel of cells from the different stages to see if this 
observation is consistent. Another interesting finding is SDC4 a protein that is 
significantly enriched in the carcinoma cell EVs but not detected in the other vesicle 
types, SDC4 is one of a family of plasma membrane proteoglycans and associates with 
integrins and thrombospondin receptors. Although it hasn’t yet been studied in oral 
cancer, it is a protein which has been linked to more aggressive forms of breast cancer 
(Baba et al., 2006) glioblastoma (Huang et al., 2001) and testicular cancer (Labropoulou 
et al., 2013). It is commonly associated with the acquisition of metastatic potential in 
these tumours and it would be useful to determine if this enrichment was just seen in the 
EVs or whether it is present in the producing cells as well. Searching for SDC4 in the 
Vesiclepeida and Exocarta databases, shows that it has been detected in salivary EVs, 
(Gonzalez-Begne et al., 2009) as well as in those from undifferentiated keratinocytes 
(Chavez-Muñoz et al., 2009) and various cancer cells (Demory Beckler et al., 2013; 
Hurwitz et al., 2016). 
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Searching for a protein with SDC4 like extremes of expression in the dysplastic 
cell vesicle types was not as successful. Although some laminin subunits appear to be 
enriched in the mild dysplastic EVs, they are absent from the severe dysplastic EVs but 
are found in both the metastatic and carcinoma cell EVs. Likewise, agrin which is 
present in the mild dysplastic cell EVs and absent from those of the severe dysplastic 
cells, but it is also present in the carcinoma cell derived EVs. The differential 
distribution of agrin is interesting when placed in the context of two separate pieces of 
work on the role of heparan sulphate proteoglycans (HSPGs) in EVs. Firstly, a paper 
from 2013 which demonstrated that heparin treatment reversibly blocked the transfer of 
EVs between cells (Atai et al., 2013). The second paper demonstrated that TGFβ 
tethered to the surface of EVs by HSPGs was functionally active in receptor cells 
(Webber et al., 2010). HSPG supporting proteins potentially then have an influence on 
both the functions and destinations of EVs, the different distribution of agrin suggests 
that while the HSPGs are required for EV function the proteins that bear them can vary 
from EV to EV. It could also indicate that the vesicles enriched in agrin bear different 
HSPGs and therefore have different functions or destinations to the others. 
 
Nesprin 1 was shown to be unique to the metastatic cell derived EVs, this is a 
nuclear membrane protein which interacts with actin and has implications in the 
invasion and migration of cells. Searching for nesprin 1 in the Vesiclepeida and 
Exocarta databases reveals that this protein has not previously been detected in EVs. 
There are several proteins for which the relative label free intensities vary across the 
different vesicle samples, which is possibly an indication of changing abundance and 
therefore selective incorporation. However, the label free intensities are insufficient to 
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determine any enrichment and to confirm this densitometry experiments would need to 
be done with antibodies for these proteins. As with other interesting candidates 
identified in this chapter it is also necessary to determine their abundance in EVs from 
other cell lines from the different stages. 
 
Alongside comparing the different proteins found within these EVs types this 
chapter has begun to place these protein contents in the context of cancer and 
tumourigenesis. These initial findings show that two significant pathways, angiogenesis 
and DNA replication only have proteins in EVs from one of the cancer stages. 
Angiogenesis is now recognized as one of the hallmarks of cancer and proteins from 
this pathway are only present in the carcinoma cell derived EVs. It is not known what 
the vascular status of this patient's tumour was but as an established tumour it is likely 
to have had its own blood supply. The presence of these proteins in the EVs could then 
be interpreted as them being removed from the cells as no longer needed or alternatively 
being shipped to other cells to change the angiogenic pathways activity in them. 
 
The presence of DNA replication pathway proteins in the metastatic deposit cell 
derived EVs is interesting and closer analysis shows these to be Histone H3 and 
proliferating cell nuclear antigen. Whilst cancer cells are replicating the DNA 
replication pathway will obviously be highly dysregulated and whether these two 
proteins could affect such dysregulation alone is doubtful. Given this pathways absence 
in all other vesicle types it suggests that the metastatic cells DNA replication pathway is 
in different status to those of the other cells. Both angiogenesis and DNA replication are 
more significant in the early stages of a tumour another such pathway is the 
inflammatory pathway proteins; these proteins could be capable of establishing 
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inflammatory conditions that are favourable to the progression of the tumour. The 
largest proportion of the proteins belong to the integrin pathway, a pathway that is 
heavily implicated in oral cancer (Moilanen et al., 2017; Ramos et al., 2009) particularly 
in the invasion and migration phenotype required for metastasis. A paper from 2016 
details a mechanism in prostate cancer where the vesicle mediated transfer of αVβ3 
integrins to non-tumourigenic cells from the tumourigenic cells promotes migration 
(Singh et al., 2016). Integrin αV isn’t seen in our data but β3 is, which alongside α6 
another protein implicated in oral cancer. It is possible that the integrin proteins in these 
oral cancer EVs will play a similar role to that seen in prostate cancer in a co culture 
experiment. Integrins normally function as adhesion molecules, given they are the most 
abundantly represented proteins in these EVs and cytoskeletal regulatory proteins are 
one of the other abundant pathways it is very likely these EVs could exhibit a pro 
migratory effect on receptor cells. This role could be tested by dosing the non-metastatic 
cells with EVs from the metastatic cells and performing migration assays to determine if 
the phenotype can be transferred. Metastasis isn’t the only requirement a tumour has for 
invasion and migration, early in a tumours development the recruitment of immune cells 
and fibroblasts into the developing tumour are both beneficial. This drive could explain 
the presence of these proteins in the EVs from all the stages of tumourigenesis and 
could equally be tested in the same assays used to test the migration of tumour cells. 
 
The validation experiments performed using western blotting produced mixed 
results. While TSP1 was present in all the vesicle samples in both the mass spectrometry 
and the western blotting,EF2 was a protein detected in all bar the severe dysplastic EVs 
on the mass spectrometry but was missing from both the carcinoma and metastatic 
deposit EVs in western blotting. Likewise, major vault protein was detected in all 
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vesicle samples via mass spectrometry but was only present in the lysate of the mild 
dysplastic cells. One likely reason for these discrepancies is the relative sensitivity of 
western blotting vs mass spectrometry. The bands for major vault protein in particular 
are extremely weak and it is possible that if higher amounts of protein were loaded then 
a greater similarity between the two techniques would have been observed. The lack of 
signal for integrin α6 in the carcinoma EVs is possibly because of the low sequence 
coverage, possibly indicating that the protein is only present as a fragment in the EVs 
and that this fragment doesn’t include the antibody epitope for this particular antibody. 
Throughout this project performing western blotting on vesicle samples was fraught 
with difficulty, a recurring issue was generating sufficient protein to ensure the detection 
of the protein with the antibodies. Although 10 µg of protein was loaded as a minimum 
for each of the samples because these samples contain a mixture of proteins it is still 
evidently not sufficient to detect some low abundance proteins. Although the EVs 
protein concentration was compared to that of the whole cell lysate a lack of loading 
controls all cases prevented densitometry being performed and the bands being 
quantified. However, this comparison has revealed that thrombospondin 1 is present in 
the whole cell lysate of all the cell lines as is EF2.  
 
Despite the issues with the validation experiments, the mass spectrometry 
experiments have opened several promising avenues for further research. It is evident 
that the protein contents of the EV vary with tumour stage with several proteins that 
appear to be unique or differentially in some of our vesicle samples, these require 
further validation with western blots in the cell lysates and vesicle lysates of both the 
cells in this panel and additional cells covering the stages. Proteomics tools indicate 
several phenotypic changes these EVs could possibly drive, of these the most likely is 
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invasion and migration. But it also possible that the EVs from the carcinoma cells could 
affect angiogenesis and those from the metastatic deposit could impact on DNA 
replication. The cancer associated pathways which are well represented in the vesicle 
contents are all promising candidates to explore further with functional assays like 
transwell assays for migration or tubule forming assays for angiogenesis. Should the 
EVs impact on these pathways then a next step would be to deplete these proteins in the 
producing cells and observe any changes in this effect. Whilst this data needs further 
validation and additional experiments it does suggest that the EVs produced by oral 
cancer cell lines could have quite profound biological effects. 
 
6.7.1. Future work 
Although the western blots have confirmed some of the findings of the mass 
spectrometry such as the enrichment of LGAL3BP in the EVs of the mild dysplasia and 
the presence of TSP1 in all vesicle samples, improving the confidence in this validation 
is essential and could be achieved in a variety of ways. Firstly, additional antibodies 
with different epitopes should be used to determine if the non-detection of the proteins 
is due to the epitopes not being covered or a weak binding affinity. A second approach 
would be to identify other candidates for use with western blotting experiments, these 
targets should have a higher sequence coverage and similar patterns of expression to the 
existing targets. Another approach would be to use a higher sensitivity technique such as 
targeted mass spectrometry, this could be done using iTRAQ and whole cell lysates run 
alongside vesicle samples in an 8 plex experiment.  
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Once these issues are addressed the findings of this chapter can be expanded 
upon. Levels of proteins like SDC4, nespirin 1 and agrin should be investigated in other 
examples of cells from the different stages of oral cancer, healthy normal cells of the 
oral cavity and potentially patient samples. This would give more confidence in the 
trends spotted in these experiments are representative of changes occurring in the 
development of oral cancer. Should the enrichment of these proteins in oral cancer 
vesicles be seen to be conserved across a wider range of oral cancer samples the testing 
the impact of these proteins on the phenotype of receptor cells should be explored. This 
could be done by depleting vesicles of these proteins and performing functional assays 
that tested effects on angiogenesis, EV uptake, cell proliferation and invasion and 
migration. 
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7. Effect of oral cancer EVs on cells of the tumour microenvironment 
 
7.1. Introduction 
In recent years the role of fibroblasts within the TME has come under increasing 
scrutiny, with the fibroblasts within the microenvironment displaying a markedly 
different phenotype to their normal relatives. These CAFs have been shown to drive cell 
growth (Castells et al., 2012; Olumi et al., 1999), metastasis, angiogenesis and immune 
escape (Leef and Thomas, 2013; Togo et al., 2013). They have even been seen to 
facilitate therapy resistance (Sun and Nelson, 2012) and inflammation (Erez et al., 2010, 
Sharon et al., 2010). The activation of normal fibroblasts to CAFs is now considered to 
be one of the major steps in tumourigenesis (Hanahan and Weinberg, 2011).  
 
During tumourigenesis activation is driven by a range of biological mediators, 
primarily TGFβ1 but other proteins and RNA species have also been linked to the 
process. It has also been noted that cigarette smoke, a major risk factor in oral cancer, 
can also contribute to this activation (Pal et al., 2013). More recent work by Clayton and 
Webber has identified a role for prostate cancer EVs in the process. They initially 
showed that TGFβ1 associated with exosomes on a sucrose density gradient and that 
these exosomes were capable of activating fibroblasts in a similar way to soluble 
TGFβ1(Webber et al., 2010). Further experiments showed that the TGFβ1 was tethered 
to the surface of the EVs via betaglycans. Interestingly, although they showed that this 
activation produced morphological and some biological changes which were similar to 
those that occurred when fibroblast were treated with soluble TGFβ1, changes to mRNA 
expression were subtly different. 
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This was the first time that EVs had been linked to the activation of fibroblasts in 
cancer. Since then similar phenomena have been observed in malignant ascites (Wei et 
al., 2017), breast cancer (Baroni et al., 2016) and leukaemia (Paggetti et al., 2015). 
These are not the only signals to be passed between tumour cells and normal fibroblasts, 
Gutkin et al (2016) showed that hTERT mRNA could be passed to fibroblasts from 
immortalized tumour cells. Another paper from the same year showed that EVs from 
rhabdomyosarcoma cells carry miRNA cargos that promote the invasion of fibroblasts 
(Ghayad et al., 2016). Taken together the data shows extensive EV mediated cross talk 
between tumour cells and fibroblasts within the TME with a range of outcomes, not just 
activation of the fibroblasts, which are beneficial to the progression of the tumour. 
 
7.2. Aims and objectives 
The aims of this chapter were to study EV signalling in the TME and to test the 
hypothesis that oral cancer EVs could activate normal oral fibroblasts (NOFs) into 
CAFs. First the ability of tumour cell derived EVs to be taken up by cells of the 
microenvironment was visualised using a fluorescence-based assay. The impacts of this 
uptake on NOF growth was assessed using a range of assays. In order to assess if oral 
cancer EVs could activate NOFs, immunofluorescence, immunoblotting and qPCR for 
αSMA expression were used in combination to monitor any changes following EV and 
TGFβ1 treatment. 
 
7.3. EVs produced by oral cancer cells can be taken up by a range of cell types 
A fluorescence-based assay was used to visualise the uptake of EVs by receptor 
243 
 
cells. EVs purified from conditioned media of oral cancer cells were stained with two 
different fluorescent labels. The first of these, CellMask red, binds to the lipid 
membrane, the second is a lipid-permeable RNA dye which fluoresces green when in 
contact with RNA. Stained EVs were incubated with cells for 1 h at 37oC, alongside 
mock controls (the same volume of PBS exposed to the dyes). After 1 h the cells were 
fixed and mounted on slides and imaged on a Zeiss Axioplan microscope. The presence 
of red fluorescence in the treated samples but not in the controls indicated that the EVs 
were taken up by the carcinoma cells (figure 7.1) an immortalised oral keratinocyte cell 
line (figure 7.2) a dermal microvascular endothelial cell line (figure 7.3) and normal 
oral fibroblasts (figure 7.4). Additionally, the presence of the green fluorescence in the 
treated samples suggests that this uptake causes the release of the EV contents into the 
receptor cells.  
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EVs can be taken up by other OSCC cells 
 
Figure 7.1 EV uptake by OSCC. EVs were harvested from the medium of confluent cancer cells 
using the serial centrifugation protocol. The final EV pellet was stained with 0.01 µM Cyto RNA 
Select (Life Technologies) and CellMask Red (Life Technologies) for 1 h at 37oC. A standard dose 
of stained EVs was added to 10000 OSCC cells seeded onto coverslips in EV free medium. After 
1h at 37oC the cells were fixed in 4% paraformaldehyde and mounted on slides to image. The 
images show that EVs (RED) produced by mild dysplastic cells (A) severe dysplastic cells (B) 
carcinoma cells (C) and cells from a metastatic deposit (D) are all capable of transferring 
encapsulated RNA dye (GREEN) to OSCC. E is a EV free control where the same number of cells 
were treated with the same volume of EV free PBS. Images are representative from three 
experiments.  Scale bars are 25 µm. 
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EVs can be taken up by oral keratinocytes 
Figure 7.2 EV uptake by oral keratinocytes. EVs were harvested from the medium of confluent 
cancer cells using the serial centrifugation protocol. The final EV pellet was stained with 0.01 µM 
Cyto RNA Select (Life Technologies) and CellMask Red (Life Technologies) for 1 hour at 37oC. A 
standard dose of stained EVs was added to 10000 OKF6 cells an hTERT immortalised oral 
keratinocyte cell line seeded onto coverslips in EV free medium. After 1 h at 37oC the cells were 
fixed in 4% paraformaldehyde and mounted on slides to image. The images show that EVs (RED) 
produced by mild dysplastic cells (A) severe dysplastic cells (B) carcinoma cells (C) and cells 
from a metastatic deposit (D) are all capable of transferring encapsulated RNA dye (GREEN) to 
OKF6 cells. E is an EV free control where the same number of cells were treated with the same 
volume of EV free PBS. Images are representative from three experiments.  Scale bars are 25 µm. 
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OSCC EVs can be taken up by endothelial cells 
 
Figure 7.3 EV uptake by endothelial cells. EVs were harvested from the medium of confluent 
flasks of cancer cells using the serial centrifugation protocol. The final EV pellet was stained with 
0.01 µM Cyto RNA Select (Life Technologies) and CellMask Red (Life Technologies) for 1 h at 
37oC. A standard dose of stained EVs was added to 10000 HMEC-1 cells, a dermal microvascular 
endothelial cell line, seeded onto coverslips in EV free medium. After 1 h at 37oC the cells were 
fixed in 4% paraformaldehyde and mounted on slides to image. The images show that EVs (RED) 
produced by mild dysplastic cells (A) severe dysplastic cells (B) carcinoma cells (C) and cells 
from a metastatic deposit (D) are all capable of transferring encapsulated RNA dye (GREEN) to 
HMEC-1 cells. E is a vesicle free control where the same number of cells were treated with the 
same volume of EV free PBS. Images are representative from three experiments. Scale bars are 25 
µm. 
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OSCC EVs can be taken up by NOFs 
 
Figure 7.4 EV uptake by normal oral fibroblasts. EVs were harvested from the medium of 
confluent flasks of cancer cells using the serial centrifugation protocol. The final EV pellet was 
stained with 0.01 µM Cyto RNA Select (Life Technologies) and CellMask Red (Life 
Technologies) for 1 h at 37oC. A standard dose of stained EVs was added to 8000 normal oral 
fibroblasts seeded onto coverslips in EV free medium. After 1 h at 37oC the cells were fixed in 4% 
paraformaldehyde and mounted on slides to image. The images show that EVs (RED) produced by 
mild dysplastic cells (A) severe dysplastic cells (B) carcinoma cells (C) and cells from a metastatic 
deposit (D) are all capable of transferring encapsulated RNA dye (GREEN) to oral fibroblasts. E is 
a vesicle free control where the same number of fibroblasts were treated with the same volume of 
EV free PBS. Images are representative from three experiments. Scale bars are 25 µm. 
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7.4. Optimisation of fibroblast seeding densities in full serum and serum free conditions  
In order to assess any EV-mediated impact on NOF growth, the characteristics of 
the fibroblasts in normal conditions needed to be determined before experiments could 
be designed. Fibroblasts were seeded at various densities in a 96 well plate in full serum 
and serum free media presto blue staining was performed at 0, 24, 48 and 72 hours. 
Figure 7.5 shows the growth curves for the NOFs in normal medium (A) and serum free 
medium (B). In normal medium the cells show proliferation across the full 72 h 
incubation with an increase in fluorescence at each time point. The rate of growth slows 
between 5000 and 10000 cells per well at 72 h suggesting the wells have reached 
contact inhibition. In serum free medium the reverse is observed with almost no growth 
observed at 72 h for all cell densities. At densities up to 3000 cells there is an increase in 
fluorescence over 48 h, at higher densities a decrease in fluorescence is observed at 24 
h. For subsequent proliferation experiments densities of 2000 cells per well and medium 
containing 2% serum was used to allow some growth to occur over a 48 h period. 
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NOF growth curves in presence and absence of serum 
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Figure 7.5 Growth curves for NOFs in normal medium (A) and serum free medium (B). Varying 
densities of cells were seeded in a 96 well plate and stained with presto blue at 0, 24, 48 and 72 
hours with fluorescence at 570 nm being proportional to cell number. In normal medium the cells 
continue to replicate over the 72 h incubation, in serum free medium however the reverse is seen 
with no growth at 72 hours. At densities above 3000 cells per well in serum free medium the 
growth arrest begins at 24 hours. n=3 technical replicates. 
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7.5. EVs from cancer cells have a minimal impact on fibroblast turnover 
Firstly, the impact of EV treatment on NOFs viability was determined using a 
live/dead assay. NOFs isolated from three different patients (NOF804, NOF805 and 
NOF806) were seeded at 2000 cells per well in low serum medium and treated with 
various doses of EVs for 24 and 48 h. Cells were then incubated with an ethidium dimer 
and a spectrophotometer used to measure uptake. The percentage of dead cells was 
calculated by comparing with wells containing 100% dead cells. This assay (figure 7.6) 
shows that the uptake of EVs from all of the cancer cell lines causes a small but not 
significant increase (~10%) in cell death after 24 hours with the severe dysplastic cell 
(figure 7.6 B) derived EVs being marginally less cytotoxic than those of the mild 
dysplastic (figure 7.6 A), carcinoma cells (figure 7.6 C) and metastatic deposit cells 
(figure 7.6 D). By 48 hours however this increase in cell death relative to the negative 
control is no longer detectable. This effect does not show any dose dependency at either 
time point with all EV doses causing a similar effect at 24 hours and no effect at 48 
hours. 
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Treatment with increasing doses of OSCC EVs has no effect on NOF viability 
after 48 hours 
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Figure 7.6 Effect of EV uptake on NOF viability. NOFs (NOF 804, 805 and 806) were seeded at 
2000 cells per well in a 96 well plate and treated for 24 and 48 h with varying doses of cancer 
derived EVs in medium supplemented with 2% EV free serum. Cells were treated with 4 µM 
EthD-1, which stains dead cells, the fluorescence was read on a Tecan plate reader at 645 nm. The 
resulting values were compared to wells treated with the same volume of medium with 2% EV 
free serum. A positive control was used to measure 100% dead cells by treating with 100% 
methanol for 20 min. The fold changes in the 100% dead controls indicate an increase in the 
number of dead cells in the non EV treated samples after 48 hours in the minimal medium.  n=3 
biological replicates error bars representing SEM. Data was non-significant with both a student’s t-
test and one-way Anova with Tukeys multiple test correction.  
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Cell death is not the only aspect contributing to NOF turn over. Changes in the 
proliferation of the NOFs following EV uptake was assessed using a BRDU ELISA kit. 
NOFs from four different patients (NOF 806, NOF316, NOF319 and NOF335) were 
treated with the maximum dose of EVs used in the cell viability experiments and treated 
for 48 h. After 48 h the cells were treated with BRDU for 4 h and then incubated with 
an antibody conjugated to a peroxidase enzyme. Changes in proliferation were detected 
by treatment with tetramethyl benzidine which when cleaved by the peroxidase 
produces a blue coloured product that can be detected by a spectrophotometer. EVs 
produced by the severe dysplastic, carcinoma and metastatic deposit cells have no 
significant impact on proliferation (figure 7.7) with even a slight negative impact on the 
proliferation of fibroblasts. There was a trend of increased proliferation in NOFs treated 
with EVs from the mild dysplastic cells. However, neither of these changes were 
statistically significant. 
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Treatment with OSCC EVs produces no significant change in NOF proliferation 
after 48 hours 
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Figure 7.7 Effect of EV uptake on NOF proliferation. NOFs (NOF 806, 316, 319 and NOF335) 
were seeded at 2000 cells per well and serum starved overnight. They were then treated with 
20,000 cancer cells derived EVs per cell in medium containing 2% EV free serum and incubated 
for 48 h. cells were incubated with 10 μM BrdU labelling solution for 4 h. Cells were fixed and 
incubated with antibody solution. Following this, cells were treated with substrate and allowed to 
develop for 15 min to produce a detectable colorimetric response. Reactions were then stopped 
using 1 M H2SO4 and read at 450 nm on a Fluorstar plate reader. n=4 biological replicates error 
bars representing SEM. Results were non-significant with a student’s T test. 
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7.6. Uptake of oral cancer derived EVs causes normal oral fibroblasts to display cancer 
associated fibroblast characteristics. 
 
NOFs can be activated in vitro to adopt CAF like phenotype by treatment with 5 
ng/μl TGFβ1 (Webber et al., 2010). This activation can be characterised by an increased 
expression of alpha smooth muscle actin (αSMA), this is one of the major components 
of the stress fibres responsible for the activated fibroblast morphology. Webber et al 
(2010) have shown that treatment of lung fibroblasts with prostate, bladder and breast 
cancer cell derived EVs causes them to adopt a similar morphology (Webber et al., 
2010). NOFs from four patients were treated with a standard dose of EVs, alongside 
TGFβ1 treated controls. αSMA expression at the gene and protein level were assayed by 
qPCR and western blot, respectively. In addition, the formation of stress fibres was 
visualised by immunofluorescence.  
 
Following EV uptake by NOF803 cells the qPCR data (figure 7.8 A) indicates an 
increase in the mRNA for αSMA upon uptake of the EVs from the carcinoma and 
metastatic deposit derived EVs but not the dysplastic cell derived EVs. This increase is 
2-fold less than in the TGFβ1 treated controls. Western blotting (figure 7.8 B) shows an 
increase in αSMA protein when the fibroblasts are treated with EVs from all the cancer 
cell lines and this increase is similar to the 2-fold increase in the positive control 
samples. Fluorescent staining for αSMA (figure 7.8 C) show similar green fibres as the 
TGFβ1 treated controls that are absent in the untreated fibroblasts. 
  
Gene expression data (figure 7.9 A) showed a decrease in αSMA mRNA transcript 
when NOF316 were treated with TGFβ1 and dysplastic cell derived EVs; there is, 
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however, between a 2 and 3-fold increase in the mRNA in these cells when treated with 
the EVs from the carcinoma and metastatic deposit cell derived EVs. The western blot 
(figure 7.9 B) shows that the TGFβ1 treatment causes an increase in the amount of 
αSMA protein, in contrast to the qPCR which shows the mRNA expression has 
decreased, however EV treatment has no effect on the amount of αSMA protein in this 
fibroblast culture. NOF316 cells exhibited similar αSMA fibre formation upon EV 
treatment as the positive controls (figure 7.9 C). 
  
NOF 319 cells show a different trend at the mRNA level when treated with EV’s 
(figure 7.10 A). This cell line was again unresponsive to TGFβ1 with respect to the 
mRNA for αSMA, however there was an increase in the mRNA when they were treated 
with EVs from the mild dysplastic, carcinoma and metastatic deposit cells but not the 
severe dysplastic cells which actually caused a decrease in the amount of mRNA for 
αSMA. The western blot and associated densitometry (figure 7.10 B) shows that this 
patient fibroblasts are not responsive to TGFβ1 with respect to αSMA protein either. 
Nor does the level of αSMA protein change when they are treated with EVs from the 
cancer cell lines, with the exception of those from the metastatic deposit cell line which 
causes a very slight increase in the protein abundance. NOF319 cells (figure 7.10 C) 
show the presence of the αSMA fibres following treatment with cancer cell derived EVs 
and TGFβ1 using immunofluorescence, in keeping with the other fibroblast cultures. 
  
The qPCR data for NOF335 cells show that (figure 7.11 A), whilst the treatment 
with TGFβ1 causes no change in the mRNA for αSMA, there is also no change in 
mRNA when they are treated with EVs from the mild dysplasia, carcinoma and 
metastatic deposit cells. There is however a 20-fold increase in the αSMA mRNA when 
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treated with EVs from the severe dysplastic cells. The western blot data shows similar 
changes in the αSMA protein as the NOF319 cells (figure 7.11 B), these fibroblasts are 
not responsive to TGFβ1 with respect to αSMA protein either, and the concentration of 
αSMA protein doesn’t change when they are treated with EVs from the cancer cell lines, 
with the exception of those from the metastatic deposit cell line which causes a very 
slight increase in the protein abundance. NOF335 again shows the same stress fibre 
formations under immunofluorescence (figure 7.11 C) as the other patients fibroblasts 
following EV and TGFβ1 treatment. Taken together this data indicates that the EVs 
from oral cancer cells can cause the formation of αSMA stress fibres in oral fibroblasts 
allowing them to adopt a phenotype similar to the CAFs. However, this is always not 
accompanied by a corresponding detectable increase in αSMA mRNA and protein in all 
patients NOFs after 24 hours. 
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EV treatment of NOF803 cells produces increase in αSMA mRNA and protein and the 
formation of stress fibres 
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Figure 7.8 EV mediated activation of NOF 803 cells. NOFs were serum starved for 24 h before 
treatment with 20000 EVs per cell in serum free medium and allowed to incubate for 24 h. 
Negative controls were treated with the same volume of serum free medium, positive controls 
were treated with 5 ng/μl of TGFβ1. RNA was harvested and used to run qPCR with probes for 
αSMA, U6 was used as a housekeeping gene to allow the calculation of ΔΔCT values relative to 
the control samples (A). αSMA mRNA did not increase in samples treated with dysplastic EVs but 
did increase when samples were treated with carcinoma and metastatic EVs. Following TGFβ1 
treatment these cells showed no increase in αSMA mRNA. n=2 technical replicates error bars 
representing SEM. Data was non-significant with a student’s test Protein lysates were also 
harvested from the treated NOFS and were run on a 12% acrylamide gel before transferring to a 
nitrocellulose membrane. The membrane was probed with a mouse monoclonal antibody for 
αSMA diluted 1:500 (v/v) and a HRP conjugated rabbit monoclonal antibody for GAPDH as a 
loading control diluted 1:20000 (v/v). Densitometry of the bands was performed using ImageJ (B), 
unlike the mRNA αSMA protein increased in samples treated with all the EV samples n=1. Finally, 
cells were incubated with a FITC conjugated αSMA antibody diluted 1:1000 (v/v) with blocking 
buffer for 1 h before mounting on slides. After imaging on a Zeiss Axioplan comparable αSMA 
stress fibres were visible in EV treated samples and in TGFβ1 treated control samples with no 
fibres visible in the negative controls (C). 
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EV treatment of NOF316 cells produces no change in αSMA mRNA. except with 
the EVs from carcinoma and metastatic deposit cells, no change at the protein level but 
does produce stress fibres 
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Figure 7.9 EV mediated activation of NOF 316 cells. NOFs were serum starved for 24 h before 
treatment with 20000 EVs per cell in serum free medium and allowed to incubate for 24 h. 
Negative controls were treated with the same volume of serum free medium, positive controls 
were treated with 5 ng/μl of TGFβ1. RNA was harvested and used to run qPCR with probes for 
αSMA, U6 was used as a housekeeping gene to allow the calculation of ΔΔCT values relative to 
the control samples (A). αSMA mRNA didn’t increase in samples treated with dysplastic EVs but 
did increase when samples were treated with carcinoma and metastatic EVs. Following TGFβ1 
treatment these cells showed no increase in αSMA mRNA. n=2 technical replicates error bars 
representing SEM. Significance was tested using a student’s t-test * = p>0.05 ***= p>0.001 ****= 
>0.0001. Protein lysates were also harvested from the treated NOFS and were run on a 12% 
acrylamide gel before transferring to a nitrocellulose membrane. The membrane was probed with a 
mouse monoclonal antibody for αSMA diluted 1:500 (v/v) and an HRP conjugated rabbit 
monoclonal antibody for GAPDH as a loading control diluted 1:20000 (v/v). Densitometry of the 
bands was performed using ImageJ (B), unlike the mRNA αSMA protein increased samples treated 
by TGFβ1 but not with those treated by EVs, there was no increase in αSMA protein with any of 
the EV treatments n=1. Finally, cells were incubated with a FITC conjugated αSMA antibody 
diluted 1:1000 (v/v) with blocking buffer for 1 h before mounting on slides. After imaging on a 
Zeiss Axioplan comparable αSMA stress fibres were visible in EV treated samples and in TGFβ1 
treated control samples with no fibres visible in the negative controls (C). 
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EV treatment of NOF319 cells produces no change in αSMA mRNA. except with 
the EVs from carcinoma and metastatic deposit cells, no change at the protein level but 
does produce stress fibres 
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Figure 7.10 EV mediated activation of NOF 319 cells. NOFs were serum starved for 24 h before 
treatment with 20000 EVs per cell in serum free medium and allowed to incubate for 24 h. 
Negative controls were treated with the same volume of serum free medium, positive controls 
were treated with 5 ng/μl of TGFβ1. RNA was harvested and used to run qPCR with probes for 
αSMA, U6 was used as a housekeeping gene to allow the calculation of ΔΔCT values relative to 
the control samples (A). No increase in αSMA mRNA occurred in samples treated with TGFβ1. 
αSMA mRNA increased in the samples treated with mild dysplastic, carcinoma and metastatic EVs 
but a decreased in the samples treated with severe dysplastic derived EVs. Following TGFβ1 
treatment these cells showed no increase in αSMA mRNA. n=2 technical replicates error bars 
representing SEM. Significance was tested using a student’s t-test * = p>0.05 ***= p>0.001 ****= 
>0.0001. Protein lysates were also harvested from the treated NOFS and were run on a 12% 
acrylamide gel before transferring to a nitrocellulose membrane. The membrane was probed with a 
mouse monoclonal antibody for αSMA diluted 1:500 (v/v) and an HRP conjugated rabbit 
monoclonal antibody for GAPDH as a loading control diluted 1:20000 (v/v). Densitometry of the 
bands was performed using ImageJ (B), unlike the mRNA an αSMA protein levels increased 
samples treated by TGFβ1 but not with those treated by EVs, there was no increase in αSMA 
protein with any of the treatments except the EVs from the metastatic deposit which showed a very 
small increase in protein concentration n=1. Cells were seeded at 8000 per well on coverslips in a 
24 well plate and allowed to adhere overnight. Finally, cells were incubated with a FITC 
conjugated αSMA antibody diluted 1:1000 (v/v) with blocking buffer for 1 h before mounting on 
slides. After imaging on a Zeiss Axioplan comparable αSMA stress fibres were visible in EV 
treated samples and in TGFβ1 treated control samples with no fibres visible in the negative 
controls (C). 
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EV treatment of NOF335 cells only produces a change in mRNA levels when 
treated with EVs from severe dysplastic cells and produces no change in protein levels 
but does produce stress fibres 
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Figure 7.11 EV mediated activation of NOF 335 cells. NOFs were serum starved for 24 h before 
treatment with 20000 EVs per cell in serum free medium and allowed to incubate for 24 h. 
Negative controls were treated with the same volume of serum free medium, positive controls 
were treated with 5 ng/μl of TGFβ1. RNA was harvested and used to run qPCR with probes for 
αSMA, U6 was used as a housekeeping gene to allow the calculation of ΔΔCT values relative to 
the control samples (A). No change in αSMA mRNA expression occurred in any samples except 
those treated with severe dysplastic cell derived EVs. n=2 technical replicates error bars 
representing SEM Significance was tested using a student’s t-test * = p>0.05 ***= p>0.001 ****= 
>0. 0001.. Protein lysates were also harvested from the treated NOFS and were run on a 12% 
acrylamide gel before transferring to a nitrocellulose membrane. The membrane was probed with a 
mouse monoclonal antibody for αSMA diluted 1:500 (v/v) and an HRP conjugated rabbit 
monoclonal antibody for GAPDH as a loading control diluted 1:20000 (v/v). Densitometry of the 
bands was performed using ImageJ (B), similarly to the mRNA there was no change in the protein 
levels of αSMA in this cell line in any of the samples n-=1. There was a marginal increase in 
samples treated with EVs from a metastatic deposit cell. Finally, cells were incubated with a FITC 
conjugated αSMA antibody diluted 1:1000 (v/v) with blocking buffer for 1 h before mounting on 
slides. After imaging on a Zeiss Axioplan comparable αSMA stress fibres were visible in EV 
treated samples and in TGFβ1 treated control samples with no fibres visible in the negative 
controls (C). 
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7.7. Discussion  
Here we have demonstrated that EVs produced by cells at different stages of oral 
cancer tumourigenesis are capable of being taken up by a range of cell types that could 
be present in the TME. The fluorescence technique used indicates that the RNA contents 
of the EVs at least are released into the cells. As no green fluorescence is visible in the 
controls, which are vesicle free PBS treated with the same dyes as the vesicle samples 
and run through dye removal columns, it is likely that this fluorescent signal is caused 
by RNA internalised within EVs rather than co-precipitated free RNA. However, this 
does need to be confirmed with further experiments ideally vesicles or liposomes 
depleted of RNA and labelled with the dye alongside vesicle free RNA in PBS labelled 
with the dye and run through the spin columns should be used. The combination of such 
controls would give a better insight into the behaviour of the dye in this experiment. The 
assay does not allow the protein contents of the EVs to be monitored as neither 
fluorescent label associated specifically with proteins, but it is likely that protein 
contents are also released into the receptor cells. The fate of EV-associated proteins 
once taken up by cells, however, remains unclear. The cell types used as receptor cells 
in this assay represent cells that would be present in a developing oral tumour and each 
of them could potentially respond to the signals borne by the tumour cell derived EVs. 
  
This assay is a very crude representation of conditions within the 
microenvironment and it should be noted that both the endothelial cell line and the 
keratinocyte cell line have been artificially immortalised which may have changed their 
phenotype with respect to vesicle uptake over their normal form. It is also not clear if 
this uptake is occurring because the conditions have been rendered favourable by 
saturation kinetics. A physiologically relevant number of EVs in a system is currently 
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not possible to determine, and it is possible that the dose used in this assay exceeds the 
physiological level. It is likely that some of these EVs would not be taken up by local 
cells once released as they would be removed from the area by blood flow or that some 
EVs are prioritised for uptake by certain cell types within the area. Because this assay 
only has a single donor and receptor cell if the doses used were far above a 
physiological level it is possible that the EVs are being taken up because they have 
nowhere else to go. In its current form the assay is also unable to give an insight into 
any variation in uptake efficiencies between the different combinations tested. The assay 
could be adapted to use flow cytometry as the endpoint as opposed to fluorescence 
microscopy. This would allow comparisons of the rate of uptake of EVs from the 
different OSCC cells by the various recipient cells to be made. 
  
Limitations aside however this assay does reveal the potential for a complex 
network of EV mediated communication throughout oral cancer tumourigenesis with 
EVs being used to convey signals to normal and cancerous cells. It would be useful to 
develop this assay further to allow the kinetics of the uptakes to be quantified and 
compared, either through live cell imaging or through a FACs based microplate assay. 
Such an assay would identify any possible preferences for uptake with cell lines, 
something which hasn't been demonstrated in the literature to date. The fate of these 
EVs within the cell is beyond the scope of this assay to reveal, the fact the RNA bound 
dye remains visible and is spread throughout the cell suggests that the contents are 
trafficked quickly throughout the cell and remain intact post uptake. The dye only 
fluoresces detectably when bound to RNA, if the RNA contents of the EVs were being 
broken down it would be expected that the fluorescent signal would be reduced. This 
assay has its limitations compared to more recent advances used by other groups with 
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Cre-Lox or similar reporter systems to visualise the uptake of EVs which have the 
advantage of demonstrating that some of the EV contents remain biologically active. 
  
EVs are not normally considered to be cytotoxic, but there are a few exceptions to 
this, notably in lymphocytes the death of can benefit a developing tumour (Andreola et 
al., 2002). Although there have been studies that show macrophages can be more 
beneficial to the developing tumour alive (Huber et al., 2005). There are a number of 
studies which have transferred EVs between different cell types without reporting cell 
death upon uptake.  Our data are consistent with this, increasing doses of EVs up to 
20000 per cell were shown to have no impact on fibroblast death at 48 hours. The small 
increase in cell death at 24 h in our system is unlikely to have a significant biological 
effect. The notable caveat with this data is of course the physiological relevance of this 
EV dose is unknown. The maximum dose was established from previous fluorescence 
experiments performed before our lab had the ability to count the EVs in our samples. 
The dose used was at the lower threshold of the average EV dose used in these 
experiments, as determined by triplicate measurements using the qNano of similar sized 
preparations. It is possible that significantly higher doses of EVs could prove to be 
cytotoxic, but again the physiological relevance of such doses is unknown. 
  
Whilst tumour cell derived EVs are not often shown to be cytotoxic, they have 
been shown to have growth promoting effects (Gutkin et al., 2016; Hong et al., 2009; 
Wei et al., 2017) on a variety of cell types. This was not seen in our model system; no 
change in fibroblast proliferation was observed in any of the patient samples following 
EV treatment. However, neither of these studies focused on fibroblasts but mesothelial 
and endothelial cells respectively. Despite the variability in gender, age and smoking 
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status of the patients from which the fibroblasts used in these experiments were derived, 
the data from these experiments was more consistent than that obtained from similar 
sets of fibroblasts used in fibroblast activation experiments. 
  
This data demonstrates neatly the heterogeneity of healthy fibroblasts. The 
different fibroblasts are each taken from a different healthy volunteer and exhibit a 
range of responses in terms of αSMA mRNA and both abundance and localisation of the 
protein following EV and TGFβ1 treatment. Healthy fibroblasts normally exhibit an 
increase in αSMA protein expression when treated with TGFβ1 but both NOF319 and 
335 exhibit no change in protein level following the treatment. Only the NOF803 cells 
showed an increase in αSMA mRNA following treatment with the other three fibroblast 
lines showing no change in mRNA levels and NOF316 even showing a reduction in 
αSMA mRNA. Despite this apparent lack of response to TGFβ1 based on mRNA and 
protein levels the immunofluorescence shows that there are changes in αSMA 
organisation occurring in all the fibroblast cells lines following the treatment. A similar 
change is observed in all samples when they are treated with tumour cell-derived EVs, 
however predictably a different response is observed at the mRNA and protein level. 
  
Much of this variability will be down to inter patient variation, between NOFs 316 
and 319 there is a 51-year age range. A seventy-year-old patients fibroblasts would not 
be expected to respond as robustly as a twenty-year old as is seen in responses to UV in 
skin fibroblasts (Pernodet et al., 2016). NOF335 and 803 were both established from 
patients in their 40’s but showed a different response to TGFβ1 and EV treatments 
indicating that age is not the only contributing factor. Of the patient samples used only 
NOF316 was established from a female making it difficult to determine the impact of 
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gender on these results. Smoking status of the patient should also be taken into effect as 
exposure to the mutagenic compounds in tobacco smoke will have altered the patients 
cells. NOF335 was established from a patient who smoked, all other patients were non-
smokers, and NOF335 showed a distinctive mRNA profile for αSMA with only the 
severe dysplastic vesicles producing an increase in the mRNA levels for αSMA. 
  
Although a consistent response with respect to mRNA and protein levels of αSMA 
is not seen following EVs uptake the increased formation of αSMA stress fibres does 
indicate that the normal oral fibroblasts are activated into the cancer associated form 
following EV uptake. The more differentiated carcinoma and metastatic deposit cell 
derived EVs produce a more dramatic increase on the αSMA mRNA than that of the 
dysplastic cell derived EVs suggesting this effect is more potent in the later stages of 
tumour development. This would fit with the idea of niche construction, an increasing 
number of CAFs will create a more favourable environment for metastatic deposits to 
form, remodelling the matrix and creating an inflammation rich environment.  
 
7.7.1. Future work 
This data does however have its limitations and further work would be needed to 
confirm some of the findings. To confirm the observed changes in NOF morphology as 
activation into CAFs, Changes to different markers such as vimentin or fibronectin 
should be studied in the same way as αSMA following the uptake of EVs, it would also 
be interesting to study the changes in markers over different time scales than those used 
in this study. Lastly these EV activated fibroblasts should be compared to TGFβ1 
activated fibroblasts and cancer associated fibroblasts from patient samples in functional 
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assays like contractility and invasion assays to compare any differences in the types of 
activated cells.  
 
There is much opportunity for further work with the fluorescence uptake imaging 
assay. As mentioned earlier in the chapter additional controls should be incorporated to 
confirm the green fluorescence observed in the images is produced by EV mediated 
transfer of RNA. Adapting the assay to include labels specific for lipid or protein 
components of the EVs could allow for those to be tracked in the same fashion. Use of 
super resolution microscopy and pH sensitive dyes could be used to image and monitor 
endosomal escape of the EVs contents. The assay also has the potential to be adapted to 
explore the kinetics of this uptake through use of FAC sorting. 
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8. Discussion 
In the last ten years increasing attention has focused on the role of EVs in cancer 
progression with a variety of elegant studies revealing a complex signalling network. 
Oral cancer research lags behind research into other tumour types such as breast cancer. 
There are very few studies focusing on vesicle-mediated signalling in head and neck 
cancer. The few published studies focus on biomarker discovery or on tumours of the 
nasopharynx, which given that 90% of oral cancers arise from squamous cells in the 
oral cavity is perhaps a missed opportunity. Four studies explicitly use carcinomas of 
the tongue and of these, two focus on which cells of the TME the EVs can interact with 
(Al-Samadi et al., 2017; Dayan et al., 2012) others are focused on the contents of these 
EVs (Han et al., 2014; Kawakubo-Yasukochi et al., 2017). This project attempted to 
explore both questions. 
 
8.1. Method optimisation and characterization 
One of the strengths of this project is the assembly of a panel of cell lines isolated 
from the same primary anatomical site and that are representative of the distinct 
histological stages of tumourigenesis. This offered the opportunity to compare how EV 
cargo and mode of action are altered with progressing tumour stage. Whilst such a study 
has not yet been published in oral cancer, similar approaches have been used in other 
tumour models, which utilise patient samples or animal models to study EVs from the 
different stages of tumourigenesis (Liu et al., 2015; Melo et al., 2015). Those that do use 
cell lines do not have such an extensive panel of site matched cells (Lázaro-Ibáñez et 
al., 2017). Whilst patient and animal models have their advantages over 2D tissue 
culture models they are more expensive and more complicated to establish, which still 
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leaves a place for using cell lines as models particularly in such early stage studies. The 
panel of site matched cell lines allow our study to be compared favourably with the 
others that explore EV signalling in different cancer stages. Crucially our cell lines are 
accompanied by a large amount of patient information including the smoking status, 
which is particularly relevant to oral cancer. One of the differences between the two 
dysplastic cell lines is the smoking status of the patients, the mild dysplasia having 
arisen from a non-smoker, the severe dysplasia from a smoker. This difference adds an 
extra dimension to any comparisons drawn between the EVs produced by these cell 
lines as they could be caused either by the difference in tumour stage or the difference 
in smoking status. This is particularly relevant to the study of EV miRNA cargo as 
cellular miRNA expression has previously been shown to be altered on exposure to 
cigarette smoke (Pal et al., 2013). The difference in disease aetiology between these cell 
lines may mask any changes that occur purely as a result of tumour progression but 
given the correlation between smoking and oral cancer it would be difficult to find 
patients with severe oral dysplasia that are non-smokers. An ideal panel of cell lines 
would be site and patient matched so that the lesions could be compared throughout 
their development. However, whilst patients with mild dysplasias are often observed for 
malignant transformation, those with severe dysplasia normally undergo medical 
intervention and it would be unethical to allow a severe dysplastic lesion to progress to 
carcinoma for the purpose of research. This is where animal models have an advantage 
over cell lines and human samples. 
 
The first years of this project were spent establishing protocols for the purification 
and characterisation of EVs from the conditioned media of oral cancer cell lines. 
Established protocols for serial centrifugation performed on conditioned media of oral 
273 
 
cancer cells yielded EVs which were positive for protein EV markers including TSP1 
and CD63. Measurements using a qNano instrument, which was purchased part way 
through the study, showed that the serial centrifugation protocols were purifying 
particles of a size range (50-200 nm) consistent with the published literature (Johnstone 
et al., 1987 and Valadi et al., 2007). We also sought to determine if storage of EVs at -
20oC and freeze-thawing was causing a reduction in EV concentration or integrity. 
Whilst this work hasn’t explicitly analysed the effect of multiple freeze thaw cycles 
(Sokolova et al., 2011) or performed assays to check the function of the EVs is not lost 
by freeze thawing (Kalra et al., 2013) the EVs used in several of the functional assays 
and imaging experiments were subject to multiple freeze thaw cycles with no 
discernible loss of function during between the replicates. 
 
In order to generate sufficient yields of RNA and protein for the sequencing and 
proteomic experiments, respectively, this project took advantage of size exclusion 
chromatography (SEC) to purify the EVs (Böing et al., 2014). EVs purified using SEC 
were a similar size by TEM and TRPS and contained the same protein markers as those 
purified by serial centrifugation (Appendix 1). The issue of differences in functionality 
between EVs purified by different techniques is one that is currently being debated by 
the field. A recent paper showed that in a cardiac model, EVs purified by SEC produced 
a higher pERK/ERK ratio in endothelial cells post uptake than those purified by 
ultracentrifugation (Mol et al., 2017). Because this problem is one that can affect EVs 
purified from any source the most suitable functional assay would be one that tests a 
function common to all EVs allowing for a single answer to this question. However, 
such a universal function has not been identified, meaning that the question should be 
addressed in each individual model system. During this project one such function was 
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identified in oral cancer EVs, the ability to activate normal oral fibroblasts into a cancer 
associated phenotype. Whilst this function appeared to be common to all EV types the 
variability in responses from normal patient fibroblasts makes quantifying this effect too 
difficult to use in this role. It is possible that different purification techniques isolate 
subtly different populations of EVs which could result in different functional effects and 
this should be tested in every model system once a suitable function has been identified. 
Such a function would ideally be a positive or negative effect on proliferation or another 
similarly easily measurable trait. Whilst the size distribution profiles from the two 
different techniques used here are similar, size is known to be insufficient to determine 
between EV populations. The detection of the same proteins by western blots in EVs 
purified by both techniques is encouraging and does suggest that a similar EV 
population was isolated by both. Mol et al (2017) demonstrated that electron 
microscopy is unable to distinguish between the EVs purified by the different 
techniques. They showed a large amount of variability in EV structure even within grids 
containing EVs from the same source. This variability would make any differences 
observed by TEM inconclusive. 
 
8.2. Oral cancer cell derived vesicles deliver cargos to the surrounding cells of the 
tumour microenvironment 
Through the use of fluorescent dyes, the uptake of oral cancer cell-derived EVs by 
a range of normal cell types was examined. The cells used for these experiments 
included some of the major components of the OSCC TME: normal oral fibroblasts, 
endothelial cells, carcinoma cells and oral keratinocytes. Although this assay has many 
limitations it does show that EVs from oral cancer cells can be taken up by surrounding 
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normal cells in vitro. The assay used two different stains, one of which was 
encapsulated in the EV lumen and fluoresced when bound to RNA. This allowed 
visualisation of the release of luminal contents of EV after uptake. After only 60 min 
incubation with the stained EVs green fluorescence, from the RNA dye, was observed to 
be widespread across the cell. This observation indicates that the EV contents can be 
released from the EV into the recipient cell however it is still unclear whether the dye is 
remaining bound to the EV RNA or is merely being delivered unbound by the EVs. 
Experiments using EVs loaded with prestained RNA would be needed to resolve this 
uncertainty 
  
In this study we have focused on the effect of uptake of cancer-derived EVs by the 
cells of the TME. However, given reports in other tumour models that normal cells 
produce EVs capable of being taken up by the cancer cells (Hu et al., 2015) it is likely 
that this signalling is bi-directional in oral cancer, with EVs flowing between normal 
and cancerous cells as well as between cancer cells and normal cells. Isolation of EVs 
from primary stromal cells is challenging and whether sufficient EVs could be purified 
from endothelial cells or fibroblasts to produce detectable fluorescence using this assay 
remains to be elucidated. Given the range of reported functions for EVs in cancer it is 
highly likely that different populations of EVs will exhibit preferential targeting to a 
particular cell type in order to produce a desired effect. It is also possible that some 
EVs, such as those which contain cisplatin when it is shuttled out of resistant ovarian 
cancer cells (Safaei et al., 2005), are never intended to be delivered to a cell, but 
because of the limitations of an in vitro set up like this one are being taken up. Each of 
the normal cell types used in these imaging experiments has potential for further 
experiments. It would be valuable to study any changes in cell turnover following EV 
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uptake in each case as well as any changes in phenotypic behaviour such as motility or 
tubule formation. 
 
8.3. Next generation sequencing and label free mass spectrometry techniques reveal 
differences in vesicle contents which are linked to tumour stage 
IonTorrent sequencing and mass spectrometry techniques were used to elucidate the 
contents of the EVs produced by oral cancer cells. Proteomic and transcriptomic 
analysis of the EV contents have identified some patterns relative to the tumour stage of 
the producing cell (figure 8.1). A core group of miRNA and proteins were detected, 
these include the let-7 miRNA superfamily, miR-29a-3p, miR-27b-3p a, collagen α 3 
(IV) chain, histone proteins, EEF2 and major vault protein. These cargoes are 
commonly associated with tumourigenesis and their presence in EVs could be due to 
their abundance in the cells from which they originate. The release of EVs containing 
several members of anti-tumourigenic miRNA families like miR-199 miR-34 and miR-
200 from severe dysplastic cells or carcinoma cells suggests that this could be necessary 
for tumour progression. Particularly interesting is the EV-mediated export of miR-200 
from the carcinoma cells. Blocking EV-mediated export of anti-tumourigenic miRNAs 
could be a novel therapeutic strategy. Each of these proteins and miRNA represent good 
candidates for follow up, but validation in human ex vivo samples would be preferable 
before subsequent functional studies. 
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miRNA and protein enrichment in OSCC EVs changes with tumour stage 
 
 
Figure 8.1 miRNA and protein identified by proteomic analysis as being enriched in EVs 
produced by different tumour stages. Several miRNA were changed in enrichment between tumour 
stage, miR-126-3p and 5p were reduced in all EVs compared to those of the mild dysplastic cells. 
miR-181a-5p increases in EVs produced by cells of later stages. Whole families of miRNA were 
enriched in EVs of severe dysplastic cells and carcinoma cells including miR-199 and miR-200. 
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8.4. Oral cancer vesicles can promote pro-tumourigenic changes in normal oral 
fibroblasts 
The uptake of EVs produced by the oral cancer cell lines was sufficient to cause a 
rearrangement of αSMA molecules in normal oral fibroblasts which is indicative of 
them acquiring a CAF phenotype. In the laboratory this is often mimicked using 
treatment with TGFβ1. Prostate cancer-derived EVs can have a similar effect on 
fibroblasts (Webber et al., 2010). It was subsequently demonstrated that TGFβ1 tethered 
to the outside of the EVs by heparan sulphate proteoglycans was responsible for 
mediating this effect (Chowdhury et al., 2015; Webber et al., 2010). In our experiments 
TGFβ1 could not be detected in the EV either by western blotting or by mass 
spectrometry. However previous studies revealed that TGFβ1 was present in picogram 
amounts on the surface of EVs, making it unlikely that it would be present in sufficient 
quantities to detect by western blot. Mass spectrometry should have been sensitive 
enough to detect such small amounts of protein. However, it is uncertain if the sample 
processing technique would have conserved any protein tethered to surface of EVs. 
 
It is probable that a similar mechanism is responsible for this phenomenon in oral 
cancer EVs and more suitable experiments such as ELISAs with intact EV samples 
should be performed to determine if TGFβ1 is present on the EV surface. It is also 
possible that miRNA cargo could be responsible for driving the observed fibroblast 
activation. In silico analysis showed that more than 70 miRNA in each sample are 
predicted to interact with transcripts of proteins involved in the TGFβ1 pathway (figure 
8.2). However, the miRNA are predicted to target transcripts of proteins that both inhibit 
and activate the pathway. This indicates that rather than having a distinct activating or 
inhibitory impact on this pathway the EVs are more likely to have a more nuanced 
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modulatory role. It is difficult to reconcile the packaging of miRNA like miR-200, 
which has an inhibitory effect on fibroblast activation (Tang et al., 2016), into OSCC-
derived EV. It is also possible that the observed NOF activation occurs by presentation 
of EV-tethered TGFβ1 at the cell surface and is independent of the EV miRNA cargo. 
Further in silico work and more sensitive methods to detect TGFβ1 would be required to 
answer the question. 
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OSCC EV miRNA interact with regulatory members of TGFβ-1 pathway 
 
 
Figure 8.2 TGFβ1 signalling pathway and interactions with miRNA found in the EVs from oral 
cancer cells as determined by miRPath V.3 database. Proteins coloured green interact with no 
miRNAs in the EVs, those coloured in yellow interact with 1 miRNA and those in orange interact 
with multiple miRNA. miRNA interact with transcripts from proteins that both inhibit and activate 
the pathway. 
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8.5. Limitations of the study 
There are several limitations to this study, some of which are unique to this project 
and others which are experienced by the entire field. The qNano arriving a year into this 
work meant that many methods were developed and optimised without a knowledge of 
the EV concentration. This included the fluorescence imaging experiments. Had the EV 
concentrations been known at the time these experiments could have been done with a 
standardised dose of EVs possibly allowing for some quantification to be done and any 
preferential uptake to be detected. Although in later experiments the EV doses were 
reverse engineered and dose curves for EV treatment were performed, ideally these 
should have been established earlier in the project. The question of EV doses is one with 
which the field is struggling. There is still no understanding of what a physiologically 
relevant dose of EVs is.  
 
Determining this in an animal model or in a patients tumour remains a challenge. 
The fields approach to this problem is slowly changing, with many early studies using 
µg of EV protein as a measure of EV dose. It is now more common to use particle 
number as a dose which is determined by qNano or Nanosight instruments. Although 
our EV doses did not cause cell death and were observed to produce a physiological 
response in normal oral fibroblasts, suggesting that they are physiologically relevant, it 
is also possible that the doses of EVs used are significantly higher or lower than those 
experienced by cells in vivo, which is why a phenotypic effect is observed. Solving the 
question of physiologically relevant doses of EVs remains a priority for the field 
particularly if EVs are to become established therapy options. 
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Whilst the cell lines used in this study were site matched and were associated with 
a large amount of patient data, they do not represent a perfect model of tumourigenesis. 
Ideally, they would originate from the same patient, allowing actual changes in the 
composition of the EVs to be directly linked to stage changes in a patients tumour. The 
current panel only includes one cell line for each pathological stage; this makes it 
difficult to be certain if any changes in behaviour or contents are typical of all cells of 
that stage or just the ones in our panel. Any changes or behaviours detected in the EVs 
of these cells should be validated in other cells from the same site and stage but from 
different patients. A second problem with the cells is an issue common to many studies, 
a lack of available non-immortalised normal cells. There are two different immortalised 
normal cell lines used routinely in our lab, the first of these, OKF6, are hTERT 
immortalized oral keratinocytes and were found to be suitable for some experiments but 
could not be grown in sufficient numbers to harvest enough EVs for transcriptomic and 
proteomic analysis. The second is FNB6 which are also hTERT immortalized, and while 
these can be grown in higher volumes they cannot be grown without a feeder layer. 
These are normally irradiated mouse fibroblasts, which will be producing EVs of their 
own making them unsuitable for use in our experiments. The same issue arises when 
using primary keratinocytes. 
 
In order to generate sufficient RNA and protein yields for the next generation 
sequencing and mass spectrometry experiments EVs were prepared by SEC. This was 
done to combat a combination of the low yields of RNA and protein produced from the 
EVs and the limited capacity of our ultracentrifuge rotor. While limited work was done 
to compare the EVs purified by the two different techniques, no extensive comparison 
of the functions or contents of these EVs were performed. The EVs were similar in size 
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and bear the same markers suggesting consistency between the EVs purified by the two 
techniques. The lack of a suitable functional assay to test any differences in function 
between the two methods is a limitation of this project. Other limitations are presented 
by the single biological replicates for the next generation sequencing and mass 
spectrometry experiments, although protein and RNA samples were collected from a 
pool of several different EV preparations thereby introducing some biological variation. 
The addition of at least one biological replicate would help to offset some of the issues 
in the quality of this data notably the much higher number of detected RNA but the 
lower mapped reads percentage in the D35 RNA and the huge variation in proteins 
detected in each of the EV types. Both of these issues have had some impact on the data 
analysis for these samples. 
  
The research field of EVs is a relatively young one and it is important to 
appreciate how rapidly the field is progressing. Many studies have use lipophilic dyes, 
such as PKH26, for labelling EVs used in uptake experiments. It has only recently been 
noted that these dyes form micelles of similar proportions to EVs, resulting in artefacts 
in fluorescence experiments (Morales-Kastresana et al., 2017). Fortunately, no such 
structures were observed in our experiments. The weaknesses of the commonly used 
dyes and the advent of new technologies have led to a range of approaches being used. 
A recently published paper used a thiol-based dye (Roberts-Dalton et al., 2017) that is 
well characterised and is known not to impair EV formation or function by the 
introduction of bulky fluorophores. Fusion tagging of proteins found in EVs with 
fluorescent labels (Lai et al., 2015) and advanced microscopy techniques have produced 
high resolution images and videos of EV uptake. Another advance is the application of 
Cre-lox reporter systems (Zomer et al., 2016). These systems are complicated and 
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expensive but have significant potential for imaging the movement of EVs between 
cells of a model system. Whilst these advances offer something beyond that offered by 
the techniques used in this project, simple fluorescence assays performed with the 
correct controls still have a place in the field for confirming that EVs can be exchanged 
between cells. 
 
One of the major issues that continues to present problems for the EV research 
community is EV heterogeneity. It has increasingly become accepted that because 
current technology does not allow EV classes to be fully separated then extensive 
characterization of the EVs being studied should be carried out by all groups. A paper 
from 2016 demonstrates the extent to which the current proteins used as markers are 
probably inadequate (Kowal et al., 2016). The use of western blotting or targeted 
proteomics for the candidates identified by the Théry group should become standard for 
EV experiments where the role of a distinct population of EVs is being tested. This 
would ensure that the vesicles populations being used are characterized and defined as 
stringently as current methods allow and would serve to increase the reproducibility of 
experiments.  Although this wasn’t a stated goal of this project the addition of this 
information would allow for far more detail to be given on the EVs produced by oral 
cancer cells. 
  
Another change in focus concerns the RNA content of the EVs. Much of the RNA 
cargo research focuses on miRNA but work done in breast cancer (Tosar et al., 2015) 
and our own data suggest that miRNA represent one of the least abundant RNA types in 
the EVs. In breast cancer cell EVs the majority of the RNA were tRNA fragments, but 
despite this no studies have been published that focus on tRNA cargo of EVs. The 
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majority of EV RNA in our study was classified “other” RNA, which includes a mix of 
poorly understood non-coding RNA species including vault RNA and Y-RNA. Given 
that they make up the majority of the RNA in our samples the analysis of these species 
is arguably more important than the study of the miRNA. This is an area of EV research 
that is yet to be explored in great depth but as our understanding of those RNA types 
improves additional functions of these EVs may be revealed. 
 
8.6. Further work 
The immediate priority for further work should be to improve the validation of the 
proteomics data. This should be done using a combination of approaches to ensure the 
detection of the validation candidates in the EV samples. Successful validation of this 
data set would identify a number of candidates for verification in patient samples. A 
range of interesting candidates have been identified in both the RNA and protein 
contents of the EVs, these include miRNA such as miR-181a-5p and the miR-200 
family proteins like SDC4 and nesprin 1 which were shown to be differentially 
packaged into the EVs from the different tumour stages. If the patterns seen in the RNA 
sequencing and mass spectrometry were replicated by qPCR and western blotting, 
respectively, then further experiments could be performed to determine if these proteins 
or RNA molecules have any functional effects. In order to determine if any of these 
molecules could function as biomarkers the abundance of these molecules in the EVs in 
patient biofluid samples should be determined.  
  
It was intended to explore the impact of EV uptake on other cell types of the oral 
cancer micro environment. Transfer experiments have shown that EVs from the tumour 
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cells can be taken up by endothelial cells, other carcinoma cells and oral keratinocytes. 
Given the contents of these EVs include a number of proteins and RNA implicated in 
angiogenesis it is possible that there will be an effect of the EVs on the ability of 
endothelial cells to form tubules, which could be quantified in tubule formation assays. 
Many of the RNA have been linked to invasion and metastasis and it is likely that the 
EVs can change the ability of cells to migrate. This should be tested using transwell 
assays on carcinoma cells, fibroblasts and immune cells, which are all beneficial to 
various stages of a tumours development. Before any such transfers are performed 
similar experiments to those performed in the fibroblasts should be performed in order 
to test if EV uptake has a detrimental effect on the receptor cells. As has been alluded to 
previously, it is unlikely that the EV signalling in the TME is entirely one directional. If 
appropriate normal cells could be sourced, or if sufficient quantities of vesicles could be 
purified from the NOFs used in this study, it would be instructive to perform similar 
experiments to see if there are any similarities in EV contents and if these EVs can have 
any effect on tumour cells. As with all of the experiments these should ideally be 
performed in multiple cell lines representative of the different stages of a tumour, which 
would enable a more reliable picture of the changes in EV signalling with cancer stage 
to be determined. 
  
A more ambitious direction to take this work would be to continue exploring the 
EV uptake visualised by the fluorescence imaging experiments. The fluorescence 
approach used in this study to image EV uptake could potentially be adapted to study 
the kinetics of EV uptake. This could be done using a technique such as flow cytometry 
to track the kinetics of different combinations of EV doses and receptor cells. Whilst 
these assays have begun to identify some possible branches of a more complicated EV 
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signalling network the experiments performed are simple in nature and are in an in vitro 
model. Establishing a 3D culture model would create a more realistic tumour model in 
which to study EV signalling. Such a model has recently been published by a group in 
Finland (Al-Samadi et al., 2017) which utilised myoma discs and zebrafish as models 
for studying EV signalling. A combination of these models with Cre lox techniques for 
visualising EV uptake in vivo could allow for a more comprehensive picture of EV 
signalling in a tumour to be created. The oral cavity is not a static environment and 
several groups have started to use fluid flow chambers to represent this (Nithiananthan 
et al., 2017). An extremely ambitious model combining a flow chamber style set up with 
cells producing fluorescently labelled EVs could even allow for real time imaging of the 
EV signalling network in the oral cancer microenvironment. 
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8.7. Conclusion  
The data generated during this project has begun to answer some of the major 
questions regarding the role of EVs in oral cancer progression. EVs have been shown to 
be produced throughout oral cancer tumourigenesis. Fluorescence assays have shown 
that these EVs can be delivered to various cells of the oral cancer microenvironment and 
that upon uptake the contents of these EVs are released into the receptor cells. The RNA 
and protein contents of EVs are predicted to have a range of potential pro-tumourigenic 
effects as well exhibiting some differential packaging which could distinguish between 
the tumour stage of the producing cells. Lastly the EVs produced by the oral cancer 
cells activate fibroblasts into a CAF like phenotype which would benefit a developing 
tumour by creating favourable conditions for its continuing progression. Whilst these 
experiments complete part of the jigsaw there are other parts still to complete. EVs have 
the potential to play an important role in the progression of oral cancer and could 
represent a vital source of diagnostic biomarkers. 
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10. Appendix 
10.1. Comparison of EVs purified by serial centrifugation and SEC 
 
Figure 10.1 Characterisation of EVs purified by serial centrifugation and size exclusion 
chromatography. EVs purified by SEC (B) cover the same size ranges as those purified by serial 
centrifugation (A) although there is a greater proportion of larger EVs purified by the size 
exclusion columns. EVs purified by both techniques were positive for CD63 and TSP1 by western 
blot (C). Error bars SEM for n=4 biological replicates and western blots representative of at least 3 
experiments. 
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10.2. miRNA sequencing data table 
Gene D20 D35 H357 B22 
hsa-let-7a-1_hsa-let-7a-5p 55 539 144 25 
hsa-let-7a-2_hsa-let-7a-5p 32 527 124 29 
hsa-let-7a-3_hsa-let-7a-5p 51 480 153 31 
hsa-let-7b_hsa-let-7b-5p 80 873 188 42 
hsa-let-7d_hsa-let-7d-3p 0 303 0 0 
hsa-let-7d_hsa-let-7d-5p 0 931 118 0 
hsa-let-7e_hsa-let-7e-5p 0 416 0 0 
hsa-let-7f-1_hsa-let-7f-5p 32 682 104 34 
hsa-let-7f-2_hsa-let-7f-5p 25 713 116 22 
hsa-let-7g_hsa-let-7g-5p 46 855 79 23 
hsa-mir-100_hsa-miR-100-5p 198 468 184 173 
hsa-mir-101-1_hsa-miR-101-3p 0 428 0 16 
hsa-mir-103a-2_hsa-miR-103a-3p 19 511 133 24 
hsa-mir-106b_hsa-miR-106b-5p 70 1187 151 45 
hsa-mir-10a_hsa-miR-10a-5p 0 298 0 0 
hsa-mir-10b_hsa-miR-10b-5p 47 655 0 0 
hsa-mir-125a_hsa-miR-125a-5p 52 848 0 31 
hsa-mir-125b-1_hsa-miR-125b-5p 47 1936 0 37 
hsa-mir-125b-2_hsa-miR-125b-5p 47 1892 0 50 
hsa-mir-126_hsa-miR-126-3p 427 705 103 108 
hsa-mir-126_hsa-miR-126-5p 400 1277 148 105 
hsa-mir-1285-1_hsa-miR-1285-3p 0 0 0 21 
hsa-mir-1285-1_hsa-miR-1285-5p 74 0 99 93 
hsa-mir-1307_hsa-miR-1307-3p 0 0 64 0 
hsa-mir-139_hsa-miR-139-5p 47 0 0 0 
hsa-mir-140_hsa-miR-140-3p 22 841 0 0 
hsa-mir-140_hsa-miR-140-5p 0 0 0 0 
hsa-mir-141_hsa-miR-141-3p 0 0 123 0 
hsa-mir-143_hsa-miR-143-3p 0 206 0 0 
hsa-mir-144_hsa-miR-144-3p 0 0 0 25 
hsa-mir-146a_hsa-miR-146a-5p 0 0 0 19 
hsa-mir-149_hsa-miR-149-5p 0 236 56 0 
hsa-mir-151a_hsa-miR-151a-5p 62 442 85 37 
hsa-mir-152_hsa-miR-152-3p 0 231 0 0 
hsa-mir-15a_hsa-miR-15a-5p 0 328 43 29 
hsa-mir-16-1_hsa-miR-16-5p 38 680 50 18 
hsa-mir-16-2_hsa-miR-16-5p 42 589 54 0 
hsa-mir-17_hsa-miR-17-5p 49 645 92 30 
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hsa-mir-181a-1_hsa-miR-181a-5p 180 1050 1650 397 
hsa-mir-181b-2_hsa-miR-181b-5p 19 0 614 39 
hsa-mir-182_hsa-miR-182-5p 0 467 0 0 
hsa-mir-183_hsa-miR-183-5p 0 446 0 0 
hsa-mir-185_hsa-miR-185-5p 26 615 142 26 
hsa-mir-186_hsa-miR-186-5p 0 531 55 30 
hsa-mir-18a_hsa-miR-18a-5p 83 3120 157 60 
hsa-mir-191_hsa-miR-191-5p 109 1967 163 75 
hsa-mir-193a_hsa-miR-193a-5p 0 0 0 20 
hsa-mir-193b_hsa-miR-193b-3p 44 227 58 50 
hsa-mir-197_hsa-miR-197-3p 0 0 34 0 
hsa-mir-199a-1_hsa-miR-199a-3p 0 1117 0 0 
hsa-mir-199a-2_hsa-miR-199a-3p 0 1121 0 0 
hsa-mir-199b_hsa-miR-199b-3p 0 1094 0 0 
hsa-mir-19a_hsa-miR-19a-3p 45 481 106 55 
hsa-mir-19b-1_hsa-miR-19b-3p 69 931 108 58 
hsa-mir-19b-2_hsa-miR-19b-3p 86 992 133 64 
hsa-mir-200a_hsa-miR-200a-3p 0 0 610 0 
hsa-mir-200b_hsa-miR-200b-3p 0 0 103 0 
hsa-mir-200c_hsa-miR-200c-3p 0 0 291 0 
hsa-mir-20a_hsa-miR-20a-5p 154 1908 309 100 
hsa-mir-22_hsa-miR-22-3p 43 2496 90 98 
hsa-mir-221_hsa-miR-221-3p 42 2493 179 99 
hsa-mir-222_hsa-miR-222-3p 32 778 74 24 
hsa-mir-223_hsa-miR-223-3p 130 578 63 104 
hsa-mir-23a_hsa-miR-23a-3p 598 8799 1332 544 
hsa-mir-25_hsa-miR-25-3p 0 193 0 0 
hsa-mir-26a-1_hsa-miR-26a-5p 126 494 82 70 
hsa-mir-26a-2_hsa-miR-26a-5p 114 439 84 50 
hsa-mir-27a_hsa-miR-27a-3p 93 3183 259 116 
hsa-mir-27b_hsa-miR-27b-3p 41 515 84 73 
hsa-mir-29a_hsa-miR-29a-3p 196 6412 434 234 
hsa-mir-29b-1_hsa-miR-29b-3p 24 739 36 0 
hsa-mir-301a_hsa-miR-301a-3p 0 339 0 0 
hsa-mir-3074_hsa-miR-3074-5p 108 2307 183 69 
hsa-mir-30a_hsa-miR-30a-5p 51 876 492 84 
hsa-mir-30b_hsa-miR-30b-5p 36 326 0 18 
hsa-mir-30d_hsa-miR-30d-5p 85 2972 203 94 
hsa-mir-30e_hsa-miR-30e-5p 51 625 49 20 
hsa-mir-31_hsa-miR-31-3p 30 316 0 17 
hsa-mir-31_hsa-miR-31-5p 318 4514 247 140 
hsa-mir-342_hsa-miR-342-3p 45 212 0 21 
hsa-mir-34a_hsa-miR-34a-5p 0 1717 0 0 
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hsa-mir-34b_hsa-miR-34b-3p 0 325 0 0 
hsa-mir-34b_hsa-miR-34b-5p 0 413 0 0 
hsa-mir-34c_hsa-miR-34c-5p 0 729 0 0 
hsa-mir-361_hsa-miR-361-5p 36 0 0 20 
hsa-mir-365a_hsa-miR-365a-3p 30 0 0 16 
hsa-mir-365b_hsa-miR-365b-3p 21 0 0 0 
hsa-mir-374b_hsa-miR-374b-5p 0 247 0 29 
hsa-mir-376c_hsa-miR-376c-3p 63 180 0 33 
hsa-mir-378a_hsa-miR-378a-3p 46 1589 40 164 
hsa-mir-423_hsa-miR-423-3p 32 630 70 33 
hsa-mir-423_hsa-miR-423-5p 27 524 0 19 
hsa-mir-424_hsa-miR-424-5p 0 364 66 19 
hsa-mir-425_hsa-miR-425-5p 24 235 0 0 
hsa-mir-494_hsa-miR-494-3p 20 0 0 0 
hsa-mir-503_hsa-miR-503-5p 0 229 0 0 
hsa-mir-574_hsa-miR-574-5p 51 0 70 81 
hsa-mir-590_hsa-miR-590-5p 0 0 39 16 
hsa-mir-625_hsa-miR-625-3p 0 0 43 0 
hsa-mir-652_hsa-miR-652-3p 0 226 0 0 
hsa-mir-708_hsa-miR-708-5p 0 239 0 0 
hsa-mir-92a-1_hsa-miR-92a-3p 67 223 46 36 
hsa-mir-92a-2_hsa-miR-92a-3p 46 210 50 37 
hsa-mir-92b_hsa-miR-92b-3p 38 0 57 15 
hsa-mir-93_hsa-miR-93-5p 60 954 191 52 
hsa-mir-99a_hsa-miR-99a-5p 20 220 0 0 
hsa-mir-99b_hsa-miR-99b-5p 0 393 0 0 
Table 10.1 Counts of miRNA sequences detected in OSCC derived EVs with minimum of 1000 
RPM 
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10.3. Label free mass spectrometry data tables 
Protein names D201 D202 D351 D352 
Collagen alpha-2(I) chain 0 0 0 0 
Apolipoprotein B-100 25.7024 25.91397 0 0 
Spectrin beta chain, non-erythrocytic 1 0 0 0 0 
Clathrin heavy chain 25.72328 25.73332 0 21.80266 
Ribosome-binding protein 1 25.01465 24.64427 0 22.09045 
Collagen alpha-1(V) chain 0 0 28.47158 28.53204 
Collagen alpha-2(V) chain 0 0 23.07811 22.96476 
40S ribosomal protein S16 0 22.00734 0 0 
Collagen alpha-1(VI) chain 25.3867 25.51244 24.12171 25.83843 
Aggrecan core protein 23.76101 23.58325 0 0 
Elongation factor 1-delta 0 22.1774 0 0 
TNFAIP3-interacting protein 1 0 0 0 0 
Peroxiredoxin-1 23.70113 0 0 0 
Integrin-linked protein kinase 23.25954 23.01716 0 0 
40S ribosomal protein SA 0 23.59229 0 0 
Nesprin-1 0 0 0 0 
Ras-related protein R-Ras2 21.66622 0 0 0 
Band 4.1-like protein 1 0 0 0 0 
Heat shock 70 kDa protein 1B 26.15898 25.52561 0 0 
HLA class I histocompatibility antigen, A-2 alpha chain 0 0 0 0 
Fatty acid synthase 0 0 0 0 
60S ribosomal protein L7 22.78863 0 0 0 
Heterogeneous nuclear ribonucleoproteins C1/C2 0 0 0 0 
Ubiquitin-60S ribosomal protein L40 24.48438 24.70783 0 0 
Epithelial cell adhesion molecule 0 0 0 0 
GTP-binding nuclear protein Ran 24.85296 24.47376 0 0 
Myosin light polypeptide 6 23.97272 0 0 0 
T-complex protein 1 subunit epsilon 22.16653 22.50516 0 0 
Tax1-binding protein 1 0 0 0 0 
Ras-related protein Rab-7a 0 23.30048 0 0 
Latent-transforming growth factor beta-binding protein 1 0 0 0 0 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit 
beta-2 0 0 0 0 
Catenin delta-1 0 0 0 0 
Collagen alpha-1(XII) chain 24.49467 24.49796 0 0 
Collagen alpha-3(VI) chain 24.35286 24.71167 25.50027 25.69846 
Ezrin 25.39999 24.00033 0 0 
Thrombospondin-4 0 0 0 0 
Multifunctional protein ADE2 21.85308 0 0 0 
Unconventional myosin-Ib 0 23.7349 0 0 
Receptor protein-tyrosine kinase 0 0 0 0 
329 
 
Alpha-1,4 glucan phosphorylase 23.10064 22.621 0 0 
Protein transport protein Sec16A 0 0 0 0 
Pre-mRNA-processing factor 19 0 0 0 0 
Lactadherin 25.87462 25.95178 26.38096 26.17807 
4F2 cell-surface antigen heavy chain 25.22008 25.25501 0 0 
High mobility group protein HMGI-C 0 0 0 0 
C-1-tetrahydrofolate synthase, cytoplasmic 0 0 0 0 
Tubulin alpha-1C chain 27.20965 27.31363 0 0 
Neutral alpha-glucosidase AB 0 0 0 0 
Sodium-coupled neutral amino acid transporter 2 0 0 0 0 
Laminin subunit beta-1 27.00378 27.19103 0 0 
60S ribosomal protein L18 23.4086 0 0 0 
60S ribosomal protein L28 21.83295 0 0 0 
Ras-related protein Rab-11A 0 23.9872 0 0 
Envoplakin 0 0 0 0 
Kunitz-type protease inhibitor 2 0 0 0 0 
Choline transporter-like protein 2 0 0 0 0 
Amino acid transporter 0 0 0 0 
Matrilin-2 0 0 0 0 
Agrin 27.65963 27.96339 0 0 
Syntenin-1 23.30605 23.46712 0 0 
Disintegrin and metalloproteinase domain-containing protein 
10 0 0 0 0 
Laminin subunit alpha-5 27.73363 27.52223 0 0 
D-3-phosphoglycerate dehydrogenase 0 22.20117 0 0 
Charged multivesicular body protein 2a 0 0 0 0 
EGF-like repeat and discoidin I-like domain-containing 
protein 3 0 0 0 0 
WD repeat-containing protein 1 24.20769 24.05614 0 0 
Core histone macro-H2A.1 24.58314 25.31731 0 0 
Filamin-B 0 0 0 0 
Isocitrate dehydrogenase [NADP] cytoplasmic 0 0 0 0 
Serine protease 23 0 0 0 0 
Myelin protein zero-like protein 1 0 0 0 0 
L-lactate dehydrogenase A chain 0 0 0 0 
Phosphoglycerate kinase 1 24.47574 24.58761 0 0 
Adenylate kinase isoenzyme 1 0 0 0 0 
Coagulation factor X 26.21442 26.23916 0 0 
Collagen alpha-1(I) chain 0 0 0 0 
Fibronectin 31.32876 31.38082 31.72212 31.75736 
Transferrin receptor protein 1 0 23.43224 24.50531 24.65119 
Annexin A1 0 23.14389 0 0 
Glyceraldehyde-3-phosphate dehydrogenase 26.80403 26.83232 0 0 
Heat shock protein beta-1 24.07227 24.36058 0 0 
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Guanine nucleotide-binding protein G(i) subunit alpha-2 24.77077 24.76537 0 0 
Sodium/potassium-transporting ATPase subunit alpha-1 21.73851 0 0 0 
Integrin beta-3 23.22133 23.24648 0 0 
Integrin beta-1 23.97044 23.53991 0 0 
Keratin, type I cytoskeletal 18 24.17104 24.28093 0 0 
ATP synthase subunit beta, mitochondrial 0 0 0 0 
Alpha-enolase 25.15538 24.97115 0 0 
Nucleophosmin 0 0 0 0 
L-lactate dehydrogenase B chain 23.71754 23.48873 0 0 
Annexin A2 24.44556 24.56866 0 0 
Tubulin beta chain 25.08614 26.29843 0 0 
Profilin-1 0 0 0 0 
Bifunctional glutamate/proline--tRNA ligase 0 0 0 0 
Heat shock protein HSP 90-alpha 24.63511 24.738 0 0 
Tyrosine-protein kinase Lyn 0 0 0 0 
Thrombospondin-1 27.97388 28.25327 24.09772 23.51701 
Heat shock protein HSP 90-beta 26.63215 26.70491 0 0 
Collagen alpha-2(IV) chain 0 22.20009 0 0 
U1 small nuclear ribonucleoprotein 70 kDa 0 0 0 0 
Guanine nucleotide-binding protein G(k) subunit alpha 0 0 0 0 
Glutathione S-transferase P 0 0 0 0 
Tumor-associated calcium signal transducer 2 0 23.38706 0 0 
Poly [ADP-ribose] polymerase 1 0 0 0 0 
Histone H2A.V 24.79853 24.57911 27.20247 26.72025 
Histone H2A type 1-J 23.42355 0 27.60936 25.84283 
Histone H1.4 23.81157 23.74283 23.54333 23.20597 
78 kDa glucose-regulated protein 23.31935 23.18728 0 0 
Laminin subunit gamma-1 27.48108 27.23105 23.49045 23.20054 
Heat shock cognate 71 kDa protein 26.90403 27.09295 24.86122 25.19648 
Solute carrier family 2, facilitated glucose transporter 
member 1 0 0 0 0 
Proliferating cell nuclear antigen 0 0 0 0 
Proto-oncogene tyrosine-protein kinase Src 0 0 0 0 
Versican core protein 24.05565 24.55877 0 0 
Elongation factor 2 24.4612 24.43835 0 0 
Nidogen-1 24.02471 23.68517 0 0 
Alcohol dehydrogenase [NADP(+)] 0 0 0 0 
Pyruvate kinase PKM 27.98338 27.94949 24.28503 0 
Junction plakoglobin 21.84774 21.53635 0 0 
Desmoplakin 23.36306 22.45513 0 0 
CD44 antigen 0 0 0 0 
Integrin beta-4 24.19551 24.1187 0 0 
HLA class I histocompatibility antigen, A-31 alpha chain 23.29334 23.40133 0 0 
Histone H1.5 22.62999 0 23.08328 22.99455 
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Histone H1.3 26.01663 24.21875 0 0 
Histone H1.2 0 0 0 0 
High mobility group protein HMG-I/HMG-Y 0 0 0 0 
T-complex protein 1 subunit alpha 23.64053 22.67659 0 0 
Nucleolin 0 0 0 0 
Plasma membrane calcium-transporting ATPase 1 0 0 0 0 
Filamin-A 27.12888 26.62073 22.36768 0 
5-nucleotidase 0 0 0 0 
Integrin alpha-6 0 0 0 0 
Adenosylhomocysteinase 23.22535 23.381 0 0 
Histone H2B type 2-E 0 0 0 0 
Cofilin-1 25.15723 25.62293 0 0 
Tenascin 0 0 0 0 
Integrin alpha-3 0 0 0 0 
Pentraxin-related protein PTX3 27.48554 28.37057 30.77109 30.58701 
Moesin 0 23.35917 0 0 
Elongation factor 1-gamma 22.85772 22.64469 0 0 
14-3-3 protein theta 0 0 0 0 
Ephrin type-A receptor 2 0 0 0 0 
HLA class I histocompatibility antigen, B-41 alpha chain 0 0 0 0 
HLA class I histocompatibility antigen, B-48 alpha chain 23.0239 22.92575 0 0 
HLA class I histocompatibility antigen, Cw-12 alpha chain 0 0 0 0 
Syndecan-4 0 0 0 0 
14-3-3 protein beta/alpha 24.09523 23.34516 0 0 
14-3-3 protein sigma 0 0 0 0 
Desmoglein-3 0 0 0 0 
Glypican-1 0 0 0 0 
Catenin beta-1 0 0 0 0 
Myosin-9 28.44932 28.46599 22.77024 22.39679 
Myosin-10 0 0 0 0 
Transgelin-2 24.05225 23.34489 0 0 
T-complex protein 1 subunit zeta 0 0 0 0 
26S protease regulatory subunit 6B 0 0 0 0 
ATP-dependent DNA helicase Q1 0 0 0 0 
60S ribosomal protein L5 0 0 0 0 
Ras GTPase-activating-like protein IQGAP1 0 0 0 0 
T-complex protein 1 subunit gamma 22.0013 22.27787 0 0 
Vasodilator-stimulated phosphoprotein 0 0 0 0 
T-complex protein 1 subunit delta 24.24858 23.63721 0 0 
Ras-related protein Rab-5C 0 0 0 0 
Coatomer subunit alpha 0 0 0 0 
Monocarboxylate transporter 1 0 0 0 0 
Laminin subunit beta-2 0 0 0 0 
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Histone H2B type F-S 0 0 0 0 
Actin, cytoplasmic 2 29.96719 29.8804 26.61765 26.92082 
Eukaryotic initiation factor 4A-I 23.47098 23.44443 0 0 
40S ribosomal protein S20 0 0 0 0 
Cell division control protein 42 homolog 0 0 0 0 
Ras-related protein Rab-14 0 0 0 0 
Ras-related protein Rap-1b 25.83584 25.58938 0 0 
60S ribosomal protein L15 0 22.5316 0 0 
Transforming protein RhoA 0 0 0 0 
Heterogeneous nuclear ribonucleoprotein K 22.20958 0 0 0 
14-3-3 protein gamma 0 0 0 0 
40S ribosomal protein S8 0 0 0 0 
14-3-3 protein epsilon 24.17585 25.47584 23.27242 0 
40S ribosomal protein S4, X isoform 0 0 0 0 
Histone H4 27.50059 27.52694 27.09587 26.85436 
60S ribosomal protein L11 0 0 0 0 
Peptidyl-prolyl cis-trans isomerase A 25.87185 26.0254 0 0 
14-3-3 protein zeta/delta 24.78721 25.02707 0 0 
Guanine nucleotide-binding protein subunit beta-2-like 1 0 0 0 0 
Actin, alpha skeletal muscle 0 0 0 0 
Putative elongation factor 1-alpha-like 3 26.71607 26.31772 0 0 
Tubulin beta-4B chain 26.92717 26.92717 0 0 
Histone H3.2 27.34121 27.22361 26.00084 25.93017 
T-complex protein 1 subunit beta 0 23.63112 0 0 
DNA-dependent protein kinase catalytic subunit 0 0 0 0 
Brain acid soluble protein 1 0 0 0 0 
Rho-related GTP-binding protein RhoG 0 0 0 0 
Tumor necrosis factor-inducible gene 6 protein 0 0 26.16795 26.283 
Fibulin-2 0 0 0 0 
Basement membrane-specific heparan sulfate proteoglycan 
core protein 26.9927 27.00764 22.42083 25.14942 
Ephrin-B1 0 0 0 0 
Adenylyl cyclase-associated protein 1 21.86793 22.66336 0 0 
Large neutral amino acids transporter small subunit 1 24.28912 24.57496 0 0 
Caveolin-1 0 0 0 0 
Fibromodulin 23.36252 23.56186 0 0 
Galectin-3-binding protein 25.75142 25.69139 0 0 
Neuroblast differentiation-associated protein AHNAK 0 0 0 0 
Sequestosome-1 0 0 0 0 
Laminin subunit beta-3 27.42021 27.4453 0 0 
Laminin subunit gamma-2 27.73014 27.01945 0 0 
Nuclear receptor coactivator 4 0 0 0 0 
Desmoglein-2 0 0 0 0 
Eukaryotic translation initiation factor 3 subunit A 0 0 0 0 
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Cytoplasmic dynein 1 heavy chain 1 0 0 0 0 
Fibroblast growth factor-binding protein 1 22.66967 0 0 0 
Major vault protein 26.22422 26.83461 0 22.573 
Plectin 20.62123 20.21585 0 0 
Non-POU domain-containing octamer-binding protein 0 22.64498 0 0 
Transforming growth factor-beta-induced protein ig-h3 24.82978 25.25782 0 0 
Fascin 22.6046 22.37616 0 0 
Histone H2A type 2-C 28.31103 28.91767 28.69395 28.69508 
Laminin subunit alpha-3 27.47723 27.43484 0 0 
Histone H3 0 0 0 0 
Golgi-associated plant pathogenesis-related protein 1 0 0 0 0 
von Willebrand factor A domain-containing protein 1 0 0 0 0 
Staphylococcal nuclease domain-containing protein 1 0 0 0 0 
Cytoplasmic FMR1-interacting protein 1 0 0 0 0 
Lipolysis-stimulated lipoprotein receptor 0 0 0 0 
Misshapen-like kinase 1 0 0 0 0 
Retinoic acid-induced protein 3 0 0 0 0 
Programmed cell death 6-interacting protein 23.06511 22.54753 0 0 
Histone H1x 0 0 0 0 
Histone H2A type 1-C 0 0 0 0 
Multivesicular body subunit 12A 0 0 0 0 
Phosphatase and actin regulator 3 0 0 30.64349 30.55161 
Histone H2B type 1-M 28.40625 28.25106 27.57542 27.62101 
EMILIN-2 0 0 0 0 
Protein tweety homolog 3 0 0 0 0 
Tubulointerstitial nephritis antigen-like 0 0 0 0 
Ras-related protein Rab-1B 24.28263 23.97176 0 0 
EH domain-containing protein 1 0 0 0 0 
Myoferlin 0 0 0 0 
Prostaglandin F2 receptor negative regulator 0 0 0 0 
Brain-specific angiogenesis inhibitor 1-associated protein 2-
like protein 1 0 0 0 0 
Collagen alpha-1(XVII) chain 22.56788 22.0142 0 0 
Plakophilin-3 0 0 0 0 
Talin-1 26.32459 26.4381 0 0 
Junctional adhesion molecule A 0 0 0 0 
Table 10.2 Log2 of label free intensity scores for proteins in EVs derived from mild dysplastic (D20) and 
severe dysplastic (D35) cells 
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Protein names H3571 H3572 B221 B222 
Collagen alpha-2(I) chain 0 0 25.74778 25.78576 
Apolipoprotein B-100 24.59645 0 25.60916 25.50857 
Spectrin beta chain, non-erythrocytic 1 20.98266 20.92477 0 0 
Clathrin heavy chain 27.47676 27.66296 26.80501 27.20154 
Ribosome-binding protein 1 23.91342 23.88092 0 0 
Collagen alpha-1(V) chain 22.81613 22.58265 0 0 
Collagen alpha-2(V) chain 0 0 0 0 
40S ribosomal protein S16 22.91417 23.52886 0 0 
Collagen alpha-1(VI) chain 25.53905 25.34313 25.6086 25.33067 
Aggrecan core protein 0 0 23.9304 23.17521 
Elongation factor 1-delta 22.90558 22.27378 0 0 
TNFAIP3-interacting protein 1 23.61414 23.19877 0 0 
Peroxiredoxin-1 24.85681 25.18639 0 0 
Integrin-linked protein kinase 0 0 0 0 
40S ribosomal protein SA 24.55491 24.69259 0 0 
Nesprin-1 0 0 28.35477 27.88116 
Ras-related protein R-Ras2 23.26112 23.04312 22.40678 22.21511 
Band 4.1-like protein 1 22.03049 22.29964 0 0 
Heat shock 70 kDa protein 1B 26.96521 26.91171 0 22.48375 
HLA class I histocompatibility antigen, A-
2 alpha chain 24.68448 24.68565 0 0 
Fatty acid synthase 26.19669 26.34755 0 0 
60S ribosomal protein L7 22.96408 23.01076 0 0 
Heterogeneous nuclear ribonucleoproteins 
C1/C2 23.31424 23.32649 0 0 
Ubiquitin-60S ribosomal protein L40 27.02739 27.01977 25.35269 25.00222 
Epithelial cell adhesion molecule 22.8906 22.48353 0 0 
GTP-binding nuclear protein Ran 25.86992 25.83641 24.17965 24.11807 
Myosin light polypeptide 6 24.29214 23.67799 0 0 
T-complex protein 1 subunit epsilon 24.3761 24.69285 0 0 
Tax1-binding protein 1 24.60286 24.93674 0 0 
Ras-related protein Rab-7a 24.30096 24.06069 0 0 
Latent-transforming growth factor beta-
binding protein 1 0 0 22.88575 23.05696 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-2 24.34279 24.48971 0 0 
Catenin delta-1 22.80499 22.42949 0 0 
Collagen alpha-1(XII) chain 24.11434 25.17874 24.73567 24.7305 
Collagen alpha-3(VI) chain 23.97088 23.68785 24.79877 24.76172 
Ezrin 24.4562 23.99524 24.41693 0 
Thrombospondin-4 24.26234 24.18246 23.53908 23.71051 
Multifunctional protein ADE2 22.44615 21.96406 0 0 
Unconventional myosin-Ib 23.85984 23.48984 0 0 
Receptor protein-tyrosine kinase 25.77548 25.94639 0 0 
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Alpha-1,4 glucan phosphorylase 0 0 0 0 
Protein transport protein Sec16A 22.09713 21.6197 0 0 
Pre-mRNA-processing factor 19 22.38311 22.25491 0 0 
Lactadherin 24.83374 24.73159 0 0 
4F2 cell-surface antigen heavy chain 27.56776 28.08507 0 0 
High mobility group protein HMGI-C 24.54256 24.83128 0 0 
C-1-tetrahydrofolate synthase, cytoplasmic 21.70083 21.99924 0 0 
Tubulin alpha-1C chain 27.84308 27.93708 26.30933 26.13759 
Neutral alpha-glucosidase AB 24.48031 24.07594 0 0 
Sodium-coupled neutral amino acid 
transporter 2 25.03616 25.20494 0 0 
Laminin subunit beta-1 28.69395 28.76468 25.36806 25.3656 
60S ribosomal protein L18 24.05383 23.68817 0 0 
60S ribosomal protein L28 21.92405 21.94271 0 0 
Ras-related protein Rab-11A 24.15027 24.08894 0 0 
Envoplakin 21.86676 21.68466 0 0 
Kunitz-type protease inhibitor 2 24.15074 23.50506 0 0 
Choline transporter-like protein 2 21.45186 21.21371 0 0 
Amino acid transporter 25.12617 24.88758 0 0 
Matrilin-2 24.90238 24.89855 0 0 
Agrin 29.41127 29.40696 0 0 
Syntenin-1 28.45838 28.48174 24.52349 24.48456 
Disintegrin and metalloproteinase domain-
containing protein 10 22.81039 22.93485 0 0 
Laminin subunit alpha-5 29.96761 29.95782 24.31603 22.95752 
D-3-phosphoglycerate dehydrogenase 0 0 22.72334 22.93135 
Charged multivesicular body protein 2a 22.22406 22.26651 0 0 
EGF-like repeat and discoidin I-like 
domain-containing protein 3 28.51454 28.57091 0 0 
WD repeat-containing protein 1 23.9227 24.19061 0 0 
Core histone macro-H2A.1 25.75055 25.73611 0 0 
Filamin-B 24.77077 25.20023 0 0 
Isocitrate dehydrogenase [NADP] 
cytoplasmic 22.45046 22.44559 0 0 
Serine protease 23 24.31389 24.28574 0 0 
Myelin protein zero-like protein 1 22.7915 22.45151 0 0 
L-lactate dehydrogenase A chain 23.48038 23.41002 23.15208 22.87049 
Phosphoglycerate kinase 1 25.46896 25.25184 25.30414 24.32711 
Adenylate kinase isoenzyme 1 0 0 22.20437 22.63482 
Coagulation factor X 25.15896 25.08103 25.08456 0 
Collagen alpha-1(I) chain 0 0 28.97345 28.81754 
Fibronectin 28.97076 29.07143 30.07304 30.51944 
Transferrin receptor protein 1 25.47503 25.5013 0 0 
Annexin A1 25.68798 25.75159 0 0 
Glyceraldehyde-3-phosphate 
dehydrogenase 27.80833 27.65731 23.55754 0 
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Heat shock protein beta-1 24.70282 24.4318 0 0 
Guanine nucleotide-binding protein G(i) 
subunit alpha-2 25.26374 25.46404 25.62182 25.25238 
Sodium/potassium-transporting ATPase 
subunit alpha-1 24.98676 25.11898 24.84929 23.89791 
Integrin beta-3 0 0 0 0 
Integrin beta-1 25.11012 25.1047 23.829 23.67885 
Keratin, type I cytoskeletal 18 24.38949 24.33831 0 0 
ATP synthase subunit beta, mitochondrial 23.49424 24.04068 0 0 
Alpha-enolase 25.83632 25.838 25.18711 25.27789 
Nucleophosmin 23.64482 23.28334 0 0 
L-lactate dehydrogenase B chain 24.09507 24.01929 0 0 
Annexin A2 25.57707 25.7399 0 0 
Tubulin beta chain 26.80082 26.92298 25.39575 25.65155 
Profilin-1 24.80149 24.84795 23.3041 0 
Bifunctional glutamate/proline--tRNA 
ligase 23.63079 23.53077 0 0 
Heat shock protein HSP 90-alpha 24.99131 25.08042 0 23.87371 
Tyrosine-protein kinase Lyn 22.83169 22.70493 0 0 
Thrombospondin-1 29.6211 29.66731 26.11054 25.51812 
Heat shock protein HSP 90-beta 27.39149 27.47127 26.16465 26.4186 
Collagen alpha-2(IV) chain 22.74049 22.77102 0 0 
U1 small nuclear ribonucleoprotein 70 kDa 22.83289 22.65412 0 0 
Guanine nucleotide-binding protein G(k) 
subunit alpha 22.91554 22.02726 0 0 
Glutathione S-transferase P 24.61201 24.57358 0 0 
Tumor-associated calcium signal 
transducer 2 26.78382 26.67976 0 0 
Poly [ADP-ribose] polymerase 1 25.17249 25.41451 0 0 
Histone H2A.V 26.63132 26.24235 0 23.90591 
Histone H2A type 1-J 25.33892 23.05089 0 0 
Histone H1.4 25.27888 25.22424 0 24.18858 
78 kDa glucose-regulated protein 23.6919 23.78377 22.90356 22.94482 
Laminin subunit gamma-1 29.02773 29.00045 25.06275 25.57868 
Heat shock cognate 71 kDa protein 28.28604 28.06466 27.16087 27.35658 
Solute carrier family 2, facilitated glucose 
transporter member 1 26.48336 26.27272 0 0 
Proliferating cell nuclear antigen 22.75485 22.98591 0 0 
Proto-oncogene tyrosine-protein kinase Src 22.3888 22.24203 0 0 
Versican core protein 22.70257 0 31.07947 31.29313 
Elongation factor 2 26.54113 26.21091 0 21.28506 
Nidogen-1 23.34611 0 0 0 
Alcohol dehydrogenase [NADP(+)] 22.53101 22.68207 0 0 
Pyruvate kinase PKM 28.78216 28.82429 24.57473 22.99127 
Junction plakoglobin 25.92375 26.14297 0 0 
Desmoplakin 21.72134 21.78141 0 0 
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CD44 antigen 24.45676 24.51473 0 0 
Integrin beta-4 28.18494 28.2102 0 0 
HLA class I histocompatibility antigen, A-
31 alpha chain 27.11575 26.93495 0 0 
Histone H1.5 24.57109 24.64471 22.25098 0 
Histone H1.3 26.90598 26.63159 26.66262 25.02335 
Histone H1.2 24.72458 24.66947 0 0 
High mobility group protein HMG-
I/HMG-Y 25.10238 25.01372 0 0 
T-complex protein 1 subunit alpha 24.12084 23.68667 23.23371 0 
Nucleolin 23.97885 23.92107 0 0 
Plasma membrane calcium-transporting 
ATPase 1 21.90481 21.91783 22.03523 20.97358 
Filamin-A 27.4243 27.07051 25.07423 24.66281 
5-nucleotidase 25.79504 25.92352 0 0 
Integrin alpha-6 25.50827 25.54575 0 0 
Adenosylhomocysteinase 24.50567 24.40795 0 0 
Histone H2B type 2-E 26.57012 26.52409 0 0 
Cofilin-1 26.90001 26.94347 24.65687 24.83384 
Tenascin 26.18221 25.77651 0 0 
Integrin alpha-3 24.31997 24.49082 0 0 
Pentraxin-related protein PTX3 27.22509 27.25647 0 0 
Moesin 22.94113 23.39859 23.60128 0 
Elongation factor 1-gamma 25.59571 25.85291 23.76253 23.16451 
14-3-3 protein theta 24.281 24.21111 0 0 
Ephrin type-A receptor 2 25.48965 24.97719 0 0 
HLA class I histocompatibility antigen, B-
41 alpha chain 26.63104 26.63575 0 0 
HLA class I histocompatibility antigen, B-
48 alpha chain 0 0 0 0 
HLA class I histocompatibility antigen, 
Cw-12 alpha chain 23.1321 23.29348 0 0 
Syndecan-4 24.67395 24.67417 0 0 
14-3-3 protein beta/alpha 23.55532 24.92565 23.0462 22.45521 
14-3-3 protein sigma 22.35318 22.41359 0 0 
Desmoglein-3 23.92098 24.05573 0 0 
Glypican-1 24.28122 24.06472 0 0 
Catenin beta-1 22.78592 23.06558 0 0 
Myosin-9 29.0714 29.03113 24.27006 23.80745 
Myosin-10 24.64284 24.7601 0 0 
Transgelin-2 24.20015 24.16745 0 0 
T-complex protein 1 subunit zeta 24.44594 25.21022 0 0 
26S protease regulatory subunit 6B 22.90575 23.28433 0 0 
ATP-dependent DNA helicase Q1 24.32649 24.21156 0 0 
60S ribosomal protein L5 23.95145 23.73562 0 0 
Ras GTPase-activating-like protein 
IQGAP1 23.57635 23.89393 0 0 
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T-complex protein 1 subunit gamma 22.92691 23.9778 0 0 
Vasodilator-stimulated phosphoprotein 22.58302 23.42944 0 0 
T-complex protein 1 subunit delta 23.98163 23.89587 0 0 
Ras-related protein Rab-5C 23.56848 23.43721 0 0 
Coatomer subunit alpha 23.57369 23.9558 0 0 
Monocarboxylate transporter 1 24.0525 24.13148 0 0 
Laminin subunit beta-2 26.11973 26.16321 0 0 
Histone H2B type F-S 24.29411 24.28651 0 0 
Actin, cytoplasmic 2 30.17795 30.25631 29.29195 29.12263 
Eukaryotic initiation factor 4A-I 25.46151 25.49314 23.05522 23.15936 
40S ribosomal protein S20 23.68571 23.51196 0 0 
Cell division control protein 42 homolog 23.67088 23.69954 0 0 
Ras-related protein Rab-14 24.71177 24.69285 0 0 
Ras-related protein Rap-1b 25.27675 25.20594 25.16242 24.7494 
60S ribosomal protein L15 22.9186 22.78835 0 0 
Transforming protein RhoA 20.86597 20.88762 0 0 
Heterogeneous nuclear ribonucleoprotein 
K 23.31174 23.4789 0 0 
14-3-3 protein gamma 23.70187 24.15012 0 0 
40S ribosomal protein S8 23.41687 24.44297 0 0 
14-3-3 protein epsilon 24.26749 24.50045 23.78945 0 
40S ribosomal protein S4, X isoform 23.22747 23.14272 0 0 
Histone H4 30.65523 30.71849 29.22023 29.41135 
60S ribosomal protein L11 22.46107 21.99106 0 0 
Peptidyl-prolyl cis-trans isomerase A 26.89053 27.02707 25.81448 26.16806 
14-3-3 protein zeta/delta 25.51479 25.34432 0 0 
Guanine nucleotide-binding protein 
subunit beta-2-like 1 24.20873 24.19069 0 0 
Actin, alpha skeletal muscle 26.02711 25.64694 0 0 
Putative elongation factor 1-alpha-like 3 26.88635 26.89192 26.29964 26.09834 
Tubulin beta-4B chain 27.39966 27.6238 25.67128 26.27067 
Histone H3.2 29.9986 29.93719 28.63291 28.4241 
T-complex protein 1 subunit beta 24.37901 23.62522 0 23.03261 
DNA-dependent protein kinase catalytic 
subunit 23.1584 22.89783 0 0 
Brain acid soluble protein 1 23.72119 23.61661 0 0 
Rho-related GTP-binding protein RhoG 23.33906 23.11717 0 0 
Tumor necrosis factor-inducible gene 6 
protein 0 0 0 0 
Fibulin-2 0 0 24.87446 25.03946 
Basement membrane-specific heparan 
sulfate proteoglycan core protein 29.19254 29.22073 29.07824 28.763 
Ephrin-B1 23.19 23.26442 0 0 
Adenylyl cyclase-associated protein 1 0 0 22.22973 0 
Large neutral amino acids transporter small 
subunit 1 26.93225 26.70807 0 0 
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Caveolin-1 25.50609 25.62469 0 0 
Fibromodulin 23.69094 23.68228 0 0 
Galectin-3-binding protein 26.32095 26.27402 0 0 
Neuroblast differentiation-associated 
protein AHNAK 21.86748 22.27002 0 0 
Sequestosome-1 25.47599 25.03481 0 0 
Laminin subunit beta-3 27.88361 28.06301 0 0 
Laminin subunit gamma-2 28.44498 28.32989 0 0 
Nuclear receptor coactivator 4 22.6051 22.64566 0 0 
Desmoglein-2 24.33497 24.50561 0 0 
Eukaryotic translation initiation factor 3 
subunit A 22.69867 22.5354 0 0 
Cytoplasmic dynein 1 heavy chain 1 22.75367 22.85308 0 0 
Fibroblast growth factor-binding protein 1 24.26363 23.84019 0 0 
Major vault protein 26.42824 26.47964 21.766 23.27483 
Plectin 27.22748 27.68966 0 0 
Non-POU domain-containing octamer-
binding protein 22.58866 23.11924 0 0 
Transforming growth factor-beta-induced 
protein ig-h3 23.53517 23.60332 0 0 
Fascin 25.79558 25.00475 22.54868 0 
Histone H2A type 2-C 30.93473 31.10681 29.29404 29.57322 
Laminin subunit alpha-3 27.47939 27.59049 0 0 
Histone H3 23.55497 23.4706 22.97701 23.17359 
Golgi-associated plant pathogenesis-
related protein 1 0 0 24.7902 24.55614 
von Willebrand factor A domain-
containing protein 1 23.63954 23.64548 0 0 
Staphylococcal nuclease domain-
containing protein 1 22.75185 22.87897 0 0 
Cytoplasmic FMR1-interacting protein 1 22.2556 22.41227 0 0 
Lipolysis-stimulated lipoprotein receptor 24.11521 24.11402 0 0 
Misshapen-like kinase 1 22.585 22.83842 0 0 
Retinoic acid-induced protein 3 26.63312 26.83858 0 0 
Programmed cell death 6-interacting 
protein 27.32294 27.44829 23.25262 0 
Histone H1x 22.69562 23.02692 0 0 
Histone H2A type 1-C 24.53077 24.78387 25.54451 26.07672 
Multivesicular body subunit 12A 23.72972 23.95465 0 0 
Phosphatase and actin regulator 3 0 0 0 0 
Histone H2B type 1-M 30.68937 30.66746 29.84634 29.4751 
EMILIN-2 0 0 22.56769 22.62136 
Protein tweety homolog 3 22.5968 22.18307 0 0 
Tubulointerstitial nephritis antigen-like 25.53623 25.76946 26.30855 26.40991 
Ras-related protein Rab-1B 24.75781 24.62968 0 0 
EH domain-containing protein 1 23.30131 23.26399 0 23.91807 
Myoferlin 25.47908 25.47568 0 0 
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Prostaglandin F2 receptor negative 
regulator 25.85875 26.16728 22.12405 0 
Brain-specific angiogenesis inhibitor 1-
associated protein 2-like protein 1 22.64705 22.63387 0 0 
Collagen alpha-1(XVII) chain 25.41529 25.09527 0 0 
Plakophilin-3 23.58474 23.8261 0 0 
Talin-1 26.39226 26.17957 24.86561 24.05283 
Junctional adhesion molecule A 23.96367 23.83123 0 0 
Table 10.3 Log2 of label free intensity scores for proteins in EVs derived from carcinoma (H357) and 
metastatic deposit (B22) cells 
 
 
